Natural Killer cell activation and evasion during chronic hepatitis C virus infection by Pembroke, Thomas
 
Natural Killer cell activation and evasion 
during chronic hepatitis C virus infection 
 
 
Thomas Peter Ignatius Pembroke 
 
 
A thesis submitted to Cardiff University in Candidature for the 
Degree of Doctor of Philosophy 
 
 
Institute of Infection and Immunity, 
School of Medicine, 
Cardiff University, 
Heath Park, 
CARDIFF. 
 
2014
 	   i	  
 
DECLARATION 
 
This work has not been submitted in substance for any other degree or award at this or any other 
university or place of learning, nor is being submitted concurrently in candidature for any degree 
or other award. 
 
 
Signed ………………………………………… (candidate)       Date ………………………… 
 
 
STATEMENT 1 
 
This thesis is being submitted in partial fulfillment of the requirements for the degree of 
…………………………(insert MCh, MD, MPhil, PhD etc, as appropriate) 
 
Signed ………………………………………… (candidate)       Date ………………………… 
 
 
STATEMENT 2 
 
This thesis is the result of my own independent work/investigation, except where otherwise stated. 
Other sources are acknowledged by explicit references.  The views expressed are my own. 
 
Signed ………………………………………… (candidate)       Date ………………………… 
 
 
STATEMENT 3 
 
I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter-
library loan, and for the title and summary to be made available to outside organisations. 
 
Signed ………………………………………… (candidate)       Date ………………………… 
 
 
STATEMENT 4: PREVIOUSLY APPROVED BAR ON ACCESS 
 
I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter-
library loans after expiry of a bar on access previously approved by the Academic Standards 
& Quality Committee.  
 
Signed ………………………………………… (candidate)       Date ………………………… 
  
 	   ii	  
Acknowledgements 
I am grateful to the European Society of Infectious Diseases and Clinical Microbiology 
for a research grant and the Welsh Assembly Government for financial support for my 
PhD project through the Welsh Clinical Academic Tract. 
 
I very much appreciate the on going support and help of my supervisors Awen Gallimore 
and Andy Godkin during this research period and for all the advice as a novice clinical 
lecturer. The lab has always been an extremely enjoyable and supportive place to work, 
for this I am also grateful to all the PhD students and post docs. In particular I am very 
grateful to Emma Jones and Rich Stanton for the time they have spent teaching me 
techniques and skills with incredible levels of patience. I am also indebted to Gavin 
Wilkinson and Eddie Wang for their discussions, guidance and support.  
 
Finally, of course my wife, Catherine and Isabelle, our daughter, and our families for the 
loving support, understanding and distractions throughout the PhD period. 
  
 	   iii	  
Summary 
 
Hepatitis C virus (HCV) infects 3% of the global population and HCV-related liver 
inflammation is a major cause of liver failure and hepatocellular carcinoma. Current 
treatments are based upon long courses of interferon-α (IFNα) injections, which have 
significant side effects and are only effective in 40-80% of individuals depending on viral 
genotype. Natural killer (NK) cells are innate lymphocytes, which can kill virally infected 
cells and are stimulated by IFNα. To establish a chronic infection HCV must evade 
immune responses. I hypothesised that NK cells are important for the successful 
eradication of HCV and that chronic HCV infection impinges upon NK cell function to 
prevent viral clearance. I found that NK cell function was reduced in chronic HCV and 
correlated with the proportion of NKp46+ NK cells in vitro. In keeping with these findings 
NKp46-rich intrahepatic NK cell populations were more activated and the proportion of 
these cells correlated with liver inflammation. During interferon-α treatment individuals 
who had the greatest increase in NK cell function in response to increasing stimulation 
had the fastest rate of viral clearance and were most likely to successfully clear the virus. 
Using a novel adenovirus vector expressing HCV proteins I have discovered that NS5B 
protein reduces NK cell cytotoxicity and cytokine production. Therefore, in this thesis I 
have described novel insights into the mechanisms of HCV immunoevasion, HCV-related 
disease pathogenesis with implications for viral eradication therapy.  	  	   	  
 	   iv	  
	  
Table of contents 
 Page 
 Declaration i 
 Acknowledgements ii 
 Summary iii 
 Table of contents iv 
 List of figures vii 
 List of tables x 
 Abbreviations xi 
   
 Chapter 1 Introduction 1 
1.1 Hepatitis C virus from syndrome to identification 2 
1.2 Classification and structure of HCV 4 
1.3 Epidemiology of HCV infection 8 
1.4 HCV in Wales 11 
1.5 Natural history of HCV infection 13 
1.6 HCV- current treatments & recent advances 15 
1.7 Assessing liver disease in chronic HCV infection 17 
1.8 
1.9 
Summary of outstanding clinical problems in the management of HCV 
The innate and adaptive immune systems 
18 
19 
1.10 Interferons and viral infection 22 
1.11 Investigation of immune response to chronic HCV infection 26 
1.12 Natural Killer cells 30 
1.13 NK cells and the adaptive immune system 39 
1.14 NK cell memory 41 
1.15 NK cell responses to HCV exposure & acute infection 43 
1.16 NK cells in chronic HCV infection 47 
1.17 Chronic HCV & intrahepatic NK cells 50 
1.18 Intrahepatic NK cell phenotype in chronic HCV infection 52 
1.19 NK cell function in chronic HCV infection 54 
1.20 HCV NK – immunoevasion strategies 57 
1.21 NK cells during IFNα treatment of chronic HCV infection 59 
1.22 Hypothesis, objective & aims 61 
  
 	   v	  
 Chapter 2 Materials & Methods 62 
2.1 Patient recruitment 63 
2.2 Patient samples & study protocol 67 
2.3 Tissue culture 71 
2.4 NK phenotyping and cytotoxic assays 74 
2.5 NK cell gating strategy 77 
2.6 Intrahepatic and peripheral blood NK cell phenotype and functional 
immunostaining 
81 
2.7 Immunohistochemistry 82 
2.8 Viral load analysis 83 
2.9 HCV protein expression using an adenovirus vector  84 
2.10 HCV gene selection 84 
2.11 Advec expression system overview 88 
2.12 pAL1141 90 
2.13 Adenovector recombineering 92 
2.14 Transfection &titration of adenovirus vectors 96 
2.15 Statistical analysis 99 
   
 Chapter 3 Results: Peripheral blood NK cells & chronic HCV infection 101 
3.1 Peripheral blood NK cell phenotype & function in chronic HCV 103 
3.2 The proportion of peripheral NK cells is reduced in chronic HCV infection 104 
3.3 NK cell phenotype in chronic HCV 106 
3.4 NK cell cytotoxic function in health and chronic HCV infection 110 
3.6 NK cell phenotype and cytotoxic function 112 
3.7 NK activating receptor ligand expression on target cells 117 
3.8 IFNα treatment of HCV infection – viral clearance and rate of viral control 122 
3.9 NK cell phenotype and IFNα treatment outcome in chronic HCV infection  113 
3.10 In vitro NK cytotoxic function & rate of viral clearance 126 
3.11 Functional ratio 128 
3.12 HCV specific CD4+ T cell & NK cell responses following IFNα treatment 130 
3.13 Discussion 135 
   
   
 	   vi	  
Chapter 4 Intrahepatic NK cells in chronic HCV and during IFNα  treatment 145 
4.1 Intrahepatic NK cell phenotype and function in chronic HCV 146 
4.2 FNA sampling 147 
4.3 Intrahepatic NK cells in chronic HCV and non viral chronic liver disease 153 
4.4 Intrahepatic NK cell phenotype 155 
4.5 Intrahepatic NK cell function 160 
4.6 Intrahepatic NK cells and hepatitis C viral load 163 
4.7 Markers of liver inflammation 165 
4.8 Intrahepatic NK cells and liver inflammation 169 
4.9 Intrahepatic NKp46 expression and NK cell function 173 
4.10 Measurement of NKp46: Proportion v MFI 177 
4.11 Intrahepatic NK cells during IFNα treatment 179 
4.12 Discussion 186 
   
Chapter 5 Identification of NK cell evasion strategies employed by HCV 193 
5.1 HCV and NK cell function 194 
5.2 HCV protein expression by adenovirus vectors 195 
5.3 The impact of HCV protein expression on NK cell function 202 
5.4 Discussion 210 
   
Chapter 6 Discussion – NK cell activation and evasion during chronic HCV 
infection 
213 
   
Appendix I  Histological scoring systems of liver inflammation and fibrosis 221 
   
 Bibliography 223 
   
 Publications 236 
 
   
 
 
 
 	   vii	  
List of Figures 
Chapter 1: Introduction        Page 
1.1 Flaviviridae phylogenic tree 6 
1.2 HCV polyproteins and cleaved proteins 7 
1.3 Global distribution of HCV genotypes 10 
1.4 HCV in Wales 12 
1.5 The natural history of HCV infection 14 
1.6 Advances in the treatment of chronic HCV 16 
1.7 NCR structures and signalling motifs 38 
1.8 HLA – KIR inhibitory interactions 44 
1.9 The reported proportion of NK cells in chronic HCV 48 
1.10 Reported proportions of intrahepatic NK cells in chronic HCV 51 
1.11 HCV NK-immunoevasion 58 
   
Chapter 2: Materials and Methods 
2.1 Study protocol schematic  70 
2.2 NK cell gating strategy 78 
2.3 FMO controls and NK cell phenotype 80 
2.4 HCV proteins and polyproteins recombineered into adenovirus vectors 85 
2.5 Advec expression system overview 89 
2.6 Adenovirus vector in pAL1141 plasmid 91 
   
Chapter 3: Peripheral blood NK cells & chronic HCV infection  
3.1 The proportion of peripheral NK cells in chronic HCV  105 
3.2 NK cell phenotype in chronic HCV infection 107 
3.3 HCV genotype and NK cell activating receptor phenotype 109 
3.4 NK cell degranulation in chronic HCV infection 111 
3.5 NK cell degranulation and changes in activating receptor phenotype 113 
3.6 NKp46 correlates with degranulation in chronic HCV infection at low-level 
stimulation 
115 
3.7 NKp46 and NK cell function at high-level stimulation 116 
3.8 Huh7.5 & K562 NK activating receptor ligand expression 118 
3.9 Rate of viral control during IFNα treatment 121 
 	  viii	  
3.10 NK cell phenotype & treatment outcome 123 
3.11 NK cell phenotype & rate of viral clearance during IFNα treatment 125 
3.12 NK cell cytotoxic function & response to treatment  127 
3.13 Functional ratio and treatment outcome 129 
3.14 IFNα induced rapid control of hepatitis C virus results in SVR in the 
absence of robust CD4+ T cell responses 
131 
3.15 NK cells and CD4+ T cell responses to IFNα treatment 134 
3.16 Models of immune responses to viral pathogens and development of 
adaptive immunity 
140 
3.17 NKp46+ NK cells and CD4+ T cell responses during IFNα treatment of 
chronic HCV 
143 
   
Chapter 4: Intrahepatic NK cells in chronic HCV and during IFNα  treatment 
4.1 Analgesia requirements following FNA and liver biopsy 148 
4.2 Lymphocyte gating strategy for intrahepatic & peripheral blood samples 150 
4.3 Intrahepatic NK cell isolation by permeabilisation & density gradient 152 
4.4 Intrahepatic NK cells as a proportion of lymphocytes 154 
4.5 Intrahepatic NK cell phenotype 156 
4.6 Intrahepatic NKp46 expression 159 
4.7 NK cell functional markers 161 
4.8 Viral load and NK cell phenotype & function in chronic HCV 164 
4.9 Necroinflammatory and Fibrosis scores 167 
4.10 Intrahepatic NK cell proportion, NKp46, CD107a and NI score 170 
4.11 Intrahepatic NK cell phenotype, function & NI score 172 
4.12 Intrahepatic NKp46 expression & NK cell function 174 
4.13 NKp46 and liver inflammation 176 
4.14 NKp46 measured by MFI and proportion 178 
4.15 Intrahepatic NK cells during IFNα-based treatment of HCV 180 
4.16 NK cell phenotype and function during IFNα treatment of HCV 183 
   
Chapter 5: Identification of NK cell evasion strategies employed by HCV  
5.1 HCV protein expression in HFF by adenovirus vectors- Western blots 197 
5.2 JFH protein expression by immunofluorescence in HFF CAR+ cells 199 
 	   ix	  
5.3 Rep1b protein expression by immunofluorescence in HFF CAR+ cells 200 
5.4 The impact of HCV protein expression on NK cell cytotoxic function 204 
5.5 HCV protein impingement upon NK cell cytokine production 206 
5.6 Summary- NK cell response to HCV protein expression in target cells 209 
   
Chapter 6: Discussion- NK cell activation and evasion during chronic HCV 
infection 
 
6.1 NK cells and chronic HCV infection 216 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	   x	  
List of Tables           
Chapter 1: Introduction  
1.1 Summary of reported CD4+ & CD8+ T cell responses in chronic HCV 
infection 
29 
1.2 NK cell activating and inhibitory receptors 33 
1.3 Summary of reported NK cell phenotype in chronic HCV infection 
compared to healthy donors 
49 
1.4 Summary of phenotypic changes upon intrahepatic NK cells in subjects with 
chronic HCV infection  
53 
1.5 Published reports NK cell function in HCV compared to healthy donors 56 
   
Chapter 2: Materials and Methods  
2.1 Donor Characteristics 65 
2.2 Antibodies used for flow cytometry 76 
2.3 Adenovirus vector expressed HCV proteins and primers 86 
2.4 Adenovirus vector sequencing primers 94 
2.5 Reagents and suppliers 100 
   
Chapter 5: Identification of NK cell evasion strategies employed by HCV  
5.1 Summary of HCV proteins expressed in HFF and HEK 293 cells using 
adenovirus vectors 
201 
   	  
 
   
   
 
  
 	   xi	  
Abbreviations 
a.a   amino acid 
ADCC   Antibody Dependent Cell-mediated Cytotoxicty 
ALT   Alanine aminotransferase 
APC   antigen presenting cell 
BAC   Bacterial Artificial Chromosome 
BAT 3   HLA-B associated transcript 3 
BCR   B-cell antigen receptor 
bp   Base pair 
BSA   bovine serum albumin 
CAR   Coxsackie virus and adenovirus receptor 
CBS   Central Biotechnology Services 
CD   Cluster of differentiation  
cDNA   complementary deoxyribonucleic acid 
Cr   Chromium 
DAP12  DNAX-activation protein 12  
DC   Dendritic cell 
DMEM  Dulbecco’s Modified Eagle Medium 
DMSO   Dimethyl sulphoxide 
DNA   Deoxyribonucleic acid 
dNTPase  monodeoxyribonucleoside triphosphate hydrolase 
DTT   dithiothreitol 
EDTA   ethylenediaminetertraacetic acid 
FCS   Fetal Calf Serum 
FMO   Fidelity minus one 
FNA   Fine needle aspiration 
H&E   Haematolxylin and eosin 
HAV   hepatitis A virus 
HBV   hepatitis B virus 
HCC   Hepatocellular carcinoma 
HCMV  human cytomegalovirus 
HCV   Hepatitis C virus 
HDACi  Histone deactylase inhibitors 
HF   human fibroblast 
HFF   human foreskin fibroblast 
HIV   Human Immunodeficiency Virus 
HLA   Human Leukocyte Antigen 
HRP   horseradish peroxidase 
IFN   Interferon 
IFNα   Interferon alpha 
IL   Interleukin 
ISGs   Interferon stimulated genes 
ITAM   immunoreceptor tyrosine activation motif 
 	   xii	  
IVDU   Intravenous drug use/user 
JAK   Janus kinase 
JFH-1   Japanese Fulminant Hepatitis -1 
KIR   Killer cell immunoglobulin like receptor 
LAMP-1  Lysosomal-associated membrane protein-1 (CD107a) 
LB   Luria-Bertani media 
LCMV   lymphocytic choriomeningitis virus 
LLT1   Lectin-like transcript 1  
MCMV  mouse cytomegalovirus 
MFI   mean fluorescence intensity 
MHC   Major Histocompatability Complex 
MICA   MHC class I chain-related A 
MICB   MHC class I chain-related B 
MOI   multiplicity of infection 
MxA   myxovirus resistance 1 
NANBH  Non A, Non B Hepatitis 
NCR   Natural cytotoxicity receptor 
NK   Natural Killer cell 
NP40   nonyl phenoxypolyethoxylethanol 
NS   Non-structural 
OAS-1   2-5 oligoadenylated synthase-1 
ORF   Open reading frame 
PBMC   Peripheral blood mononuclear cells 
PBS   Phosphate buffered saline 
PCR   polymerase chain reaction 
pfu   plaque forming units 
PKR   double stranded RNA-dependent protein kinase 
PMA   phorbol 12-myristate 13-acetate 
pSTAT  phosphorylated signal transducer and activator of transcription 
RNA   Ribonucleic acid 
RPM   revolutions per minute 
RPMI   Roswell Park Memorial Institute media 
STAT   signal transducer and activator of transcription 
SVR   sustained viraemic response 
TAE   Tris, acetic acid and EDTA buffer 
TH1   T helper 1 
TH17   T helper 17 
TH2   T helper 2 
TRAIL  Tumor necrosis factor-related apoptosis induced ligand 
TRIS   tris(hydroxymethyl)aminomehtane 
UHW   University Hospital of Wales 
UTR   Untranslated region 
VSV   vesicular stomatitis virus 
SOCS-1  Suppressor of cytokine signalling-1 
 	   1	  
 
 
 
Chapter 1: 
Introduction
Chapter 1:   Introduction 
 
	   2	  
1.1  Hepatitis C virus from syndrome to identification 
In the 1940s it was recognised that hepatitis could be transmitted by enteric infection or 
by vertical transmission. These two infections were originally named “infectious 
hepatitis” and “homologous serum hepatitis” 1 and subsequently renamed type A and type 
B hepatitis respectively. In 1967 a DNA virus was identified as the causative agent of 
hepatitis B and was the first member of the Hepadnaviridae family of viruses.2 Shortly 
after this discovery it was established that an acute Picornaviridae infection causes 
hepatitis A. These discoveries allowed the development of serological diagnosis of viral 
hepatitis. However, it was noted that hepatitis occurred following transfusion, injection of 
Factor VIII concentrate and on haemodialysis units in the absence of serological markers 
for hepatitis A or B viruses; this disease was named “non-A, non-B hepatitis” (NANBH).3  
 
Unlike hepatitis A virus (HAV) infection NANBH established a chronic disease in a 
similar pattern to hepatitis B virus (HBV). Initially the disease was described as milder 
than HBV, with lower elevations in transaminases and bilirubin and a reduced incidence 
of jaundice. However, it was recognised that fulminant hepatic failure could occur with a 
50% mortality rate.4 Further evidence that NANBH was infectious was gathered from 
chimpanzee models in which a chronic transaminitis disease state, with similar 
histological changes to NANBH, was induced following inoculation of blood products 
from patients with NANBH. In the same study it was demonstrated that the infectious 
agent responsible was susceptible to lipid solvents and could pass through 80nm filters 
suggesting a small-enveloped virus.5 
 
Plasma with a high NANBH infectious titre was derived from infecting chimpanzees with 
NANBH serum. Choo et al constructed a library of complementary DNA (cDNA) by 
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inserting nucleic acids from chimpanzee plasma, which was known to contain a relatively 
higher infectious titre, into a bacteriophage using random reverse transcriptase primers.  
The resulting library of 106 recombinant phage was screened with the serum of a chronic 
NANBH patient as a source of antibodies to reveal rare clones. A larger overlapping clone 
was then derived from the library. Failure to hybridise cDNA with human and 
chimpanzee DNA by Southern blot analyses, confirmed a non-host non-human clone. The 
cDNA clone hybridised with RNA from the infected liver confirming the presence of an 
RNA virus as the cause of NANBH.6 At the time of discovery the causative virus was 
estimated to be 5000 to 100000 nucleotides with a single open reading frame (ORF) and 
was designated hepatitis C virus (HCV). The ability to clone HCV allowed the same 
group to coat micro-titre plates with the resulting polypeptide to develop an assay to 
measure serum antibody levels thus giving a diagnostic test for HCV.7 The discovery of 
HCV identified a major human pathogen that causes significant global mortality and 
morbidity and forms a major focus of hepatology, virology and immunology.  
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1.2 Classification and structure of HCV 
HCV forms the hepacivirus genus of the Flaviviridae family of viruses; the other genuses 
are flavivirus, which includes Dengue and Western Nile virus, pestiviruses and hepatitis G 
virus (Figure 1.1). More than 100 strains of HCV have been identified and the HCV has 
been grouped into 6 genotypes.  
 
Flaviviridae are positive sense RNA viruses, thus the open reading frame of the virus can 
be directly translated into peptides by the host ribosomes without further modification. 
HCV has an RNA genome of approximately 9600 bases. The ORF consists of 9000 bases 
and encodes a single polypeptide which is then cleaved to form core protein, envelope 
proteins 1 & 2 (E1 & E2) and non-structural proteins p7, NS2, NS3, NS4 and NS5A and 
B (Figure 1.2). At either end of the ORF there are untranslated regions (UTR), which are 
required for viral replication. At the 5’ UTR there is a clover-leaf shaped RNA structure 
that inserts into the host ribosome and binds to ribosomal RNA to initiate the viral 
translation.8 
 
HCV is replicated by an RNA polymerase, which lacks a mechanism for screening for 
translation errors and thus, has an error rate of 1 in 10,000-100,000 base pairs copied.9 
This error rate combined with the high rate of virus production of 1012 virions per day 10 
results in a wide diversity of RNA sequences or viral quasi-species found in the same 
individual. This diversity is more apparent between geographic areas has resulted in the 
six major genotypes of HCV being defined with 30-35% difference in the nucleotide 
sequences between the genotypes.11  
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Hepatitis G virus, genetically the most similar flavivirus to HCV, remains to be fully 
defined both phylogenetically and as a human pathogen.12 Recently Stapleton and 
colleagues have proposed that hepatitis G forms a novel flavivirus genus of Pegivirus.13 
Pegiviruses are positive sense single strand RNA viruses, which appear to transiently 
infect horses and establish chronic infections in multiple rodent species.12,14 At present the 
relationship between HCV and pegiviruses and the potential of pegiviruses to provide 
animal models of HCV remains to be fully established.  
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Figure 1.1. Flaviviridae phylogenic tree 
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Figure 1.2 HCV polyprotein and cleaved proteins 
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1.3  Epidemiology of HCV infection 
HCV genotypes are most commonly found originating from distinct geographical regions. 
Genotypes 1, 2 and 3 most commonly seen in Europe and North America, genotype 4 in 
the Middle East, genotype 5 in Africa and genotype 6 in Asia (Figure 1.3). World Health 
Organisation estimates of the prevalence of HCV infection are approximately 2-3% of the 
global population, representing 130 million individuals.15,16 The global prevalence is 
estimated from nationally reported seroprevalence in blood donors and individuals with 
chronic liver disease and varices. There is marked variation between countries from a 
prevalence of less than 0.5-2% in the United States and Western Europe, 2-3% in Russia 
and Eastern Europe, 2.5-6.5% in India and Pakistan and the highest reported 
seroprevalence, 22%, is from Egypt.15 
 
HCV transmission 
HCV transmission is often associated with blood borne spread. In England, prior to the 
identification of HCV, 1 in 520,000 blood donations were HCV infected. However, after 
the introduction of blood product screening in 1991 the incidence of HCV contaminated 
blood products has reduced to an estimated 1 in 30 million transfusions.17 Currently the 
primary mode of transmission in United States and Europe is intravenous drug use 
(IVDU). A prospective study of a British cohort found a rate of HCV infection of 41.8 per 
100 IVDU years compared to 4.2 per 100 IVDU years for HIV infection.18 Unsafe 
therapeutic injections remain a source of HCV outbreaks in lesser-developed countries 
and historically therapeutic injections have been a major source of HCV transmission. 
The most striking example of iatrogenic spread is from the Egypt; reuse of contaminated 
glass syringes during schistosomiasis treatment campaigns have resulted in a HCV 
seroprevalence of 22%.19 Similarly, prior to 1990, haemodialysis was a major source of 
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iatrogenic HCV infection with transmission rates of 20-30% in Europe.20 Perinatal spread 
of HCV is thought to be low and transmission is estimated to be 6% with an increased risk 
in mothers with a high viral load.21 Sexual activity is also associated with low risk of 
HCV transmission and data from an Egyptian cross-sectional survey of seroprevalence 
suggested that 6% of transmissions were among spouses.22 Occupational spread is thought 
to occur rarely and observed risk of transmission from a contaminated needle stick injury 
is less than 1%.23 
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Figure 1.3.  Global distribution of HCV genotypes 
 
 Genotype 1 and to a lesser extent Genotype 2 (denoted by blue line         ) predominates 
in the Americas Europe and northern Asia. 
Genotype 3 (denoted by orange line            ) originates from the Indian subcontinent 
although it is also prevalent within intravenous drug users in Europe and the United Sates. 
Genotype 4 (denoted by green line  ) predominates in Egypt and the Middle East. 
Genotype 5 (denoted by red line  ) predominates in Southern Africa 
Genotype 6 (denoted by black line   ) predominates in the Far East 
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1.4 HCV in Wales 
Antibody screening suggests that approximately 14,700 individuals (0.5% of the 
population) have been infected with HCV in Wales.24 Public Health Wales estimates that 
approximately 12,000 individuals (0.4% of the population) have chronic HCV infection. 
The annual incidence of confirmed cases is 6-15 cases per 100,000 population between 
2003 and 2013 with marked geographical variation (Figure 1.4).24 Ninety per cent of 
chronic HCV infections in Wales are estimated to result from intravenous drug use. 
Within Cardiff it is estimated that two thirds of HCV infections are genotype 1 and the 
majority of the remainder are genotype 3. The geography of Wales appears to impact 
upon the distribution of HCV. Unsurprisingly rural Powys has the lowest rate of HCV in 
Wales. The Taff Valley has predominantly genotype 1 patients whilst the neighbouring 
Rhondda valley which lies parallel to the west has an almost exclusively genotype 3 HCV 
population. The incidence of these 2 genotypes represents an example of infection spread 
following the majors routes of communication (rail and road), which run north-south to 
Cardiff from both valleys with poor transport links over the central ridge.   
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Figure 1.4: HCV in Wales 
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1.5  Natural history of HCV infection 
HCV is a major cause of cirrhosis, liver failure and HCC. Acute HCV infection is usually 
asymptomatic and frequently not identified. Following transfusion related transmission, 
with inherently high inoculating viral loads, symptoms occur in 20-30% of individuals 
and include general malaise, anorexia, tiredness and jaundice. ALT levels can reach 10 
times the upper limit of normal indicating significant hepatocyte necrosis 2-8 weeks 
following transfusion.25 Persistent infection occurs in 70-80% of individuals in whom 
infection is confirmed by seroconversion (Figure 1.5).  
 
Persistent chronic HCV infection is often silent for 20-30 years. During this time there 
may be mild elevations in serum transaminases. Diagnosis of HCV often occurs after 
raised transaminases are noted, leading to screening investigations for the potential causes 
including HCV, or by screening high-risk groups such as prisoners with an IVDU history. 
Of these individuals with chronic HCV infection the replication of virus within the liver is 
not directly cytopathic. However, in 20% of infections the chronic inflammatory response 
can result in advanced fibrosis and cirrhosis. HCC in chronic HCV infection results from 
the increased turn over of hepatocytes and hepatic inflammation and occurs at the rate of 
approximately 1% per year.26 The standardised mortality rate of viral hepatitis related 
cirrhosis and its complications, including portal hypertension and liver failure, is 
approximately 10 times that of the general population in the first year after hospital 
admission. This mortality rate has remained unchanged in the UK between 1968 and 
1999.27 Factors that increase the risk of cirrhosis and liver failure are male sex, HIV / 
HBV co-infection and alcohol excess. 
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Figure 1.5: The natural history of HCV infection 
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1.6  HCV – current treatments & recent advances 
The main therapeutic strategy in the management of HCV infection is to intervene during 
the chronic infection to avoid the development of established cirrhosis, liver failure or 
HCC. The aim of treatment is to successfully clear the virus from the body and is 
demonstrated by the undetectable viral PCR both at the end of treatment and 6 months 
following the completion of treatment. This is termed sustained viraemic response (SVR). 
Initially in the late 1980s IFNα was used to treat NANBH and HCV,28 but with poor 
levels of success. The introduction of pegylated IFNα given weekly and the inclusion of 
ribavirin, a nucleoside inhibitor, has led to better treatment responses (Figure 1.6).29 
Approximately 40-50% of patients with genotype 1 and 80% of genotypes 2 and 3 
infection successfully achieve SVR with treatment. Over the last decade new protease 
inhibitors (telaprevir and boceprevir) have been developed and found to increase 
treatment success in selected genotype 1 patients.30,31 Early viraemic response, a 2log 
reduction in viral load at 12 weeks, is associated with SVR and a negative viral PCR 
allows reduction of the length of treatment.32 Currently treatment regimens last 12-24 
weeks for genotype 2 and 3 patients and 24-48 weeks for genotype 1 patients depending 
on the initial response to treatment. Standard IFNα and ribavirin treatment is complicated 
by side effects in up to 75% of patients including anaemia, rash, psychiatric disturbances 
(depression, psychosis), flu-like malaise, nausea and vomiting, autoimmune illness 
(Graves’ disease, rheumatoid arthritis and vasculitits) and birth defects related to 
ribavirin. The addition of protease inhibitors markedly increases the risk of adverse 
reactions particularly anaemia and rash and increase the early discontinuation of treatment 
in 21% of patients compared to 11% of patients receiving IFNα and ribavirin alone.30 
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Figure 1.6: Advances in the treatment of chronic HCV 
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1.7 Assessing liver disease in chronic HCV infection 
Liver biopsy remains the clinical gold standard to assess liver fibrosis and inflammation 
and can provide invaluable diagnostic information. However, there is a mortality and 
morbidity associated with liver biopsy underlined by the recent interest and development 
of biochemical and non-invasive markers (i.e. liver elastography) to assess chronic liver 
disease.33 Percutaneous liver biopsy has a mortality rate of 1 in 10,000 and the most 
common complication is abdominal or right shoulder pain in 25% of patients.34 Whilst the 
parenchyma of the liver has a relative paucity of nerve fibres, the liver capsule is well 
innervated and together with the skin requires infiltration with lignocaine local 
anaesthetic. In spite of this some patients may require simple (or occasionally opiate) 
analgesia. Other risks associated with liver biopsy include bleeding (blood transfusion rate 
of 1%), pneumothorax, perforation of the bowel and gallbladder and peritonitis.34  
 
Inflammatory lymphocytes and polymorphs appear to drive many chronic liver diseases 
including viral hepatitis, autoimmune hepatitis and steatohepatitis. When studying these 
disorders it is recognised that peripheral blood lymphocytes may only reflect the function 
and phenotype of inflammatory cells within the liver. Fine needle aspiration (FNA) has 
been used as a research tool to sample intrahepatic lymphocytes but is not used 
clinically.35  
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1.8 Summary of outstanding clinical problems in the management of HCV  
In spite of the huge improvements in knowledge of the pathophysiology of HCV infection 
and marked improvements in treatment of the chronic disease several key clinical 
problems remain: 
• Recent advances in treatment result in SVR rates of 80%. However, 1 in 5 patients 
are unable to clear the chronic infection with treatment. 
• It is not possible to accurately identify patients who will fail treatment. 
• It is currently not possible to identify patients who are unlikely to develop the 
serious sequalae of cirrhosis and liver failure. This group may in fact benefit from 
an active monitoring programme rather than a long and difficult treatment, which 
is associated with serious complications  
• Current treatments are expensive and a considerable associated morbidity and 
mortality. 
• Anti-HCV vaccination remains elusive. 
• The exact mechanisms of IFNα based treatment are unknown. It is not clear if 
those who achieve SVR are at risk of HCV re-infection. 
 
These factors remain serious clinical problems and the basis of a broad body of ongoing 
research. 
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1.9  The innate and adaptive immune systems 
Historically the immune system has been broadly divided into the innate and adaptive 
immune responses. In this paradigm the innate immune responses are non-specific to a 
variety of pathogens whilst the adaptive immune responses are specific to an antigen or 
group of antigens. Innate immune responses have a rapid onset and are able to control an 
infection whilst adaptive immune responses develop over an extended period of time. The 
significant advantage of the adaptive response is specific lasting protective memory 
responses that prevent the clinical illness of repeated infection. It is evident however, that 
this is a simplified model and there are complex and elegant interactions between these 
two components of the immune system with significant functional overlap (described in 
detail in Section 1.13). Effective innate and adaptive immune responses are 
interdependent and are both essential for the maintenance of health. 
 
In the context of viral infections innate immune responses are characterised by cytokine 
and cellular responses. Interferons (IFN) are powerful anti-viral cytokines and have a 
direct anti-viral effect, induce apoptosis in infected cells and a broad range of responses in 
a variety of effector immune cells. The effector cells of the innate immune system include 
natural killer (NK) cells, which produce cytokines and can recognise and kill virally 
infected cells through release of cytotoxic granules. NK cells recognise infected cells 
through a series of receptors expressed on the cell surface. The control of the NK cell 
repertoire is described in detail below. Innate-like lymphocytes, which include natural 
killer T (NKT) cells and γδ T cells, have a limited repertoire of antigen receptors. These 
cells are able to respond to a series of pathogen related peptides and rapidly induce 
cytokine production. 
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Macrophages and dendritic cells form an important bridge between the innate and 
adaptive immune systems and are termed professional antigen presenting cells (APCs). 
APCs are rapidly activated during viral infections and are further stimulated by cytokines 
produced by the innate immune response. APCs are able to phagocytose virally infected 
cells and process viral antigens, which are presented to naïve T lymphocytes.   
 
Naïve B lymphocytes possess immunoglobulin receptors (B-cell antigen receptor; BCR) 
that express highly specific binding sites to a huge range of chemical structures ranging 
from proteins and glycoproteins to viral particles and bacterial cells in the presence of co-
stimulatory molecules. Upon binding to viral antigen the BCR initiates intracellular 
signalling pathways, which induce B cell proliferation and differentiation into antibody 
secreting cells and memory B cells. B cells may also act as APCs for naïve T cells as the 
bound antigen is processed and presented on the surface bound to MHC class II. 
Alternatively CD4+ T effector cells may recognise the peptide:MHC class II complex and 
secrete cytokines that stimulate B cell proliferation. 
 
T lymphocytes express antigen specific receptors (T-cell receptors; TCR) upon the cell 
surface. Naïve T lymphocytes require antigen to be presented upon MHC class I / II 
molecules by APCs to differentiate into two broad subtypes of T effector cells. CD8+ 
cytotoxic T cells recognise antigen bound to MHC class I molecules and are able to kill 
virally infected cells bearing their cognate antigen. Helper T cells express the marker 
CD4, which binds to antigens presented upon MHC class II molecules, engage in 
coordinating the immune response. Within the CD4+ T cell population there are a number 
of subsets that perform different functions. The phenotype and function of these subtypes 
are controlled by transcription factors, as described below, giving certain characteristics 
Chapter 1:   Introduction 
 
	   21	  
of stable lineages. However, potential plasticity in the transcription factors allows some 
flexibility in CD4+ T cell responses.36 TH1 cells express transcription factor T-bet and 
stimulate macrophages, CD8+ and B cells through IFNγ and IL2 production. In addition to 
activation of these anti-viral effector cells IFNγ also has a direct antiviral role. TH2 cells 
express Gata3 and secrete IL4, IL5 and IL13. IL4 production stimulates B cells to produce 
IgE, a critical factor in immunity to multicellular helminths. TH17 cells express 
transcription factors STAT3 and RORγT and mediate host neutrophil responses to 
extracellular bacteria and fungi through IL17, IL6, IL1 and TNFα production. TReg cells 
express FoxP3 and control the immune response predominantly through IL10 and TGFβ 
to prevent immunopathology. The clonal expansion of activated adaptive immune cells, 
such as T and B cells, can result in memory to pathogen specific antigens.37 
 
As discussed in detail below robust CD4+ T cell adaptive immune responses are crucial to 
the successful spontaneous clearance of acute HCV infection. In chronic HCV infection 
and during the successful IFNα based treatment of HCV the role and relative importance 
of the innate and adaptive immune responses are less clear.  	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1.9 Interferons and viral infection 
IFNα has been central to anti-HCV therapies since the 1980s, when it was proposed that a 
virus was the cause of NANBH. Issacs and Lindenmann first described IFN in 1957 as an 
inhibitor of influenza virus growth.38 IFNs are cytokines that form a potent part of the 
immune armoury against viral infections and can be divided into type I (IFNα, β and ω), 
type II (IFNγ) and type III (IFNλ).  Type I IFN are encoded on chromosome 9, there are 
over 13 recognised IFNα subtypes whilst IFNβ and IFNω each comprise a single subtype. 
Virally infected cells including endothelial cells, epithelial cells and fibroblasts release 
type I IFN, as do lymphocytes and plasmacytoid dendritic cells.39 Lymphocytes may be 
activated by type I IFNs augmenting the immune response to viral infection.40 IFNγ is 
produced by activated lymphocytes and serves to coordinate and promote inflammatory 
responses. In addition IFNγ has direct anti-viral effects and potentiates the effects of type 
I IFNs.41 IFNλ acts in a similar manner to IFNα but primarily targets epithelial cells, 
which express its receptor.42,43 
 
IFNα has a direct anti-viral role stimulating a cascade of gene transcription factors that 
interfere with viral replication and can induce apoptosis of infected cells.44 IFNα binds to 
the ubiquitous cell surface type I IFN receptor and signals through the JAK-STAT 
pathway. The JAK-STAT pathway is a major signalling mechanism for a broad range of 
cytokines, including interferons, erythropoietin and growth hormone that direct cell 
growth, metabolism and immunoregulation.45 Binding of IFNα to the type I receptor 
drives JAK and STAT phosphorylation resulting in the active pSTAT 1 molecules. 
pSTAT 1 traffics to the nucleus where it up regulates the expression of interferon 
stimulated genes (ISGs) which drive an antiviral state. The range of ISGs and their 
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functions have not been fully identified although the following proteins have been 
implicated as important in viral infections including HCV:  
 
• myxovirus resistance 1 (MxA), a cytoplasmic protein that binds to cytoskeleton 
proteins, acts as a guanonsine triphosphatase and inhibits intracellular the transport 
of RNA viral capsids.46,47 
• 2-5 oligoadenylate synthetase-1 (OAS-1) binds to double stranded RNA of viral 
origin, which it breaks down.48,49 
• Double stranded RNA-dependent protein kinase (PKR) inhibits viral replication 
upon binding to double stranded RNA.48  
 
The intrahepatic expression of ISGs during HCV infection varies between individuals. 
The initiation of IFNα treatment can induce varying relative increases of ISG expression 
to a maximal level. Individuals with low expression of ISGs at baseline in whom IFNα 
treatment induces marked up regulation of ISG expression are more likely to achieve SVR 
than those who have a higher expression at baseline line with a lower relative increase 
during treatment.50,51  
 
IFNλ3 & -4 in HCV infection 
Genome wide association studies (GWAS) are an analysis of genetic epidemiology that 
compares multiple genetic variations within a study population. Commonly a case-control 
design is used and the prevalence of susceptibility alleles, usually single nucleotide 
polymorphisms (SNPs), is compared.52 In September 2009 an association was made 
between spontaneous- and treatment-induced HCV clearance and polymorphisms in the 
IFNλ gene.  A SNP polymorphism (rs1279860) 3 kilobases upstream from the IFNλ3 
gene, on Chromosome 19, was associated with spontaneous clearance of HCV infection. 
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C/C genotype (as opposed to T/T) was found to be favourable in European, Asians and 
Africans, although the C/C polymorphism was far more common in those of European 
and Asian ancestry.53 The same polymorphism was found to be strongly associated with 
IFNα based treatment induced HCV clearance, providing a potential explanation for the 
higher SVR rates found in Europeans and Asians compared to those of African ancestry.54 
Further GWAS studies from Japan, Australia & Europe and Switzerland identified further 
SNP polymorphisms upstream from the IFNλ3 gene (rs809917 and rs4803217, G/G 
favourable compared to T/T in both) associated with SVR response to HCV treatment.55-57 
The exact mechanisms of how these polymorphisms impinged upon viral clearance were 
not immediately clear.  
 
The HCV associated IFNλ3 SNP rs1279860 has been reported to be in strong linkage 
disequilibrium with a dinucleotide variant: ss469415590.58 Located upstream from the 
IFNλ3, ss469415590 TT or ΔG variants result in a frame shift that creates a gene 
encoding the novel interferon designated IFNλ4. IFNλ4 induces expression of hepatoma 
cell ISGs in vitro. The ss469415590 variants were found in this study to be superior at 
predicting poor treatment outcome in individuals of African ancestry than the rs1279860 
SNP. Therefore, expression of IFNλ4 provides a mechanism for the favourable 
associations of IFNλ3 polymorphisms and HCV clearance.  
 
An alternative mechanism of favourable rs4803217 polymorphism activity may relate to 
the expression of myosin-encoding gene miRNAs by HCV infected hepatocytes. These 
miRNAs induce degradation of IFNλ3 mRNA thus reducing IFNλ3 expression. The 
miRNAs are able to bind to the unfavourable T/T, but not the beneficial G/G, 
Chapter 1:   Introduction 
 
	   25	  
polymorphism. This mechanism of HCV immunoevasion provides potential therapeutic 
applications for novel miRNA therapy.59  
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1.11 Investigation of immune response to chronic HCV 
Following the identification of HCV, it became evident that exposure to HCV virus does 
not result in seroconversion in all individuals. In 1994 the Irish Blood Transfusion service 
found that anti-Rhesus D immunoglobulin, used to prevent perinatal Rhesus 
isoimmunisation was contaminated with HCV by a single infected donor (from two 
separate donations). It is estimated that between 1880 and 6016 women were exposed to 
these samples.60 Seven hundred and four women were HCV antibody positive. Of these, 
390 were HCV RNA positive indicating a chronic infection and 314 were RNA negative 
indicating that they had spontaneously cleared the viral infection. The broad range of 
women estimated to have been exposed suggests that many women might have been 
exposed to HCV and yet did not develop an acute or chronic infection.60 Similarly in a 
carefully detailed study of 93 health care workers exposed to HCV by accidental needle-
stick injuries only 5 became infected and of these 1 spontaneously cleared the virus.61 
These studies suggest that i) exposed individuals may clear the infection by innate 
mechanisms. ii) infected subjects may clear the virus and the adaptive immune response 
may play a role. 
 
Adaptive immune responses in HCV 
The ability of CD4+ T cells to infer lasting immunity to viral infections and coordinate 
CD8+ effector T cell responses resulted in several early immunological studies focusing 
upon anti-HCV adaptive cellular responses.  
Individuals who spontaneously clear acute HCV demonstrate robust CD4+ and CD8+ 
adaptive immune response to a broad range of HCV antigens (Table 1.1).61-69 However, in 
three cohorts of individuals with acute HCV treated with IFNα CD4+ and CD8+ T cell 
responses were not associated with treatment outcome and the long-term CD4+ T cell 
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response was diminished in treated cohorts compared to those who spontaneously cleared 
without treatment.70,71 
 
Chronic HCV infection 
The association between a robust adaptive immune response in acute HCV infection and 
spontaneous viral clearance has lead to in depth immunological investigation during the 
chronic phase, and IFNα based treatment, of HCV. These investigations have 
predominantly focused upon CD4+ T cell proliferation and IFNγ ELISpot responses. 
Individuals who have spontaneously cleared HCV have increased CD4+ T cell 
proliferation to HCV antigens, with increased IFNγ and reduced IL10 production 
compared to those with chronic HCV (Table 1.1).62-65,67,72 Depletion of CD25+ regulatory 
T cells has been associated with a further increase in CD4+ T cell responses in a 
spontaneously cleared cohort but not in a chronic viraemic cohort. This suggests a failure 
of CD4+ T cell priming in chronic HCV rather than regulatory T cell suppression of 
adaptive immunity.72 In chronic untreated disease increasing magnitude of CD4+ and 
CD8+ T cell, and B cell responses, has been associated with both a more benign 65 and a 
more aggressive disease pattern.73 
Viral impingement upon DC antigen-presenting function is a potential mechanism of 
impaired T cell responses in chronic HCV infection.74 HCV surface glycoproteins E1 and 
E2 can bind to the activating receptor DC-SIGN upon dendritic cells facilitating viral 
internalisation into the non-lysosomal compartment.75 The proportion of positive and the 
negative strand HCV RNA detected in peripheral blood DCs suggests only very low-
levels of replication.76,77 HCV replication does not however, appear to be required to 
impair DC function. Core and NS3 proteins inhibit DC allostimulatory functions, 
including reduced IL12 secretion, and induce IL10 thus inhibiting T cell proliferation.78,79  
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During IFNα based treatment of HCV robust CD4+ T cell responses have been 
demonstrated in patients who achieved SVR.80,81 However, further studies did not 
demonstrate a robust lasting adaptive immune responses associated with successful 
treatment outcome.82,83 Viral genotype may impinge upon adaptive immune responses 
with genotype 1 patients having a reduced magnitude of CD4+ T cell responses (measured 
by ELISpot) compared to genotype 2 and 3 infections, which are more amenable to 
treatment.83 Robust early CD8+ T cell responses have been associated with rapid viral 
decline in the first weeks of treatment.84  
 
Initial studies were hampered by a relatively high cut off for PCR viral load detection 
assay (300-1000 IU/ml) thus rendering it difficult to confirm true viral clearance as 
opposed to viral suppression following treatment. Furthermore genotype 1 viral antigens 
are those that are available commercially but study patients have often been infected with 
a variety of genotypes, raising the possibility that immune responses have not been 
accurately measured. 
 
Taken together these data suggest that whilst a failure to mount an effective CD4+ and 
CD8+ T cell response results in a chronic infection, a significant proportion of patients are 
able to effectively clear HCV with IFNα based treatment without establishing a lasting 
robust CD4+ T cell response (summarised in Table 1.1). This raises the question of 
whether there is another cell type that has a significant effector function in the successful 
treatment of chronic HCV. NK cells represent a potential candidate as they are known to 
have an effective antiviral role and are stimulated by IFNα. 
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Table 1.1 Summary of reported CD4+ & CD8+ T cell responses in chronic HCV 
infection 
 
	  
CD4+	  T	  cells	  
	  
Spontaneously	  cleared	  
vs.	  chronic	  HCV	  
	  
	  
SVR	  vs.	  Failed	  treatment	  
Proliferation	  
	  
Boterelli	  1993	  Diepolder	  1995	  Lechmann	  1996	  Cramp	  1999	  Day	  2002	  Kamal	  2004	  Godkin	  2001	  
Lasarte	  1998	  Cramp	  2000	  
Unchanged	   	   Barnes	  2002	  Rahman	  2003*	  Kaplan	  2005	  Lauer	  2005*	  
IFNγ	  
	   Cramp	  1999	  Godkin	  2001	  Day	  2002	  Kamal	  et	  al	  2004	   Cramp	  2000	  Rahman	  2003*	  
Unchanged	   	   Barnes	  2002	  Wiegand	  2004*	  Kaplan	  2005	  Lauer	  2005*	  
IL10	   Unchanged	   Cramp	  1999	   	  
	   Godkin	  2001	   	  IL2	    	   Lasarte	  1998	  
	  
CD8+	  T	  cells	  
	   	  
Proliferation	   	   Wedemeyer	  2002	   Pili	  2007	  Unchanged	   	   Lauer	  2005*	  
IFNγ	   	   Missale	  1996	  Wedemeyer	  2002	   Pili	  2007	  Unchanged	   	   Lauer	  2005*	  *These	  studies	  investigated	  T	  cell	  responses	  during	  the	  IFNα	  treatment	  of	  acute	  HCV	  infection.	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1.12  Natural Killer cells 
Natural Killer (NK) cells are large granular lymphocytes and form part of the innate 
immune system. NK cells were first described in 1975 and derive their forceful name 
from the observed ability to destroy leukaemic cells without prior stimulation.85,86 Kärre 
et al. first proposed the mechanism of NK cell activation was by identifying potential 
target cells which lack or have reduced expression of MHC class I: the missing-self 
hypothesis.87 However, further observations demonstrated that NK cells could kill 
autologous MHC-matched tumour cells leading to a paradigm whereby NK cell activation 
is controlled by the balance of signals received from an array of inhibitory and activating 
receptors. Kärre compared this to attempts by the Swedish navy to enlist the general 
population in submarine surveillance during the Cold War. The navy felt the simplest 
approach was to publish pictures of the 3 types of Swedish submarine in service and 
requested to be notified if any other type of submarine was seen (missing-self or lack of 
inhibition activation). The tabloid press however, printed a wide range of pictures 
showing foreign submarines that could stray into Swedish waters; representing positive 
activation.88 
 
NK cell maturation and subsets 
NK cells are often defined phenotypically as lymphocytes expressing CD56, also known 
as neural cell adhesion molecule, a glycoprotein expressed on neural and skeletal muscle 
cells. In the peripheral blood NK cells make up 5-15% of the total lymphocyte population. 
CD56 expression varies on NK cells with approximately 10% of peripheral blood NK 
cells expressing high levels of CD56 (CD56Bright NK cells) and the remainder expressing 
lower levels (CD56Dim NK cells). CD56Dim NK cells are considered to represent a more 
mature subset that have greater cytotoxic potential and are able to release cytokines.89 
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CD56Bright NK cells are the first lymphocytes to reconstitute the peripheral blood 
compartment following haematopoietic stem cell transplantation.90,91 The maturation of 
NK cells from CD56Bright to CD56Dim is associated with a stepwise reduction in NKG2A 
expression and an upregulation of Killer-cell Immunglobulin-like receptors (KIR).92 Both 
of these NK cell receptors are inhibitory and further described below. 
 
A further subset of CD56- CD16+ (an FcγIII receptor described below) NK cells were 
initially described in HIV positive patients.93 These cells are thought to represent 
approximately 5-10% of peripheral blood NK cells.94 The exact role of CD56- NK cells 
remains unclear but they are thought to be more mature cells with reduced cytotoxic 
function and cytokine secretion but maintained chemokine secretion.95  
 
Mechanisms of NK cell activation and killing 
NK cells and cytotoxic T cells are thought to share mechanisms of activation and target 
cell killing. Cytotoxicity relies on formation of an immunological synapse and release of 
granules containing perforin, granzymes and Fas ligand.96,97 NK cells demonstrate a 
hierarchical functional response to increasing stimulation. Low-level stimulation may 
induce leukocyte functional antigen (LFA)-1 mediated adhesion whilst stronger activation 
is required is required for degranulation and IFNγ production, reflecting an increased 
number of signalling cascades to induce these responses.98 As in T cell activation LFA-1 
signalling rapidly promotes convergence of cytotoxic granules to the NK cell microtubule 
organising centre.99 Polarisation of lytic granules to the immunological synapse is 
dependent upon talin, WASP and CD3ζ activation, which are the result of poorly defined 
additional pathway signalling.100  Release of Ca2+ into the cytoplasm from the 
endoplasmic reticulum triggers granule exocytosis. CD16 signalling can induce Ca2+ 
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release on its own and studies of knockout mice suggest a critical role for 
phosphatidylinositol specific phospholipase C-γ (PLC-γ) dependent inositol triphosphate 
in non-antibody directed cellular cytotoxicity.101,102 PLC-γ enzymes are indispensable 
component of signal transduction complex and are also required for transcription of IFNγ 
and TNFα genes.101 
 
NK activating receptors 
NK cells can respond to activation through direct cellular cytotoxicity and the production 
of chemokines and inflammatory cytokines. NK cell activating receptors bind to ligands 
on host cells upon which proteins are up regulated in response to oncogenic 
transformation or viral infection (Table 1.2). To date not all the ligands for NK cell-
activating receptors have been identified. 
 
CD16 is an FcγIII receptor, which binds to the constant region of human antibodies and 
activates NK cells. Thus NK cells can recognise and be activated by targets that are 
antibody coated (using the constant region of the antibody).103 Signalling occurs through 
the immunoreceptor tyrosine-based activation motif (ITAM). NK cell activation in this 
manner is termed Antibody-Dependent Cell-mediated Cytotoxicity (ADCC). 
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Table 1.2 NK cell activating and inhibitory receptors 
 
Activating receptors Ligands 
CD16 Antibody Fc 
DNAM-1 (CD226) CD112, CD155 
2B4 CD48 
Natural Cytotoxicity Receptors 
NKp30 BAT3, B7H6, HCMV-pp65 
NKp44 Viral haemagglutinin and neuraminidase 
mixed-lineage leukaemia 5 protein 
NKp46 Viral haemagglutinin and neuraminidase 
heparin sulphate 
C type lectin like receptors 
NKp80 Activation induced C-type lectin 
NKG2D MICA, MICB 
CD94/NKG2C HLA-E 
 
Inhibitory receptors 
 
Ligands 
KLRG-1 E-cadherin 
Killer Ig-like receptors 
KIR2DL/ KIR3DL/ KIR2DS HLA-C /-A /-B 
C type lectin like receptors 
CD94/NKG2A HLA-E 
 
Adapted from Viver et al 2011104 and Jewett et al 2013.105  
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NKG2D is a C-type lectin-like transmembrane activating receptor that is expressed on 
NK and CD8+ T cells. NKG2D is known to bind to two stress ligands MICA or MICB.  
These ligands are up regulated on cancer cells and virally infected cells.106-108 
 
Natural Cytotoxicity Receptors (NCRs) are preferentially expressed on NK cells and are 
members of the immunoglobulin superfamily. The NCR activating receptors comprise 
NKp30, NKp44 and NKp46 and are associated with ITAM signalling. Phosphorylation of 
the NCR adaptor molecules, ITAMs, initiates the ZAP70 and SYK signalling pathways. 
These pathways lead to Ca2+ influx and cytoskeletal reorganisation resulting in 
cytotoxicity and IFNγ and TNFα production.109,110 Each NCR Ig-like domain is formed as 
a sandwich-like structure of two facing β sheets held together by conserved disulphide 
bonds. The arrangement of disulphide bonds alters the lengths of surrounding loop 
regions potentially significantly altering the Ig-like domain’s binding potential.111 NKp46 
is termed a C-like Ig receptor, which reflects a shorter a.a. residue between the disulphide 
bonds than that found in the NKp30 and NKp44, which are categorised as V-type Ig 
receptor (Figure 1.6).110,111 The importance of NCRs is underlined by acute myeloid 
leukaemia cell resistance to NK cytotoxicity in individuals with low NCR expression.112-
114 
 
NKp46, the first NCR to be identified by the Moretta group,115 is a 46kDa glycoprotein 
and consists of a single transmenbrane and two extracellular Ig-like domains. To signal 
the NKp46 transmembrane domain associates with CD3ζ and FcεRI (Figure 1.6). The 
NKp46 Ig-type domain dimerization is essential for NKp46 mediated NK cytotoxicity but 
is not found in NKp30 or NKp44.116 The NKp46 Ig-like domains are held at 85° to each 
other by a hinge region, which has been proposed as a potential ligand binding site.117,118 
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NKp46 is the only NCR with an orthologue in mice (called NCR1) and other 
species,110,117,119 the NKp46 gene is located upon chromosome 19.120 This evolutionary 
conservation suggests NKp46 expression confers a significant host advantage of pathogen 
and tumour recognition. However, whilst heparin sulphate and viral haemaggluttinins and 
neuraminidase have been identified as ligands for NKp46,121-123 other ligands have yet to 
be identified. 
 
NKp44 was the second NCR to be identified: the extracellular domain is a V-type Ig 
molecule and the intracellular domain associates with DAP12 for signalling (Figure 
1.6A).112 NKp44 is expressed at a low level unless NK cells are stimulated with 
interleukin-2 (IL-2).124 NKp44 is coded by the class III region of the MHC locus, as is 
NKp30 with which it shares similar structural properties (Figure 1.6B). Recently mixed-
lineage leukaemia-5 protein (MLL5) has been identified as a ligand for NKp44.125 
Blocking experiments suggest engagement of a single NCR can result in activation of the 
signalling cascades of other NCRs suggesting cross talk between NKp30, NKp44 and 
NKp46 during NK cell activation.112,124 
 
NKp30 is a single V-type Ig-like protein with a short 5 a.a. stalk. The transmembrane 
domain associates with CD3ζ (Figure 1.6A).126 Ligands for NKp30 have also remained 
elusive, it is known that tumour cells release nuclear factor HLA-B-associated transcript 3 
(BAT3) that binds directly to NKp30 and results in NK cell cytotoxicity.126,127 B7-H6 has 
been recognised as an activating ligand for NKp30 expressed on human K562 
erythroblastic leukaemic cells.128 Moreover, the ligands that NKp30 recognises appear to 
be distinct to NKp46 ligands as differing target cells show varying susceptibility to these 
activating molecules.129 Following activation by mature DCs NK cells can kill immature 
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DCs in an NKp30-dependent manner, representing an important step in the development 
of a coordinated immune response.130 Jarahian et al. demonstrated in a mouse poxvirus 
and human fibroblast model that ectromelia virus haemagglutinin serves as a ligand for 
NKp30 and, to a lesser extent, NKp46. In vaccinia infection viral haemagglutinin blocks 
NKp30 activation, through an unknown mechanism, whilst NKp46 activation is retained 
resulting in reduced NK cell activation.121 These results demonstrate a viral 
immunoevasion mechanism for the NCR receptors. 
 
NK inhibitory receptors 
NK cells were first defined by their cytotoxic activity against tumour cells lacking MHC 
class I molecules. Thus the presence of MHC class I inhibits NK cells and loss of 
inhibition results in NK cell activation.87 MHC class I molecules are part of the Human 
Leukocyte Antigen (HLA) complex and comprise six proteins encoded in a highly 
polymorphic region of chromosome 6. Of the HLA genes, HLA-A, -B and -C are 
polymorphic and HLA-E, -F and -G are conserved. NK cells recognise and are inhibited 
by HLA-A, -B and -C through Killer cell immunoglobulin-like receptors (KIRs) and 
HLA-E by NKG2A an inhibitory C-type lectin-like receptor.131 
 
Development of the NK cell repertoire 
The KIR locus, on Chromosome 19 encodes 13 different genes and there is marked 
polymorphisms within KIR genes.132 Each NK cell expresses an individual repertoire of 
KIR with potential for differing receptor expression as well as number and combination of 
KIRs.133 The expression of KIR genes can be induced by cell-to-cell contact signalling 
between NK progenitors and bone marrow-derived stromal cells.134 It remains unclear, 
however, if tolerance of compatible HLA class I is induced at this stage of NK cell 
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development. The expression of endogenous KIR within NK clones is further dependent 
upon DNA methylation, which can silence KIR genes.135 Exposure to CMV infection, but 
not other herpes viruses, may educate NK cell populations to induce stable expression of 
particular KIR genes, resulting in an increase in self-specific inhibitory KIR expression.136 
The impact of chronic HCV infection upon KIR expression independently to CMV 
infection remains to be elicited.137 
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Figure 1.7  NCR structure and signalling motifs 
A) 
 
The external domains of NKp30 (green) NKp44 (blue) and NKp46 (purple) with 
disulphide bonds are shown in yellow. The cell membrane (blue) and cytoplasm (grey) 
with the specific NCR intracellular signalling motifs: NKp30 & NKp46 - CD3ζ & FcεRIγ 
and NKp44 – DAP12. Arrow indicates NKp46 dimerization hinge joint. Adapted from 
Koch et al 2013.110 Ribbon cartoons created by Dr Chris Holland, Cardiff University 
using PyMol software (SourceForge.net). 
 
 
 
B) Overlay ribbon cartoon of NKp30 (green) and 
NKp44 (blue) demonstrating NK activating receptor 
homology. 
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1.13 NK cells and the adaptive immune response 
Activated NK cells contribute to the development of a specific long-term adaptive 
immune response as well as providing an immediate innate immune response. Virus-
specific CD4+ T cells play an important role in the control or elimination of viral 
infections. The development of adaptive immune responses requires a longer period of 
time than those of the innate response. T cell priming may start within a few hours of 
infection if viral antigen penetrates the peripheral lymphoid compartment and appropriate 
co-stimulation is given to T cells.138 However, in certain infections, such as HCV, T cell 
priming may be delayed by several weeks, the reasons for the delay being unclear.61 After 
the virus specific CD4+ T cells have received the necessary stimulation there is a short 
lag-phase before they undergo clonal expansion over 7-10 days.139  
 
Natural Killer and Dendritic cell cross talk 
NK cells can directly and indirectly augment the development of the adaptive immune 
response. NK cell release of IFNγ and proinflammatory cytokines in viral infections can 
promote antigen processing and presentation to T cells.140 IFNγ release will polarise the 
inflammation towards a TH1 cell responses.141 In a mouse influenza model Ge et al. 
demonstrated that NK cell depletion reduces DC antigen presentation and limits the 
recruitment of both DC and T cells into the thoracic draining lymph nodes in an IFNγ-
dependent manner.142 DC stimulation may further promote NK activation through the 
release of inflammatory cytokines (IL-2, IL-12 and IL-18) by DCs.141 This bidirectional 
stimulation between DCs and NK cells is the of MCMV immunoevasion. Mandaric et al 
have demonstrated that MCMV IL-10 suppresses NK-DC cross talk and therefore, 
reducing IL-12 expression which results in CD4+ T cell suppression.143 
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 In addition to stimulation of DCs NK cells can further promote a robust specific adaptive 
immune response through the lysis of immature DCs expressing MHC class I at lower 
levels than mature DCs in a NKp30 dependent manner.130 This is a potential feedback 
mechanism to ensure a limited supply of DCs to prime a focused, co-ordinated immune 
response. 
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1.14 NK cell memory 
Immunological memory describes the ability of certain cell to mount a greater, faster 
response following repeated antigen exposure. Classical antigen-specific memory 
responses mediated by B cells and T cells are the hallmark of adaptive immunity. 
Traditionally NK cells have been thought to belong solely to the innate immune system 
without adaptive immunological features such as memory. However, there is evidence, 
from mouse models that NK cells can demonstrate features of memory responses to 
highly diverse antigens.144  
 
O’Leary et al. demonstrated that following initial contact exposure (sensitisation) T and B 
cell deficient mice can mount an antigen-specific hapten induced contact hypersensitivity 
response up to 4 months following initial exposure.145 This memory was observed after 
adoptive transfer of NK cells to naïve mice. The NK cells, which demonstrated the hapten 
specific response, were Ly49C(+/-)I+ and localised to the donors’ livers but not spleens 
potentially reflecting functionally distinct NK cells within different tissues. 
 
Mouse NK cells can acquire long-lived (up to 12 weeks) memory of MCMV, VSV, 
influenza A and HIV-1 following vaccination and rechallenge.146,147 Previous exposure to 
influenza antigen conferred a survival benefit compared to naïve mice when inoculated a 
lethal dose of influenza A, however, the cognate antigen remained unclear. Again the 
memory NK cells localised to the donors’ livers following adoptive transfer and expressed 
the chemokine CXCR6.146 The ligand for CXCR6 is CXCL16, which is constitutively 
expressed within the liver sinusoidal endothelium. Antibody blockade of CXCR6 
inhibited NK cell responses to haptens and viruses in vivo although CXCR6 blockade did 
not impinge upon hapten recognition in vitro. These data suggest CXCR6 is crucial for 
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memory NK maintenance in vivo rather than function.146  In a mouse model of MCMV 
infection, Sun and colleagues identified m157 as the antigen, which drove a memory 
population of Ly49H expressing memory NK cells.147 Whether there are antigens that 
induce NK memory responses in human disease and if they are truly needed remains to be 
demonstrated.148  
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1.15 NK cell responses to HCV exposure & acute infection 
There is a body of evidence suggesting that NK cells can play a protective role in 
preventing HCV viraemia and seroconversion following exposure. Golden-Mason et al 
compared a cohort of 25 intravenous drug users who were repeatedly exposed to HCV; 11 
remained uninfected and 14 became infected over a median time course of 90 days. It was 
found that exposed but uninfected cohort of individuals had a higher proportion of 
CD56Dim cytotoxic NK cells, higher activating receptor NKp30 expression and ex vivo 
cytotoxic function than individuals who seroconverted following exposure.149  
 
HLA-C molecules, the ligands for the inhibitory KIR receptors can be divided into C1, 
which binds to KIR2DL2 and KIR2DL3, and C2, which binds to KIR2DL1.150 The 
relative binding strength of these HLA-C and KIR interactions vary as laid out below 
(Figure 1.7). The NK cell inhibitory receptor KIR2DL3 forms a weak bond with its 
cognate HLA-C ligand and can be overcome more easily than the other HLA-KIR 
combinations. This promotes activation of NK cells in individuals during viral infections. 
In a study of intravenous drug users exposed to HCV Knapp et al. demonstrated that 
KIR2DL3 homozygous individuals with the HLA-C1 were more likely to remain 
seronegative and aviraemic than other exposed individuals (odds ratio 3.1).151  
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Figure 1.8  HLA – KIR inhibitory interactions 
 
HLA-C KIR interactions bind with varying strengths resulting in a activating/ inhibitory 
hierarchy. The KIR2DL3 – C1 genotype is protective against chronic HCV infection and 
confers greater treatment success rates. Adapted from P. Parham 2005.150 
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Acute HCV infection 
The role of NK cells in acute HCV infection, confirmed by seroconversion remains to be 
fully elucidated.  A genetic study of over a thousand anti-HCV antibody positive 
individuals shows that HLA-C1 allele and KIR2DL3 genotype confers protection against 
chronic HCV infection at low dose exposure but at high dose exposure the authors found 
no association. The authors concluded that the innate immune response was overwhelmed 
by the high dose of virus.152 In a study of 22 individuals with acute HCV infection 
Amadei et al. reported an increase in expression of activating receptor NKG2D on NK 
cells and IFNγ in all individuals regardless of self-limiting infection or progression to a 
chronic infection. Subgroup analysis of HLA-C1 specific KIRs revealed that NK cells 
expressing these receptors demonstrated increased cytotoxicity, which was maximal in 
individuals who spontaneously cleared the infection.153  
 
A further examination of peripheral blood NKs during acute HCV infection by Alter and 
colleagues indicated that the proportion of lymphocytes that are NK cells increases. The 
expression of the activating receptors NKp30 and NKp46 were reduced and NKG2A and 
CD94 were increased during acute HCV infection. Of note individuals who achieved viral 
clearance during the acute infection (i.e. became HCV antibody positive but HCV RNA 
negative) had lower expression of NKp30, NKp46 and the inhibitory receptor CD161 
(which binds to LLT1 molecule) compared to those in whom a persistent infection was 
established. The authors concluded that NK cells with higher expression of NCRs may be 
trafficked to the liver resulting in a relative paucity in the peripheral blood. Furthermore 
lower expression of CD161 may result in a lower NK activation threshold and play a 
major role in the control of acute HCV infection.154  
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In conclusion acute hepatitis C virus infection is spontaneously cleared in a proportion of 
patients. The efficacious immune response may be augmented by NK cell cytotoxicity 
and IFNγ production.  
 
 
 
  
Chapter 1:   Introduction 
 
	   47	  
1.16 NK cells in chronic HCV infection 
For over 15 years NK cells have been examined as a potential effector against HCV 
infection.155 Whilst the findings can appear contradictory, possibly as a result of 
methodological issues and differences in patient populations, some consistent features of 
NK phenotype and function in chronic HCV infection have emerged from these studies 
(Tables 1.3 & 1.4). Most published findings focus upon peripheral blood NK cells rather 
than intrahepatic NK cells.  
 
Twelve studies compared peripheral blood NK cells as a proportion of lymphocytes in 
chronic HCV infection and healthy donors. Six have reported no change 155-160 and six 
reported a reduction in peripheral blood NK cell proportion in the HCV cohort 149,161-165. 
The six reporting a reduction tended to have a larger sample number within the HCV 
cohort (cohort range 28-42, mean 33) and healthy controls (range 18-30, mean 25) than 
those not reporting a difference (HCV cohort range 11-34, mean 22, healthy donor range 
10-23, mean 15, Figure 1.9). These findings and the modest reported reductions in NK 
cell proportion in chronic HCV infection suggest that type II statistical errors (i.e. the null 
hypothesis is not rejected as the sample size is too small) may be contributing to conflicts 
within the literature.  
 
There is an overall consensus that in chronic HCV infection the proportions of CD56Bright 
161,163,164,166 and NKG2A+ NK cells are increased.158,163,165,167-170 However, there is no 
consensus in the literature regarding the expression of the NCRs, NKp30, NKp44 and 
NKp46 or NKG2D, these reports are summarised in Table 1.3.158,159,162,165-167,171,172 These 
reports imply that varying technical factors, practical techniques and methods of analysis 
may contribute to conflicting reports of NK cell phenotype in chronic HCV infection. 
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Figure 1.9  The reported proportion of NK cells in chronic HCV 
 
 
A) Studies with larger cohorts, shown in red, appear more likely to demonstrate a 
reduction in the proportion of lymphocytes that were NK cells (mean NK cell proportion 
Healthy donors 11.7% v HCV donors 7.7%). 
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Table 1.3 Summary of reported NK cell peripheral blood phenotype in chronic 
HCV infection compared to healthy donors
 Increase No change Decrease 
%NK  
Corado 1997 
Kawarabayashi 2000 
Duesberg 2001 
Nattermann 2006 
Yamagiwa 2008 
Sene 2010 
 
Meier 2005 
Morishima 2006 
Golden-Mason 2008 
Bonorino 2009 
Oliviero 2009 
Dessouki 2010 
CD56Bright: 
CD56Dim 
ratio 
Meier 2005 
Morishima 2006 
Bonorino 2009 
Bozzano 2011 
 
Jinushi 2004 
  
NKG2A 
Jinushi 2004 
Nattermann 2005 
Nattermann 2006 
Golden-Mason 2008 
Ahlenstiel 2010 
 
Bonorino 2009 
Dessouki 2010  
NKG2D Oliviero 2009 
Nattermann 2006 
Sene 2010* 
 
Dessouki 2010 
Yoon 2011 
NKp30 De Maria 2007 Dessouki 2010 
Nattermann 2006 
Bozzano 2011 
Yoon 2011 
 
NKp44 Ahlenstiel 2010†  
Nattermann 2007 
De Maria 2007 
 
NKp46 De Maria 2007 Ahlenstiel 2010† Dessouki 2010 Nattermann 2006 
*  NKG2D expression was reduced when measured by MFI 
†    NKp44 and NKp46 expression was unchanged when measured by MFI 
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1.17 Chronic HCV & Intrahepatic NK cells 
In 1998 Norris et al. characterised the resident lymphocyte subsets in blood and liver 
biopsy samples taken from non-living donors at the time of donor organ retrieval.173 This 
cohort consisted of 15 individuals who died of subarachnoid haemorrhage (7), road traffic 
accidents (7) and an individual who died of a brain tumour. It was reported that all donors 
had normal liver function tests and no known liver disease. The biopsies were 
mechanically disrupted stained with CD3 and CD56 monoclonal antibodies and examined 
by flow cytometry. It was demonstrated in this cohort that the mean intrahepatic NK cell 
proportion of lymphocytes was 30.6% (range 11.6-51.3) and 12% in the peripheral blood 
(range 1-22%). In chronic HCV infection lower proportions of intrahepatic NK cells have 
been reported, with a range of proportions of NK cells compared to total intrahepatic 
lymphocytes of 2.7 – 18% (Figure 1.10).157,159-161,163,174,175 
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Figure 1.10 Reported proportions of intrahepatic NK cells in chronic HCV  
 
The proportion of intrahepatic NK cells reported by 7 studies (red bars mean= 11.6%) and 
the number of sample donors in each cohort (white bars. Proportion of NK cells and 
sample size are demonstrated on the same scale on the x axis)  
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1.18 Intrahepatic NK cell phenotype in chronic HCV infection 
The phenotype of NK cell activating receptors determines NK cell function with higher 
expression of activating receptors conferring greater effector potential.121,176 However, it 
is known that NK cell activating receptors can be down regulated on activated cells,103 
which would impact upon the overall phenotype of the NK cells within the setting of 
chronic inflammation. NK cell phenotype within the intrahepatic compartment of HCV 
infected individuals is not fully determined and, as highlighted above, reports are often 
based upon relatively small cohorts.  
 
 In the largest study to date of intrahepatic NK cells in chronic HCV, 70 HCV+ 
individuals were biopsied and a phenotypic analysis of each NCR activating receptor was 
analysed on a subsets of 13-20 individuals.174 This study did not find an alteration in the 
proportion of cells expressing NCRs compared to non-HCV control biopsies. However, as 
outlined in the studies comparing peripheral blood samples, there is a conflict amongst 
studies over phenotypic changes (Table 1.4).158,159,161,162,167 Krämer et al used MFI rather 
than proportions to measure NK cell phenotype and categorised NKp46 expression as 
NKp46High and NKp46Dim and NKp46- subgroups. There was a marked increase in 
NKp46High population within the intrahepatic compartment.175  
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Table 1.4 Summary of phenotypic changes upon intrahepatic NK cells in subjects 
with chronic HCV infection 
 
Intraheptic NK cells v Peripheral blood NK cells from HCV+ donors 
 
 Increase No change Decrease 
% NK  
Meier 2005 
 
 
Yamagiwa 2008 
Sene 2010 
Bonorino 2009 
 
In cirrhosis – 
Kawarabayashi 2000 
CD56Bright: 
CD56Dim 
ratio 
Meier 2005 
 
 
  
NKG2A Bonorino 2009    
NKG2D 
Oliviero 2009 
Sene 2010 
 
  
NKp30  Nattermann 2006  
 
NKp44  Nattermann 2006  
NKp46 Ahlenstiel 2010 Kramer 2012 
Nattermann 2006 
 
 
 
 
 
HCV+ donor Intrahepatic NK cells v non HCV donors 
 
NKp30  Varachetta 2012 Nattermann 2006 
NKp44  Varachetta 2012 Nattermann 2006 
NKp46  Varachetta 2012 Nattermann 2006 
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1.19 NK cell function in chronic HCV infection 
Multiple studies have considered the impact of chronic HCV infection on NK cell 
function. The use of various experimental methodologies including i) varying stimulating 
cytokines ii) target cells iii) outcomes measured iv) time of stimulation in these studies 
which has lead to apparently conflicting results. Studies have reported increased, 
162,165,167,168 reduced 155,159,161,166,171 and unaltered 156,158,162,164,168 NK function in chronic 
HCV infection compared to healthy controls (Table 1.5).  
 
The majority of experiments utilised K562 erythroblastic leukaemic cells as targets, which 
lack MHC class I and therefore, induce a strong cytotoxic response. A broad range of 
stimulatory cytokines have been used to enhance NK cell function prior to exposure to 
targets. IFNα, the mainstay of treatment, has not been used to stimulate NK cells in HCV 
related studies. A broad pattern emerges when the length of time that NK cells remain in 
culture regardless of whether rested or stimulated, is considered: NK cytotoxic function is 
reduced in chronic HCV infection compared to healthy donors if shorter incubation times 
are employed but if cells are rested ex vivo then this impingement wanes (Table 1.5).167  
 
Studies that rested or stimulated NK cells for 48 to 72 hours with a variety of cytokines 
did not demonstrate a significant difference in NK cell function in the HCV and healthy 
donors cohorts.155,156,162,168 Furthermore, it has been noted that NK cells from healthy 
donors cultured in sera from HCV+ donors for 72 hours reduces NK function compared to 
NK cells cultured in sera from HCV- donors.155 Together these studies suggest that NK 
cell cytotoxic function may be suppressed in chronic HCV infection, but this suppression 
may wane when NK cells are rested for 24 hours or more, indicating reversible inhibition.  
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NK cells produce IFNγ in response to stimulation. Again there appears to be a divergence 
in the literature regarding IFNγ production in chronic HCV infection compared to healthy 
donors. In experiments which stimulated NK cells using cytokines or PMA/ ionomycin in 
the absence of target cells, an increase in IFNγ production was found.162,167,168 In the 
presence of target cells without cytokine stimulation NK cells from HCV+ donors had 
relatively reduced IFNγ production.159,165 These results again highlight how different 
experimental methods can produce conflicting results.  
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Table 1.5 Published reports of NK cell function in HCV compared to healthy donors  
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1.18 HCV NK - immunoevasion strategies 
These studies suggest that HCV is effective at avoiding immune clearance to establish a 
chronic infection. HCV has been reported to impinge directly upon NK cells with reduced 
cytotoxicity and IFNγ capacity following exposure to hepatocyte cell lines infected with 
HCV in vitro.172 Several studies have investigated potential mechanisms of HCV NK-
immunoevasion (Figure 1.10) and they include: 
i. HCV impingement upon hepatocyte IFNα signalling and ISG expression to alter 
NK cell activating ligands on the cell surface177. HCV core protein can act 
directly upon the IFNα-ISG pathway by selective degradation of STAT1.178  
ii. HCV mediated up-regulation of inhibitory factors including SOCS-1, which 
inhibits JAK-tyrosine kinase and prevents STAT1 phosphorylation.179,180  
iii. Upregulation of HLA-E on HCV-core protein+ hepatocytes (identified by liver 
biopsy immunohistochemistry). K562 cells transfected with Core35-44 peptide 
have increased HLA-E expression reducing NK mediated cytolysis.169  
iv. Increased NK expression of CD94/NKG2A, the inhibitory receptor for HLA-E.170  
v. NS3/4 protein down regulates NKG2D ligands MICA and MICB.181 
vi. E2 protein binding to CD81, a B cell co-receptor, resulting in CD81 crosslinking, 
has an inhibitory effect upon NK cells within a plate-bound expression 
system.182,183 However, infectious HCV virions, that solely express the structural 
proteins (core, E1 and E2), do not impinge upon NK cell function in a cell culture 
system.184  
 
Any influences of other non-structural HCV protein upon NK cells have not been 
identified to date. 
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Figure 1.10  HCV-NK immunoevasion 
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1.20 NK cells during IFNα  treatment of chronic HCV infection 
Several studies have examined the effects of in vivo IFNα treatment for HCV infection 
upon peripheral blood NK cells. It has been reported that 24 hours following the initiation 
of IFNα treatment NK cells are driven towards increased cytotoxicity and reduced IFNγ 
production through increased pSTAT1 signalling and reduced pSTAT4 
signalling.180,185,186 Ahlenstiel et al measured NK degranulation by CD107a MFI 
following exposure to K562 target cells before and 6 hours after IFNα initiation. The rate 
of the first phase of viral load decline was associated with a greater ability to increase 
CD107a MFI in patients who cleared the virus compared to those who failed treatment. In 
the same study the expression of CD16 and TRAIL was measured on NK cells derived 
from liver biopsy specimens from a cohort of 6 patients pre-treatment and a separate 
cohort of 6 patients six hours after the initiation of IFNα treatment. The 6 patients who 
were biopsied after the initiation of treatment had higher intrahepatic expression of 
TRAIL and CD16 than those biopsied pre-treatment.185 Furthermore the proportion of 
blood and intrahepatic NK cells is reported to increase in individuals who successfully 
clear HCV compared to those who have failed treatment.160,165,168 
 
In summary chronic HCV remains a major global health problem in spite of major 
advances in medical therapy. NK cells are a major effector of the innate immune response 
to viral infection and can augment adaptive T cell responses. Advantageous NK cell 
phenotype and HLA type appears to provide a protective role to individuals who are 
exposed to HCV. In chronic disease the function and proportion of NK cells appears to be 
altered. However, there remain inconsistencies within the literature, and a marked paucity 
of data regarding the activity and phenotype of NK cells within the intrahepatic 
compartment during chronic HCV infection. There is also a lack of information regarding 
Chapter 1:   Introduction 
 
	   60	  
the role that NK cells play during the successful clearance of chronic HCV infection with 
IFNα based therapies particularly within the intrahepatic compartment. 
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1.22 Hypothesis, objective & aims 
The study described here aimed to explore NK cell function in chronic HCV infection and 
its relationship with expression of NK activating receptors in order to gain further insight 
into these areas of relatively limited information. For this reason, a detailed analysis of the 
phenotype and function of intrahepatic NK cells in chronic HCV infection and during 
IFNα treatment was conducted. Finally the ability of individual HCV proteins to impinge 
on NK cells to promote viral immunoevasion has been examined ex vivo. 
 
Hypothesis  
NK cell function is important for successful eradication of HCV. HCV infection 
compromises NK cell function through modulating expression of NK cell activating 
or inhibitory ligands by infected cells. This effect of HCV can prevent successful 
virus clearance in treated individuals. 
 
Objective: 
-Identify the effect of HCV infection on NK cell phenotype and function and identify 
correlates of successful treatment 
 
Aims:  
1. Is peripheral blood NK cell function impaired in patients infected with HCV? Do HCV 
genotypes with lower treatment response rates impinge on NK cell function? 
2. Does intrahepatic NK cell activity reflect peripheral blood NK function? Is this altered 
with IFNα treatment? 
3. Do individual HCV proteins derived from different genotypes cause an alteration of 
NK cell function when expressed in a target cell? 
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2.1 Patient Recruitment 
 
Study approval 
 
Cardiff and Vale Research Review Service reviewed and approved this study  (reference 
number 10/cmc/4747). Ethical approval was granted by the South East Wales Research Ethics 
Committee (reference numbers 10/WSE02/45 and 04/WSE03/14). 
 
Patient Recruitment 
Patients were recruited from the hepatology and infectious diseases clinics at the University 
Hospital of Wales, Cardiff. The aim was to recruit a cohort of patients with chronic HCV, a 
cohort of non-viral chronic liver disease patients and a cohort of healthy donor controls.  
 
Chronic HCV infection was defined as individuals who were identified as anti-HCV antibody 
positive and had positive HCV RNA, as measured by PCR, on two occasions at least 6 
months apart. Inclusion criteria for the HCV cohort were: chronic HCV infection, over 18 
years of age and capacity to provide informed consent. Individuals with HIV or HBV co-
infection, less than 18 years old, pregnant or unable to provide consent were excluded. 
 
Patients with chronic liver disease were considered for the study if they were over 18 years 
old and had capacity to consent to participation. Individuals with HIV infection were 
excluded. The cause of chronic liver disease did not affect eligibility to enrolment. Healthy 
donor controls were recruited from within Cardiff University.  
 
Individuals identified by the medical and nursing teams in the clinic were invited to consider 
taking part in the trial and were provided with verbal and written information (Patient 
information sheet version 1.5 for HCV and chronic liver disease patients or Healthy donor 
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information sheet version 1.1). All patients participating in the trial were required to provide 
written consent prior to donating samples. 
 
In total 35 patients with chronic HCV, 22 patients with non-viral chronic liver disease and 13 
healthy donors were recruited (summarised in Table 2.1).  
 
 
Chapter 2:  Materials & Methods 
	   65	  
Table 2.1 Donor Characteristics 
 
HCV donors 
Patient Age Sex Genotype/ 
 Diagnosis 
NI  
score 
Fibrosis 
score 
Viral  
Load 
ALT Treatment 
outcome 
FNA Degranulation 
assay 
G1-01 31 F 1a 4 1 1.3 x 106 78 Failed Yes Yes 
G1-03 57 F 1a 7 1 1.7 x 106 134 Failed Yes Yes 
G1-05 45 M 1a NASH 8 5 6.5 x 105 110 Failed Yes Yes 
G1-06 36 F 1 4 0 1.7 x 106 47 - Yes - 
G1-08 62 M 1b 5 1 4.0 x 105 147 - Yes - 
G1-11 42 M 1 4 3 7.0 x 105 47 - Yes Yes 
G1-12 43 F 1A 3 0 2.3 x 106 26 - Yes - 
G1-15 58 M 1 6 5 1.2 x 107 47 - Yes - 
G1-17 52 M 1A 6 1 6.6 x 105 149 SVR Yes Yes 
G1-18 62 F 1 5 2 6.5 x 105 57 Failed Yes Yes 
G1-19 50 M 1 5 5 3.0 x 107 139 SVR Yes Yes 
G1-21 53 M 1 3 0 3.6 x 106 33 - Yes - 
G1-22 56 M 1 3 6 4.1 x 106 90 - Yes - 
G1-23 37 F 1a NASH 6 5 24000 318  Yes Yes 
G1-24 53 M 1 3 0 3.6 x 106 33 - Yes - 
G1-25 65 M 1a 4 5 3.2 x 106 90 - Yes - 
G1-41  51 M 1 & 3 5 1 3.8 x 106 38 Failed - Yes 
G1-42 27 M 1b 5 1 6.0 x 106 63 SVR - Yes 
G3-01 44 M 3 - - 5.5 x 105 66 SVR - Yes 
G3-06 42 F 3a 0 4 2.0 x 106 80 SVR - Yes 
G3-07 56 M 3a 6 6 2.3 x 106 35 SVR Yes Yes 
G3-08 41 M 3a 2 1 4.4 x 105 87 - Yes - 
G3-09 36 M 3a 6 2 2.4 x 106 332 SVR Yes Yes 
G3-10 27 M 3 7 1 3100 29 SVR Yes Yes 
G3-11 59 M 3 ND ND - 51 - Yes - 
G3-12 49 M 3 3 2 1.6 x 105 174 - Yes - 
G3-13 54 M 3 6 3 1900 179 - Yes - 
G3-14 52 M 3 5 5 2.4 x 105 90 - Yes Yes 
G3-40  58 M 3 4 6 3.1 x 105 53 Failed - Yes 
G3-41  47 M 3 - - 4.7 x 106 169 SVR - Yes 
G3-42 39 M 3 5 2 1.6 x 106 136 SVR - Yes 
G3-43 53 M 3 ND ND 3.9 x 105 26 SVR - Yes 
G3-44 67 F 3 3 1 2.2 x 105 174 SVR - Yes 
G4-01 29 F 4 ND ND 6.2 x 105 38 Failed - Yes 
G5-01  46 F 5 ND ND 7.6 x 106 52 SVR - Yes 
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Chronic Liver Disease donors 
Patient Age Sex Genotype/ 
 Diagnosis 
NI    
score 
Fibrosis 
score 
Viral 
Load 
ALT Treatment 
outcome 
FNA Degranulation 
assay 
DD03 61 F Deranged 
LFTs? Cause  
0 0  89  Yes  
DD12 40 F PBC 0 1  72  Yes  
DD13 49 F NASH 0 5-6  25  Yes  
DD14 67 F NASH 1 3-4  81  Yes  
DD15 52 F Steatosis 0 1  53  Yes  
DD16 40 M MTX use - 
NAD 
0 0  17  Yes  
DD18 58 F NASH 6-7 5-6  57  Yes Yes 
DD19 38 M Steatosis 0 0  55  Yes Yes 
DD20 46 M ALD HHC 1 1  73  Yes Yes 
DD21 69 M GH ND ND  39  Yes  
DD22 53 M ALD 0 0  34  Yes  
DD23 43 M Steatosis 2 0  96  Yes Yes 
DD24 55 M ALD HHC 2 5-6  46  Yes  
DD25 29 M NASH 1 3  122  Yes Yes 
DD28 58 M ALD HHC 2 5-6  39  Yes Yes 
DD29 55 F PBC 2 3-4  59  Yes Yes 
DD30 42 F PBC 2 3-4  179  Yes Yes 
DD32 55 M HHC 1 4  23  Yes Yes 
DD33 55 M PSC 2 1  54  Yes Yes 
DD34 51 F PBC 2 5  151  Yes  
DD35 29 M Wilsons    31  Yes  
DD36 58 M MTX / 
NASH 
   64  Yes  
 
ALD- Alcoholic liver disease, HHC- hereditary haemochromatosis, NASH – Non alcoholic 
steatohepatitis, PBC- Primary biliary cirrhosis, MTX- methotrexate, LFTs – Liver function 
tests, GH- Granulomatous hepatitis, SVR – Sustained Viraemic Response, PSC- Primary 
Sclerosing Cholangitis, NAD – no abnormality detected, ND – not done 
 
Healthy donors 
13 healthy donors peripheral blood donated only 
8 male,  age range 24-45 (mean 28) 
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2.2 Patient samples & study protocol 
Patients who entered the study were asked to donate blood samples with or without paired 
liver tissue samples.  
 
Liver biopsy 
Patients undergoing liver biopsy were asked to consent to use of residual tissue following 
normal histological examination. Biopsy samples were immediately fixed in normal buffered 
formalin solution embedded in waxed and stained with haematolxylin and eosin (H&E) in the 
histopathology department, UHW, prior to examination by a consultant hisopathologist. 
Biopsy samples taken at UHW are scored for inflammation and fibrosis using the Ishak’s 
necroinflammatory and fibrosis scoring system.187 This is a semi-numerical scoring system 
designed to give an increasing numerical score (0-18) for worsening liver inflammation, based 
on a descriptive score of portal inflammation (0-4), periportal/ periseptal interface hepatitis 
(0-4), focal lytic necrosis/ apoptosis/ focal inflammation (0-4) and confluent necrosis (0-6). A 
fibrosis stage (0-6) is also made, stages 5 - 6 are indicative of established cirrhosis. 
 
Fine Needle Aspiration (FNA) 
To gain a sufficient lymphocyte research sample for flow cytometry it has been necessary to 
perform a second pass of the biopsy needle to utilise a separate biopsy core. This separate 
core then requires physical and enzymatic degradation to isolate lymphoctyes. The not 
insignificant clinical risks associated with liver biopsy prevent the use of this technique to 
monitor lymphocytes at frequent intervals. Fine needle aspiration (FNA) consists of inserting 
a small-bore needle into a compartment to aspirate a single cell suspension for cytological 
examination. FNA of the liver provides a lymphocyte sample that correlates strongly with that 
derived from a liver biopsy.35 FNA has previously been successfully utilised to assess 
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intrahepatic lymphocytes 188 and acute rejection of renal transplants.189 In addition the smaller 
safer size of the needle represent a potential method of repeatedly sampling lymphocytes from 
within the liver at multiple time points at a relatively high frequency. 
 
I have used the following technique: 
• Patient is in the supine position with the right hand behind the head. The abdomen is 
examined and a suitable site is marked in the right mid-axillary line approximately 2 
intercostal spaces above the costal margin. The position of the liver is clinical 
confirmed by a dull percussion note in full expiration. In patients undergoing liver 
biopsy a liver ultrasound scan is performed within the last 6 months. 
• The skin is cleaned with iodine solution. 
• Up to 5ml of 2% lignocaine is infiltrated into the dermis and down to the hepatic 
capsule. The patient is asked to breath in and then exhale fully enabling lignocaine to 
be infiltrated into the liver capsule with the needle held 90° to the skin in all planes. 
• A 22 gauge spinal needle, with an internal sylet, is then inserted into the intercostal 
space. The patient is then asked to inhale and exhale fully. The needle can then be 
inserted 2-3cm into the liver parenchyma from the capsule. 
• The internal sylet is removed and a 10ml syringe filled with ice-cold RPMI 10% FCS 
is attached. Cells are then aspirated into the media as the needle is withdrawn to the 
liver capsule. 
• The needle is then removed the sylet replaced and the needle is re-inserted for a 
second aspiration. 
• The puncture site can then be dressed and the contents of the syringe are passed into a 
test tube containing RPMI 10% FCS on ice and then transported to the lab for 
immediate staining as described in Section 2.6 below. 
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It is important to note that these FNA samples are taken from the intracapsular space. As the 
liver is an extremely vascular organ it is likely that the needle may have passed through small 
sinusoids. If samples were heavily blood stained then they were discarded and the needle 
passed into fresh liver. (This occurred on less than 5 occasions during the study period.) 
 
Following FNA sampling it is possible to then continue with a liver biopsy along the same 
tract of lignocaine anaesthetic. If the patient is not having a liver biopsy, is pain free and feels 
well they may be discharged without further follow up. This technique was applied to a cohort 
of 53 patients with 9 patients having FNA samples taken at multiple time points (Table 2.1).  
 
Approximately 50ml of patient blood was drawn on each attendance. 4ml was placed in an 
EDTA test tube for serum separation and subsequent viral load analysis. The remainder of the 
sample was transferred to a 50ml test tube containing 250µl of unfractionated heparin.  
Patient paired liver and peripheral blood samples were taken before treatment, on days 1, 3, 7, 
14, months 1, 3 and 6 and 6 months following the completion of treatment. Additional blood 
and serum samples were taken on day 21 (Figure 2.1). 
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Figure 2.1 Study protocol schematic 
 
Peripheral blood, serum (open circles) and liver samples (circles) were collected at multiple 
time points before, during and after treatment (blue bars). 
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2.3  Tissue culture 
A full list of regents and suppliers is attached in Table 2.4 at the end of this chapter. 
Media 
Peripheral blood cells and K562 erythroblastic leukaemic cell line cells were washed and 
cultured in RPMI. RPMI is a phosphate rich media that utilises a bicarbonate buffering 
system for use in 5% carbon dioxide atmosphere. Huh7.5 hepatoma cells were washed and 
cultured in DMEM, which contains a higher concentration of vitamins, amino acids and 
glucose than RPMI.  
RPMI and DMEM were supplemented with the following antibiotics; 100units/ml penicillin, 
100µ/ml streptomycin and 2mM L-glutamine (Invitrogen). Further to this 10% heat 
inactivated FCS was added to maintain cells.  
 
Target cell lines 
K562 cells form a single cell suspension in RPMI 10% FCS and are incubated with 5% CO2 
at 37°C and the media was changed and cells split once they were confluent approximately 
every 36-48 hours. Huh7.5 cells are adherent cells, cultured in DMEM 10% FCS and grow 
more slowly than K562. Once the cells become confluent it is necessary to split them; the 
media was removed and the monolayer washed in PBS to remove FCS. Trypsin 0.05% was 
added and the cells incubated for 10 minutes the cells are loosened and the trypsin was 
neutralised with DMEM 10% FCS. The cells were then plated in fresh media at a lower 
concentration. 
 
Cell freezing solution 
Excess PBMC that were not used immediately were frozen for future use at -80°C or in liquid 
nitrogen in FCS supplemented with 10% DMSO. 
Chapter 2:  Materials & Methods 
	   72	  
 
Isolation of peripheral blood mononuclear cells 
Whole blood was transferred into a 50ml test tube containing 250µl heparin. The fraction of 
mononuclear leukocytes, which contains T and B lymphocytes, NK cells and monocytes, 
were isolated by density gradient centrifugation by layering 25ml of blood onto 20ml 
lymphoprep and centrifuged for 20 minutes at 2000RPM with the brake off. Cells were 
aspirated washed twice in RPMI 10% FCS and counted with a haemocytometer. Cells were 
resuspended at 5 x106 /ml in PBS for immediate staining and excess cells were frozen for 
further experiments. 
  
Purification of intrahepatic lymphocytes 
The aspirate of FNA sampling was transferred to the lab on ice and PBS was added to the 
solution. Two techniques were compared to separate intrahepatic lymphocytes from aspirated 
debris. The methods are described below and the impact of these techniques was compared 
and the second was predominantly used as a higher lymphocyte yield was achieved with this 
method as outlined in Results Chapter 4, section 4.2: 
 
Method 1. Initially samples were passed through a 70 µm cell strainer and centrifuged at 1600 
RPM for 5 minutes. The pellet was resuspended in 5ml of RPMI 10% FCS and layered over 
Lymphoprep and centrifuged for 2000 RPM for 20 minutes. Although an interface was not 
evident the solution above the Lymphoprep layer was harvested and stained as described 
below. 
Method 2. Samples were washed twice in PBS and plated for fluorochrome labelled 
monoclonal antibody staining. Cell surface markers were stained. Cellular debris was further 
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broken down during 0.5% saponin permeabilisation and removed by washing samples 3 times 
in perm buffer. Intracellular cytokines were then stained. 
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2.4 NK cell phenotyping and cytotoxicity assays 
CD107a is a highly glycosylated protein that lines the membranes of cytolytic granules, upon 
degranulation granules bind to the cell membrane and as the contents are exocytosed CD107a 
is externalised and transiently expressed on the cell surface. Thus measurements of CD107a 
expression correlate strongly with target cell death as measured by 51Cr release.190 
 
Frozen PBMC samples were obtained from 23 chronic HCV patients pre-treatment, 13 
healthy and 10 CLD donors (Table 2.1).  Cells were thawed, washed and cultured overnight 
at 106/ml in RPMI-10% FBS in a 24 well plate with 1ml per well. The PBMC were incubated 
without stimulation or with 50 or 1000 IU/ml IFNα. PBMC were washed, counted and 5x105 
cells exposed to 2x105 Huh7.5 or K562 target cells in DMEM-10% FBS or rested for 4 hours. 
During this time 5µl anti-CD107a antibody was added to each well (the details of antibodies 
used for flow cytometry are outlined in Table 2.2). To maximise staining of CD107a 1µL of 
Golgi stop (monensin) was added for the final 3 hours to inhibit intracellular protein transport 
preventing re-internalisation of CD107a from the cell surface. Non-adherent cells were 
washed and stained with Aqua live/dead stain and fluorochrome labelled monoclonal 
antibodies specific for CD3-APCH7, CD14-APCH7, CD19-APCH7 to exclude T cells, 
monocytes and B cells respectively. The phenotype of NK cell activating receptors was 
defined by CD16-FITC, NKG2D-APC, NKp30-Biotin, Streptavidin-PECy7, CD56-
PerCP.Cy5 and NKp46-PB. Cells were washed, fixed with 2% paraformaldehyde solution 
and analysed by flow cytometry using a CyAn ADP flow cytometer (Beckman-Coulter).  
 
NK target cell ligands 
The expression of NK cell activating receptor ligands on Huh7.5 and K562 cells was 
analysed by flow cytometry using NKp30- and NKp46–human Fc fusion proteins with an 
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anti-human Fcγ-PE secondary antibody. The NKG2D ligands MICA, MICB and ULBP2, 
were analysed with mouse monoclonal antibodies and anti-mouse-AF647 secondary 
antibody.  
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Table 2.2 Antibodies used in flow cytometry assays 
Antibody Conjugate Clone Company Dilution 
Anti-Human IgG PE Polyconal eBioscience 1:100 
Anti-mouse IgG AF647 polyclonal Invitrogen 1:50 
CD107a FITC H4A3 BD Pharmingen 1:40 
CD107a PE H4A3 BD Pharmingen 1:40 
CD14 APC.H7 MφP9 BD Pharmingen 1:50 
CD16 FITC VEP13 Miltenyi Biotec 1:50 
CD16 PE VEP13 Miltenyi Biotec 1:50 
CD19 APC.H7 SJ25C1 BD Pharmingen 1:50 
CD3 APC.H7 SK7 BD Pharmingen 1:50 
CD56 PerCP-Cy5.5 HCD56 Biolegend 1:50 
Granzyme B APC GB11 Invitrogen 1:100 
IFNγ  e450 4S.B3 eBioscience 1:500 
Ki-67 PE Ki-67 Biolegend 1:50 
Live/Dead Aqua - Invitrogen 1:150 
MICA Mouse primary AMO1 BAMOMAB 1:50 
MICB Mouse primary BMO2 BAMOMAB 1:50 
NKG2A PE 131411 R&D Systems 1:100 
NKG2D APC BAT221 Miltenyi Biotec 1:50 
NKp30 Biotin AF29-4D12 Miltenyi Biotec 1:50 
NKp30-ligand Fc fusion protein - R&D 1:50 
NKp46 PB 9E2 Biolegend 1:25 
NKp46-ligand Fc Fusion protein - R&D 1:50 
Streptavidin PE-Cy7 - eBioscience 1:500 
ULBP2 Mouse primary BUMO1 BAMOMAB 1:50 
AF647  Alexa Fluor®647 
APC  Allophycocyanin 
APC.H7 Allophycocyanin-H7 
e450  eFluor®450 
FITC  Fluorescine-isothiocyanate 
PB  Pacific Blue 
PE  Phycoerythin 
PE-Cy7 Phycoerythin-Cyanine 7 
PerCP.Cy5.5 Peridinin chylorophyll-Cyanine 5.5 
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2.5 NK cell gating strategy 
 
Isolated PBMC were stained with fluorochrome labelled monoclonal antibodies and amine 
reactive compound as described above. Lymphocytes were defined by granularity and size, 
cells with a proportional area to width were then selected as single cells (Figure 2.2). Dead 
cells were excluded by amine reactive compound and from the remainder (>97% of the 
lymphocyte gate) NK cells were defined as CD56+ CD3, 14 and 19- to exclude T cells, 
monocytes and B cells respectively. FMO stains were then used to create positive gates for 
markers of interest. 
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Figure 2.2 NK cell gating strategy 
 
A) Lymphocyte gate Lymphocytes were defined by size and granularity on a forward and 
side scatter. B) Single cells Single cells were selected as events with proportional width and 
area. C) Alive/ Dead stain Aqua negative cells were selected as the alive population. D) NK 
cells NK cells were defined as CD56+ CD3, 14 & 19- to exclude T cells, B cells & monocytes. 
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FMO controls 
FMO controls containing all the antibodies in the panel described above apart from the 
antibody of interest. FMOs are used to determine background fluorescence and any potential 
spill over from other fluorochromes into the channel of interest, which has not been fully 
compensated out, thus giving a cut-off level between positive and negative cells (Figure 
2.3).191,192 A major advantage of FMO stains compared to isotype control stains is that there 
is protection against potential variations in the flow cytometer over the long periods of time 
that the study was expected to take. Anti-mouse compensation beads were used to stain 
positive and negative controls and to create a compensation matrix during analysis. The data 
was analysed using FlowJo software (Ashland, Oregon, USA).  
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Figure 2.3 FMO controls and NK cell phenotype 
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2.6 Intrahepatic and peripheral blood NK phenotype and functional 
immunostaining 
Intrahepatic lymphocytes were taken with paired peripheral blood. Samples were washed 
twice in PBS. All samples were stained with the following antibody panel: Aqua live/dead 
stain and anti- CD3, CD14, CD19, CD56 CD16, NKp30, NKp46, NKG2D and NKG2A 
(Table 2.2).  
 
When samples contained larger numbers of lymphocytes it was possible to stain two separate 
panels of antibodies. In the second panel cells were also stained directly ex vivo without 
further stimulation with anti-CD107a. Cells were then permeabilised with saponin, fixed with 
paraformaldehyde (Fix/Perm) and stained with antibodies to Granzyme B, Ki67 and IFNγ. 
Cells were washed, fixed and analysed by flow cytometry as described above. 
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2.7 Immunohistochemistry 
Liver biopsies were taken in the normal fashion and fixed immediately in normal Buffered 
Formalin Solution and sent to the histopathology department for clinical assessment. These 
fixed specimens were mounted on cover slips and were dewaxed with xylene and ethanol. 
Sections were then stained as follows: 
i. Antigen retrieval was performed by heating specimens in TRIS EDTA.  
ii. To prevent non-specific DAB substrate staining endogenous peroxidase activity was 
suppressed with Peroxidase Suppressor and non-specific antibody binding was 
blocked with 2.5% normal horse serum.  
iii. Sections were stained overnight with goat anti-NKp46, mouse anti-CD56 and rabbit 
anti-CD3 antibodies diluted in 1% BSA.  
iv. These antibodies were then detected with anti-goat, anti-mouse or anti-rabbit 
Immpress® reagents. The Immpress detection kit contains secondary antibodies 
conjugated to peroxidase micropolyers. 
v. To visualise antibody bound cells DAB substrate was then applied.  
vi. Sections were dehydrated with ethanol and xylene and then counterstained with 
haematoxylin and mounted with DPEX mounting medium. 
Photomicrographs were taken using a NIKON microscope. 
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2.8  Viral Load Analysis 
Serum samples were taken at multiple time points prior to and during IFNα treatment and 
frozen at -80°C. Samples were sent by batch to Lab21 (Cambridge UK) who quantified HCV 
RNA by rtPCR using Cobas Ampliprep/Cobas Taqman HCV test (Roche Diagnostic 
Systems). The lower limit of quantification was 30 copies per ml. 
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2.9 HCV protein expression using an adenovirus vector 
Professor Gavin Wilkinson’s group have developed an in-house recombinant adenovirus 
vector for the expression of individual human cytomegalovirus (HCMV) proteins.193 I applied 
this technology to answer the question “Do individual HCV proteins derived from different 
genotypes cause an alteration of NK cell function when expressed in a target cell?”  
 
2.10 HCV Gene selection 
DNA copies of the Japanese Fulminant Hepatitis-1 (JFH-1) strain of genotype 2a (Core to 
NS5B, Genbank accession number AB047639) and Genotype 1b BB7 replicon (NS3-5B, 
Genbank accession number AJ238799) were kindly provided by Professor Peter Karayiannis 
(formerly of St Mary’s Hospital, London). JFH-1 Core to E2 and Core to p7 (Figure 2.4) were 
expressed as polyproteins as E1 and E2 proteins lack signal peptides,194 which ensure 
appropriate transfer and translation in the endoplasmic reticulum. NS2, 3, 4, 5, 5A and 5B 
proteins were expressed individually. The genes were cloned with 100 base pair (bp) primers 
containing approximately 80bp homology with the adenovirus genome depending on 
predicted binding properties (Table 2.3). Analysis of sequencing and primers were designed 
using CLC Main workbench 6.8 software (CLC bio, Aarhus, Denmark). The primers were 
constructed by Sigma-Aldrich (Dorset, UK) and samples sequenced in house by Central 
Biotechnology Services, School of Medicine, Cardiff University. 
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Figure 2.4 HCV proteins and polyproteins recominbeered into adenovirus vectors 
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Table 2.3 Adenovirus vector expressed HCV proteins and primers 
  
Protein  
(gene size) 
Forward Primer Reverse Primer 
JFH-1   
Core-E2 
(2.25kb) 
5’-ATGAGCACAAAT 
CCTAAACCTCAA-3’ 
5’-TGCTTCGGC 
CTGGCCCAA-3’ 
Core-p7 
(2.44kb) 
5’-ATGAGCACAAAT 
CCTAAACCTCAA-3’ 
5’-ATGAGCACAAAT 
CCTAAACCTCAA-3’ 
NS2 
(0.65kb) 
5’-TATGACGCACC 
TGTGCACGGA-3’ 
5’-AAGGAGCTT 
CCACCCCTTG-3’ 
NS3 
(1.89kb) 
5’-GCTCCCATCA 
CTGCTTATGC-3’ 
5’-GGTCATGACC 
TCAAGGTCAG-3’ 
NS4 
(0.95kb) 
5’-AGCACGTG 
GGTCCTAGC-3’ 
5’-GCATGGGAT 
GGGGCAGTC-3’ 
NS5 
(3.07kb) 
5’-TCCGGATC 
CTGGCTCC-3’ 
5’-CCGAGCGGG 
GAGTAGGAA 
NS5A 
(1.4kb) 
5’-TCCGGATC 
CTGGCTCC-3’ 
5’-GCAGCACAC 
GGTGGTATC-3’ 
NS5B 
(1.77kb) 
5’-ATGTCATACT 
CCTGGACCG-3’ 
5’-CCGAGCGGG 
GAGTAGGAA-3’ 
 
Replicon 1b 
  
NS3 
(1.89kb) 
5’-ATGGCGCCTA 
TTACGGCCTA-3’ 
5’-CGTGACGACC 
TCCAGGTCA-3’ 
NS4 
(0.95kb) 
5’-AGCACCTGG 
GTGCTGGTA-3’ 
5’-GCATGGCGTGGA 
GCAGTCCTCGTT-3’ 
NS5 
(3.11kb) 
5’-TCCGGCTCG 
TGGCTAAGA-3’ 
5’-TCGGTTGGGGA 
GTAGATAGATG-3’ 
NS5A 
(1.34kb) 
5’-TCCGGCTCG 
TGGCTAAGA-3’ 
5’-GCAGCAGAC 
GACGTCCTCA-3’ 
NS5B 
(1.77kb) 
5’-TCGATGTCCTA 
CACATGGACAG-3’ 
5’-TCGGTTGGGGA 
GTAGATAGATG-3’ 
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PCR products were amplified using Roche Expand Hi-Fi kit. Each 50µl reaction mix 
contained 1µl template, 4µl forward primer, 4µl reverse primer, 5µl Buffer 2 (10x 
concentrate, containing MgCl2), 6µl 4mM dNTPase, 0.5µl Hi-Fi enzyme and 28.5µl double 
distilled water. Samples were synthesised using a T3 Thermocycler (Biometra Germany) with 
the following incubations: 
 
1. 95°C 2 minutes 
2. 95°C 30 seconds 
3. 55°C 30seconds  Repeat 9x cycles 24 
4. 68°C 4 minutes 30 seconds   
5. 95°C 30 seconds 
6. 55°C 30seconds   Repeat 24x cycles 57 
7. 68°C 4 minutes 30 seconds  
increasing by 20 seconds each cycle 
8. 68°C 15 minutes 
  
The PCR product was run on a 0.7% agarose gel and the bands of the correct gene size were 
excised and DNA purified using GFX columns according to the manufacturers instructions. 
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2.11 Advec expression system overview 
 
The adenovirus vector recombineering system is laid out in detail below. In summary the 
principles are shown in Figure 2.5 and described as follows: 
 
E. coli that contained a single copy of the plasmid pAL1141 and a defective bacteriophage, 
which encoded lambda red genes, were cultured. pAL1141 encoded i) bacterial artificial 
chromosome (BAC), ii) modified adenovirus genome, iii) selectable markers & iv) antibiotic 
resistance.  
1. Bacteria were cultured overnight in LB media until log phase of growth was achieved, 
which is optimal for DNA uptake. Lambda red genes were expressed by heating the 
bacterial culture to 42°C for 15 minutes.  
2.  The viral genes of interest DNA were then mixed with the bacteria and inserted into 
the E. coli by electroporation. Recombination of the gene of interest into the plasmid 
displaced two selectable markers to allow isolation of clones containing 
recombineered plasmids. 
3. The plasmid genome was then isolated by a maxiprep and the presence of the correct 
gene of interest was confirmed by sequencing. 
4. The adenovirus vector was transfected into 293T-REx cells without further digestion. 
The insert expression suppressed by tetracycline (tet) repressors. Therefore, potentially 
toxic proteins of interest were not expressed whilst the virus was grown up in 
293TREx.  
5. Once a high viral titre was achieved the virus was extracted and can infect target cells 
in which the viral protein of interest was expressed.  
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Figure 2.5 Advec expression system overview 
 
  
1.
 E
 c
ol
i 
co
nt
ai
ni
ng
 p
A
L1
14
1 
pl
as
m
id
 a
nd
 l
am
bd
a 
re
d 
ph
ag
e 
ar
e 
cu
ltu
re
d 
to
 lo
g 
ph
as
e 
of
 g
ro
w
th
 a
nd
 h
ea
te
d 
to
 
42
°C
 e
xp
re
ss
 la
m
bd
a 
re
d 
ge
ne
s t
o 
m
ax
im
iz
e 
D
N
A
 u
pt
ak
e 
 
2.
 P
C
R
 p
ro
du
ct
 o
f 
vi
ra
l 
ge
ne
 o
f 
in
te
re
st
 i
s 
in
se
rte
d 
in
to
 E
 c
ol
i 
by
 
el
ec
tro
po
ra
tio
n 
an
d 
re
co
m
bi
ne
er
ed
 
w
ith
 p
A
L1
14
1 
di
sp
la
ci
ng
 s
el
ec
ta
bl
e 
m
ar
ke
rs
 
3.
 B
ac
te
ria
l 
co
lo
ni
es
 w
hi
ch
 h
av
e 
lo
st
 s
el
ec
tio
n 
m
ar
ke
rs
 a
re
 c
ul
tu
re
d 
an
d 
la
rg
e 
vo
lu
m
e 
pl
as
m
id
 
D
N
A
 
en
co
di
ng
 
ad
en
ov
iru
s 
ve
ct
or
 
an
d 
ge
ne
 
of
 
in
te
re
st
 
is
 
ex
tra
ct
ed
 
by
 
m
ax
ip
re
p.
 
Se
qu
en
ci
ng
 
co
nf
ir
m
s 
ge
ne
 o
f i
nt
er
es
t i
s p
re
se
nt
.  
Ti
m
e 
Bacteria N
o
 
4.
 V
ec
to
r g
en
es
 a
re
 tr
an
sf
ec
te
d 
in
to
 2
93
-T
R
Ex
. H
ig
h 
tit
re
 
of
 a
de
no
vi
ru
s 
ve
ct
or
s 
ar
e 
cu
ltu
re
d 
w
ith
 s
up
pr
es
s 
of
 g
en
e 
of
 in
te
re
st
 e
xp
re
ss
io
n 
by
 te
t r
ep
re
ss
or
s 
av
oi
di
ng
 p
ot
en
tia
l 
to
xi
ci
ty
. 
H
C
V
 g
en
e 
of
 in
te
re
st
 
pA
L1
14
1 
la
m
bd
a 
re
d 
ge
ne
s 
5.
 T
ar
ge
t c
el
ls
 a
re
 in
fe
ct
ed
 a
nd
 
th
e 
vi
ra
l 
pr
ot
ei
n 
of
 
in
te
re
st
 
(  
  )
 is
 e
xp
re
ss
ed
. 
Chapter 2:  Materials & Methods 
	   90	  
2.12 pAL1141 
In detail pAL1141 (Figure 2.6) contains the adenovirus vector genome with E1 and E3 
regions deleted to prevent vector replication. The plasmid contains a HCMV promotor to 
induce transcription, chloramphenicol resistance gene, and a bacterial plasmid origin of 
replication. Following the HCMV promotor and before a V5 tag is a cassette, which encodes 
ampicillin resistance, LacZα, and SacB. This cassette is replaced during recombineering with 
the gene of interest. SacB encodes sucrose sensitivity rendering sucrose-based culture media 
toxic to bacteria. LacZα cleaves X-gal, an analogue of lactose, releasing 5-bromo-4-chloro-3-
hydroxyindole marking a colony of bacteria containing this gene as blue on a culture plate. 
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Figure 2.6 Adenovirus vector in pAL1141 plasmid 
 
 
-----------------------------------------------------------------------  
 
Construct	  
insertion	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2.13 Adenovector recombineering 
pAL1141 bacteria were cultured overnight in 5ml LB media containing 12.5µg/ml 
chloramphenicol in a shaking incubator at 32°C. The culture was increased to 25ml LB 
containing chloramphenicol and cultured for ~3 hours. As bacterial cultures in a log phase of 
growth are optimal for DNA uptake. In LB media E. coli in a log phase of growth have an 
optical density600 of approximately 0.6, this was measured using an Ultraspec 3000 
(Pharmacia Biotech). Once this optical density was reached the culture was then transferred to 
50ml test tubes and placed in a 42°C water bath for 15 minutes to induce the defective phage 
lambda red proteins. After cooling and removing supernatant the bacteria was transferred to a 
pre-cooled cuvette with 3µl of PCR product and stood on ice for 5 minutes before being 
electroporated at 2.5kV using a Biorad Micropulser. Bacteria were recovered in 1ml LB 
media and transferred to universal container with a total of 5ml LB to be cultured for a further 
3 hours to ensure that all bacteria which have had the SacB gene replaced during 
recombineering lose any sucrose sensitive proteins.  
 
Bacteria were then plated onto a salt deplete LB agar plate containing 1/1000 of 12.5mg/ml 
chloramphenicol, 1/500 of 40mg/ml X-gal and 1/500 of 100mM isopropyl β-D-1 
thiogalactopyranoside to induce LacZa. Plates were incubated at 32°C for 48 hours until white 
and blue colonies appeared. Blue colonies had not lost LacZa through appropriate 
recombineering and with the gene of interest. Therefore, four white colonies were selected 
and cultured in 5ml LB media at 32°C overnight. 
 
The plasmid DNA was isolated from colonies using Miniprep kits (Qiagen) according to 
manufacturer’s instructions. Briefly following overnight culture the colonies were centrifuged 
at 4000RPM for 5 minutes and the pellet resuspended in 250µl P1 RNAase buffer. 250µl P2 
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lysis buffer was added and incubated for 5 minutes at room temperature. 250µl P3 
neutralisation buffer was added and then centrifuged at 13000 RPM for 10 minutes. The 
supernatant containing non-nuclear DNA was transferred to a fresh tube and the DNA was 
precipitated with 250µl isopropanol and centrifuged at 13000RPM for 30 minutes at 4°C. The 
supernatant removed and the pellet was washed in 70% ethanol. The ethanol was aspirated 
and then the pellet was air dried before resuspension in distilled water. 
 
Colonies bearing DNA inserts of the correct size were identified by BamHI restriction digest. 
8µl of the DNA preparation was added to 1µl BamHI and 1µl Buffer E and incubated for 1 
hour at 37°C before running on a 0.7% agarose gel. 
 
To sequence the DNA forward and reverse primers were constructed by Sigma-Aldrich, 
designed to bind to the vector at i) the CMV promoter prior to the insert and ii) the CMV 
polyA following the V5 tag and iii) approximately every 750bp in between to ensure 
sequencing of the entire insert (Table 2.4). For each 10µl reaction 5ul of DNA was combined 
with 1µl primer and 4µl of BigDye 4.1 and run on a T3 Thermocycler with the following 
parameters: 
 
1. 95°C 5 minutes 
2. 95°C 30 seconds 
3. 55°C 10 seconds  Repeat 99x cycles 24 
4. 60°C 4 minutes   
 
 PCR reactions were cleaned through a Performa DTR column and the DNA was sequenced 
by CBS, Cardiff University.  
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Table 2.4  Adenovirus vector sequencing primers  
 
Protein Position Sequence 
CMV promoter  
Forward sequence for all constructs 
  
5’-AATGTCGTAACAACTCCG-3’ 
CMV polyA 
Reverse sequence for all constructs 
  
5’-ACCTGATGGTGATAAGAAG-3’ 
 
JFH 
  
Core-p7 1008 5’-TGCCCAGGTGAAGAATACC-3’ 
Core-p7 1402 5’-ATGATGATGAACTGGTCGC-3’ 
Core-p7 1820 5’-ACATCGAGGCTTTCCGGATA-3’ 
NS2  Sequenced from promoter & polyA 
NS3 801 5’-GGACAAGCGGGGAGCATTG-3’ 
NS3 1302 5’-CATATGCGATGAATGCCAC-3’ 
NS4  Sequenced from promoter & polyA 
NS5 618 5’-CGGCGCCAACATCTCTGG-3’ 
NS5 1419 5’-GAGGCCAGATTACCAACCG-3’ 
NS5 1882 5’-AGCCCCGAAGAGGAAAAGTT-3’ 
NS5 2704 5’-TGGGTAACACCATCACATGC-3’ 
 
Replicon 1b 
  
NS3 888 5’-CGCTGTGGGCATCTTTCGG-3’ 
NS3 1372 5’-GAGACGGCTGGAGCGCGA-3’ 
NS4  Sequenced from promoter & polyA 
NS5 874 5’-CCGGCCCCCGAATTCTT-3’ 
NS5 1301 5’-TCCAAGCGGAGGAGGATGAG-3’ 
NS5 1775 5’-TCTGCTGCTCGATGTCCTAC-3’ 
NS5 2158 5’-TTGCTGGAAGACACTGAGAC-3’ 
NS5 2664 5’-ATGTTACTTGAAGGCCGCTG-3’ 
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Once the fresh colonies with the correct inserts were identified an aliquot was frozen in 100% 
glycerol for later use. Plamsid DNA for transfection was isolated by maxiprep using 
NuceloBond BAC100 kit according to the manufacturer’s instructions. In brief bacteria 
bearing the adenovirus vector of interest were cultured in 250ml LB media 1 in 1000 
chloramphenicol overnight. The culture was then centrifuged at 6000RPM for 15 minutes at 
4°C and the supernatant discarded. The pellet was resuspended in 24ml S1 RNAase buffer 
and 24ml S2 lysis buffer was added prior to incubation for 4 minutes at room temperature. 
24ml ice-cold S3 neutralisation buffer was added and the mixture was incubated for 5 minutes 
on ice and then spun down at 6000RPM for 15 minutes. Filter columns were equilibrated with 
N2 buffer prior to adding the culture lysate. The column was washed twice with 18ml N3 
wash buffer prior to elution with 15ml N5 buffer pre-warmed to 50°C. 11ml isopropanol was 
added to precipitate the DNA and the solution was centrifuged for 30 minutes at 15000RPM. 
The isopropanol was aspirated and the DNA pellet was washed in 70% ethanol prior to air-
drying in a 37°C water bath. The DNA was resuspended in double distilled water and the 
concentration of DNA was measured using ND-1000 Nanodrop spectrophotometer. 
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2.14 Transfection & titration of adenovirus vectors 
 
293 cells are derived from embryonic kidney fibroblasts which have been immortalised by 
integration of the adenovirus E1 gene region.195 The adenovirus vector is deficient of the E1 
region which ordinarily prevents viral replication and assembly, however, in 293 cells the 
adenovirus E1 promotes viral replication and assembly allowing expansion of the viral titre. 
In addition 293 T-REx cells stably express tetracycline repressor proteins. Hence, transfected 
cells with tet operators can have protein expression controlled. Adenovirus vectors were 
transfected into 293TREx cells by lipid micelle transfection (Effectene as specified in the 
manufacturers instructions). In brief 4µg of DNA was added to a final volume of 150µl 
Buffer EC. 8µl of enhancer was added and the sample vortexed for 30 seconds. 25µl of 
Effectene transfection agent was added and the sample mixed and then incubated at room 
temperature for 10 minutes. The sample was added to media and added to a confluent 
monolayer of 293TREx cells. Cells were cultured at 37°C to allow the virus to grow. Virus 
was harvested from cells by loosening cells with trypsin and resuspending in PBS. An equal 
volume of tetrachloroethylene was added to lyse the cells but leaving the capsulated virus 
intact. The emulsion was then separated by density gradient by centrifugation and the virus 
harvested in the less dense PBS layer. 
 
Purified viruses were titrated using an accelerated plaque assay.196 In brief 293TREx cells 
were seeded onto a 12 well plate and cultured after 24 hours serial dilutions of 10-4 and 10-5 of 
the virus stock was prepared and added to the wells. After 48 hours cells infected with virus 
were identified using goat anti-adenovirus antibody with an anti-goat horseradish peroxide 
secondary antibody and DAB metal concentrate. Visible cells were counted and virus titre 
calculated as plaque forming units (pfu)/ml. 
 
Chapter 2:  Materials & Methods 
	   97	  
Adenovirus vectors proteins were used to infect human foreskin fibroblasts (HFF) expressing 
the high affinity Coxsackie virus and adenovirus receptor (CAR).197 Protein expression was 
confirmed by Western blot and immunostaining of cell lines. 
 
Western blots 
HFF CAR+ cells were infected with adenovirus vectors with a multiplicity of infection (MOI) 
of 5 for 48 hours. The media was aspirated and 100µl NuPAGE buffer with 1 in 10 DTT was 
added. The cells were then scraped off and collected. The cell lysates were then heated to 
100°C for 10 minutes prior to centrifugation at 13000RPM for 5 minutes. Samples were then 
loaded into precast NuPAGE Bis-Tris gels and run for 90 minutes at 150 volts. Gels were 
blotted onto Hybond ECL nitrocellulose membranes at 15 volts for 1½ hours. Membranes 
were blocked overnight with TRIS Tween (TRIS-T) 5% fat free milk at 4°C on a rocking 
platform. Membranes were washed in TRIS-T and then incubated with primary mouse anti-
V5 and when required anti-JFH core, anti-NS3 and NS4 antibodies on a rocking platform at 
room temperature.  Membranes were washed three times in TRIS-T and anti-mouse 
horseradish peroxidase antibody was added for 1 hour. Membranes were then incubated for 5 
minutes with Super Signal West Pico chemiluminescent substrate and exposed for imaging as 
demonstrated in results Chapter 5. 
 
Immunostaining of infected HFF cells 
Cover slips were sterilised in 70% ethanol and washed with PBS. HF CAR cells were then 
seeded onto the coverslips in a 12 well plate. After 24 hours the HF CAR were infected with 
an MOI of 5. 48 hours later the media was removed and the cells fixed in 4% 
paraformaldehyde for 15 minutes at room temperature. After washing with PBS the cells were 
permeabilised with 0.5% NP40. Cover slips were washed in PBS and cells incubated with 
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primary mouse antibodies to V5, JFH core, NS3 and NS4 for 30 minutes at 37°C. The 
coverslips were washed and the coverslips incubated with anti-mouse AF488 antibodies for 
30 minutes at 37°C. The coverslips were washed in PBS and allowed to dry prior to fixing in 
Dabco to glass slides for immunofluroscence. 
 
The overall purpose of this adenovirus recombineering was to generate a series of reagents, 
which could be used to infect target cells with either individual or a combination of the HCV 
genes. This has enabled a series of experiments to be conducted examining whether HCV 
proteins could selectively impinge on NK cell functions using the methods described in 
section 2.4. The results of these experiments are described in chapter 5. 
Chapter 2:  Materials & Methods 
	   99	  
2.15 Statistical analysis 
A comparison of phenotypic and functional markers was made using a student t-test 
assuming normal distribution of data. The kinetic parameters of viral clearance (rate constant 
k in day-1) were calculated from a non-linear regression curve best fit (y = y0e-kx + plateau; y0 
= viral concentration day 0, plateau = final viral concentration after treatment). Comparison 
of NK functional markers with activation markers and rate of viral clearance was by linear 
regression. Comparison of non-parametric data and NK markers was by Spearman’s rho 
analysis. Software employed was Excel 2011 and GraphPad Prism 5.0. 
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Table 2.5 Reagents and suppliers 
 
Reagent Description / supplier 
70µm cell strainer Fischer Scientific Loughborough UK 
Agarose gel (0.7%) 0.7% agarose powder (AGTC Bioproducts UK) in 1x TAE buffer 
(National diagnositics, Atlanta, GA)  
Anti-adenovirus 
antibody 
Goat origin Chemicon Millipore Watford UK 
Anti-goat horseradish 
peroxidase 
Abcam UK 
Anti-JFH core 
antibody 
Mouse anti JFH-1 core antibody, BioFront Technologies 
Tallahassee FL 
Anti-mouse HRP 
antibody 
Goat anti-mouse horseradish peroxidase antibody Millipore Watford 
UK 
Anti-mouse/ -goat/ -
rabbit Immpress 
Vectorlabs Peterborough UK 
Anti-NS3 antibody Mouse monoclonal to HCV NS3 Abcam Cambridge UK 
Anti-NS4 antibody Mouse monoclonal to HCV NS4 Abcam Cambridge UK 
Anti-V5 Mouse monoclonal antibody Invitrogen Paisley UK 
BamHI BamHI restriction digest enzyme Promega Southampton UK 
BigDye 4.1  DNA sequening dye, ABI, Applied Biosystems Invitrogen Paisley 
UK 
Chloramphenicol Sigma-Aldrich, Gillingham UK 
DAB Vectorlabs, Peterborough UK 
DAB metal 
concentrate 
Thermo Scientific UK 
Dabco Dabco mounting agent, Sigma Aldrich Poole UK 
DMEM 10% DMEM (Invitrogen UK) 10% FCS, 250 units 
penicillin/streptomycin, 0.26mg/ml L-glutamine, 97mg.ml sodium 
pyruvate (all from Gibco UK) 
DMSO Sigma life sciences, Gillingham UK 
DTT Sigma-Aldrich 
Effectene Lipid micelle transfection kit Qiagen Manchester UK 
Expand Hi-Fi PCR enzyme buffer kit. Roche UK  
Fix/Perm buffer 0.5% saponin permeabilisation paraformaldehyde fixation kit 
ebioscience Hatfield UK 
GFX columns PCR and Gel band purification kit. GE Healthcare Life Sciences 
Amersham UK 
Golgi stop Monensin, BD Biosciences Oxford UK 
Heparin unfractionated heparin- Wockhardt UK Ltd Wrexham 
Hybond ECL Nitrocellulose membrane for Western Blots GE Healthcare 
IFNα  Roferon Roche UK 
LB media 20mg/L of LB low salt broth (Melford Laboratories) in ddH2O 
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Lymphoprep Axis-Shield, Oslo Norway 
Miniprep kit (Qiagen) Plasmid DNA purification kit utilitsing gravity flow anion-exchange 
columns. Qiagen Manchester UK 
Normal horse serum Vectorlabs Peterborough 
Nucelobond BAC100 Anion exchange column system for large scale purification of 
plasmid DNA, Macherey-Nagel, Germany 
NuPAGE Bis-Tris 
gels 
Precast Western blot gels Invitrogen Paisley UK 
NuPAGE buffer Invitrogen 
PBS Gibco UK 
Performa DTR 
column 
PCR product purification column, Edge Biosystems Gaithersburg 
MD 
Plastic ware All standard plastic ware for cell culture was purchased from Nunc, 
Greiner or Fisher UK 
RPMI 10%  RPMI, 10% FCS, 250 units penicillin/streptomycin, 0.26mg/ml L-
glutamine, 97mg.ml sodium pyruvate (all from Gibco UK) 
SuperSignal West 
Pico 
Enhanced chemiluminescent substrate for horseradish peroxidase 
Thermo Scientific Hemel Hempstead UK 
Trypsin 0.05% Gibco UK 
Vacuette K2 EDTA 
test tube 
Greiner Bio-One, Stonehouse UK 
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3.1 Peripheral blood NK phenotype & function in chronic HCV 
 
NK cells are important in control of viral infections. As outlined in the introduction above 
there remains a lack of consensus as to NK phenotype in chronic HCV infection. Separate 
studies investigating activating receptors, such as NKp30, NKp46 and NKG2D have 
described variously reported as up-regulated,162,167,171 down regulated,158,166 or unchanged 
159,165 in chronic HCV compared to healthy donors. There remains a similar lack of 
consensus surrounds the preservation or alteration of NK cell cytotoxic function in 
chronic HCV as laid out in Table 1.3.156,162,164,165,167,168,186 
 
In this chapter the following questions are addressed 
• “Is peripheral blood NK cell function impaired in patients infected with HCV?” 
• “Do HCV genotypes with lower rates of treatment response have an increased 
impact upon NK cell function?” 
 
In order to achieve this we recruited a cohort of 27 patients with chronic HCV infection, 
13 healthy donors and 11 chronic liver disease (CLD) donors from the hepatology clinic. 
Of these patients 24 completed combined IFNα and ribavirin treatment; 7 failed to clear 
the virus and 17 achieved SVR and cleared the virus (Table 2.1 page 56). Serum samples 
were taken at multiple time points during treatment for viral load measurements and the 
rate of viral clearance was calculated for 18 patients. Pre-treatment PBMC were isolated 
by centrifuge density gradient and frozen until use. Thawed NK cells were rested or 
stimulated with IFNα overnight and then the frequency, phenotype and cytotoxic function 
of NK cells was assessed by flow cytometry. 
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RESULTS 
3.2 The proportion of peripheral NK cells is reduced in chronic HCV infection 
The proportion of NK cells in the peripheral blood was lower in individuals with chronic 
HCV infection than healthy donors (mean 10.1% and 13.3% respectively p=0.05, Figure 
3.1). Mean proportion of NK cells was also lower in the non-viral CLD cohort (mean 
9.5% v HD p=0.1). This reduction compared to healthy donors was more marked for 
genotype 1 patients (mean 9.2 p=0.036) than genotype 3 patients (mean 10.3, p=0.13). 
There was no a significant reduction in the mean proportion of NK cells of HCV infected 
and CLD controls. 
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Figure 3.1 The proportion of peripheral NK cells in chronic HCV 
A 
	    
 
NK cells as a proportion of peripheral blood lymphocytes in chronic HCV infection. 
There is a reduction in NK cell proportion in chronic HCV compared to healthy donors 
(HD). Individuals with non-viral chronic liver diseases also had a reduction in the 
proportion of NK cells but this did not statistical significance. Mean & SEM shown. 
 
B) HCV genotype and peripheral blood NK cell proportion 
 
Patients with genotype 1 HCV have a more marked reduction in peripheral blood NK cell 
proportion than genotype 3 patients compared to healthy donors. Mean & SEM shown.
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3.3 NK cell phenotype in chronic HCV 
The phenotype of NK cells from chronic HCV, CLD and healthy donors was assessed by 
flow cytometry. There was no significant difference in the proportion of the CD56Bright 
and CD56Dim subsets or of the CD16+ and NKp30+ populations. There was a trend towards 
increased NKG2D expression in the HCV and CLD cohorts although this was non-
significant reflecting the broad range of expression within the groups. There was a trend 
towards reduced NKp46 expression within the HCV cohort (p=0.06 Figure 3.2).  
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Figure 3.2  NK cell phenotype in chronic HCV infection 
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The expression of the activating receptors was compared in patients with genotype 1 or 
genotype 3 HCV infections. Of note genotype 1 patients had an increased NKG2D+ 
proportion compared to healthy donors (p=0.04) and genotype 3 patients (p=0.07). 
Conversely individuals with genotype 3 infection had a lower proportion of NKp46+ NK 
cells than healthy donors (p=0.045) whilst there was no significant difference between 
genotype 1 patients and healthy donors (Figure 3.3).  
 
As a proportion of the total lymphocyte population, there was no difference between the 2 
genotypes and healthy donors in terms of NKG2D expression (Figure 3.3). However, the 
proportion of NKp46+ NK cells as a proportion of total lymphocytes was reduced in both 
the genotype 1 and genotype 3 patients compared to healthy donors (p=0.02 & p=0.037 
respectively, Figure 3.3). This suggests that the host may respond to a reduction in the 
proportion of NK cells by increasing the proportion of NKG2D+ NK cells. However, this 
is not the case for the other activating receptor NKp46.  
 
It is tempting to speculate that these data suggest there are potentially two different 
mechanisms to achieve a reduction in the total NKp46 expression i) reduced NKp46+ NK 
cells through reduction of total NK proportion, (genotype 1 patients), or ii) combination 
of reducing total NK cell proportion and the proportion of NKp46+ NK cells (genotype 3 
patients). There was no association between the proportion of NKp30+ cells and genotype. 
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Figure 3.3 HCV genotype and NK cell activating receptor phenotype 
 
Top row: NKG2D and NKp46 expression as a proportion of NK cells in genotype 1 
and 3 patients. NKG2D expression is increased in genotype 1 and NKp30 expression is 
reduced in genotype 3 patients.  
Bottom row: NKG2D and NKp46 expressing NK as a proportion of total lymphocytes. 
There is no difference in NKG2D expression between genotypes and healthy donors, 
however, both genotype 1 and genotype 3 patients demonstrate reduced NKp46 
expression. Mean & SEM shown. 
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3.4 NK cell cytotoxic function in health and chronic HCV infection 
CD107a is a glycoprotein that coats the internal surface of lymphocyte cytolytic granules 
the exact function of CD107a remains poorly defined.198 CD107a is temporally exposed 
on the cell surface upon NK cell degranulation and CD107a externalisation has been 
shown to correlate strongly with target cell death.190   
 
Thawed PBMC were rested or stimulated overnight with IFNα and NK cell function was 
measured by CD107a externalization in 4-hour degranulation assays. NK cell function 
was measured after a relatively low-level stimulation (using Huh7.5 human hepatoma 
cells target cells following overnight stimulation with 50 IU /ml IFN-α) and a high-level 
stimulation (using K562, MHC I deficient erythroblastic leukaemic cells, and 1000 IU /ml 
IFN-α, Figure 3.4A). Low level stimulation was used to replicate the chronic 
inflammatory state of the HCV infected liver and high-level stimulation was used to 
induce maximal NK cell activation as may be seen following the administration of high 
dose IFNα during the treatment of HCV. 
 
At low-level stimulation NK cell function was reduced in the HCV cohort (mean=17.7%) 
compared to the healthy (mean=26.7%, p=0.006) and CLD donors (mean=30.8%, 
p=0.003). At high-level stimulation patients with HCV infection had reduced CD107a 
externalization compared to healthy donors (mean=36.7 v 45.1% respectively p=0.017) 
but not compared to CLD patients (mean=35.7% p=n.s), CLD patients had significantly 
reduced level of CD107a externalization compared to healthy donors (p=0.023). These 
data indicate that NK cell cytotoxic function is impaired at low-level stimulation 
compared to health donor and CLD controls and both HCV and CLD patients have 
reduced cytotoxic function compared to healthy donors at maximal stimulation. 
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Figure 3.4 NK cell degranulation in chronic HCV infection 
A. CD107a externalisation to increasing stimulation 
Representative FACS plots from a healthy donor demonstrating increasing CD107a 
externalisation to increased stimulation. 
B. NK cytotoxic function in chronic HCV infection 
 
NK cell cytotoxic function is reduced in chronic HCV (red dots) compared to healthy 
donors (X) at low-level stimulation and high-level stimulation (p=0.006 &0.017 
respectively).  
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3.6 NK cell phenotype and cytotoxic function 
 
The relationship between stimulation-induced degranulation and stimulation-
induced down regulation of NK receptors. 
NK cell activating receptors are down regulated upon degranulation.103 Figure 3.5 shows 
representative FACS plots of phenotypic changes following degranulation. CD16 
expression is most markedly altered, with the majority of CD107a+ cells not expressing 
CD16. CD16 down regulation correlates with increase in CD107a externalisation between 
unstimulated NK cells and NK cells have exposed to IFNα and K562 target cells in both 
the HCV and healthy donor cohorts (p=0.0006, r2=0.47 & p=0.024, r2=0.54 respectively). 
Marked changes were also seen in NKp30+, NKp46+ and NKG2D+ NK cell populations 
although these shifts did not correlate with degranulation at high-level stimulation. There 
was a trend towards NKp46 down regulation and increasing CD107a externalisation in the 
HD (p=0.07, r2=0.4) but not the HCV cohort (Figure 3.5).  
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Figure 3.5 NK cell degranulation and changes in activating receptor phenotype 
 
A) Representative FACS plots demonstrating CD107a & CD16 expression at baseline 
(left panel) and following high-level stimulation (centre panel). Degranulation and 
reduction in CD16+ NK cell proportion in HCV and Healthy Donor cohorts (right panel).  
B) NKp30+ C) NKp46+ D) NKG2D+ NK cell proportions. 
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The relationship between stimulation-induced degranulation and baseline NK 
receptor expression 
The proportion of NK cells expressing activating receptors on resting NK cells was 
therefore correlated with cytotoxic function following IFNα stimulation and exposure to 
target cell lines in vitro.  At low-level stimulation the proportion of NKp46+ cells 
correlated with NK cell degranulation in the HCV cohort (p=0.0068, r2=0.29) but not in 
the HD or CLD cohorts (Figure 3.6). There was an inverse correlation between healthy 
donor NKG2D+ NK cells and degranulation (p=0.02, r2=0.4) but not in the HCV or CLD 
cohorts. CD16+ and NKp30+ proportions did not correlate with degranulation in the HCV, 
CLD or healthy cohorts (Figure 3.6). NK cell degranulation was measured following 
high-level stimulation (1000 IU/ml IFNα and K562 target cells). Under these conditions 
there was a trend towards NKp46 correlation and degranulation in the HCV cohort 
(p=0.076, r2=0.14, Figure 3.7). There were no associations between CD16, NKp30 or 
NKG2D and degranulation in the HCV cohort or between degranulation and NK 
phenotype in the CLD or healthy donors at high-level stimulation, which induces maximal 
degranulation. 
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Figure 3.6 NKp46 correlates with degranulation in chronic HCV infection at low-
level stimulation 
 A) CD16+ NK cell proportion at baseline and degranulation following low-level 
stimulation with 50 IU/ml and exposure to Huh7.5 target cells in HCV cohort (left panel) 
and healthy donors (X) and CLD (blue dots, right panel). B) NKp30+, C) NKp46+ and D) 
NKG2D+ NK cell proportions.  
0 10 20 30 40
40
60
80
100
HCV p=0.0068
%CD107a+
%
N
K
p4
6+
 b
as
el
in
e
0 10 20 30 40
0
20
40
60
80
100
%CD107a+
%
N
K
p3
0+
 b
as
el
in
e
0 10 20 30 40
50
60
70
80
90
100
%CD107a+
%
CD
16
+ 
ba
se
lin
e
0 10 20 30 40
0
20
40
60
80
100
%CD107a+
%
N
K
G
2D
+ 
ba
se
lin
e
0 20 40 60
40
60
80
100
%CD107a+
%
N
K
p4
6+
 b
as
el
in
e
0 20 40 60
0
20
40
60
80
100
%CD107a+
%
N
K
p3
0+
 b
as
el
in
e
0 20 40 60
50
60
70
80
90
100
%CD107a+
%
CD
16
+ 
ba
se
lin
e
0 20 40 60
0
20
40
60
80
100
%CD107a+
%
N
K
G
2D
+ 
ba
se
lin
e
HD p=0.02
HCV HD CLD
A
B
C
D
Chapter 3: Results 
Peripheral blood NK cells & HCV  
	   116	  
3.7 NKp46 and NK cell function at high-level stimulation 
 
 
 
NKp46+ proportion at baseline and degranulation following high-level stimulation with 
1000 IU/ml and exposure to K562 target cells in HCV cohort (left panel) and healthy 
donors (X) and CLD (blue dots, right panel).  
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3.7 NK activating receptor ligand expression on target cells 
The association between activating receptor and NK function is dependent upon the 
presence of the appropriate receptor ligand. The ligands for many NK receptors are 
unknown. CD16 is an Fc receptor on antibody-coated cells 103 and NKG2D binds to 
MICA, MICB and ULBP2 proteins.106-108 However, only a handful of NCR ligands are 
known and these include influenza haemaglutinins, BAT 3 and B7-H6.121,127,128 NKp30 
and NKp46-Fc fusion proteins allow the identification of known and potentially unknown 
ligands expressed on the surface of target cells. 
 
Huh7.5 and K562 target cells were stained with NKp30 and NKp46-Fc fusion proteins 
and monoclonal antibodies to MICA, MICB, ULBP2 and anti-human Fc antibody. 
NKp30 and NKG2D ligands were expressed at high levels on both Huh7.5 and K562 
target cells (Figure 3.8A&B). The anti human Fc antibody did not bind to either target cell 
lines indicating that there was no ligand for CD16 expressed on the cell surfaces. NKp46 
ligands were expressed at lower levels than NKp30 and NKG2D ligands but relatively 
better expressed on Huh7.5 than K562 cells (Figure 3.8). The relatively increased 
expression of NKp46 ligands presumably contributes to the fact that they form a superior 
target for NK cells that express high levels of NKp46 in HCV infection. 
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Figure 3.8  Huh7.5 & K562 NK activating receptor ligand expression  
 
A Huh7.5 targets cells 
 
 
Representative FACS histograms demonstrating NKp30-Fc, NKp46-Fc, MICA, MICB 
and UBLP2 staining on Huh7.5 target cells (solid grey = isotype control, black line = 
ligand of interest).  
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Figure 3.8  Huh7.5 & K562 NK activating receptor ligand expression  
 
B K562 targets cells 
 
Representative FACS histograms demonstrating NKp30-Fc, NKp46-Fc, MICA, MICB 
and UBLP2 staining on K562 cells (solid grey = isotype control, black line = ligand of 
interest).  
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3.8 IFNα  treatment of HCV infection – viral clearance and rate of viral control  
The successful IFNα treatment of HCV, a sustained viraemic response (SVR), is defined 
by two undetectable viral loads as measured by PCR 6 months apart. It is known that 
rapid viral clearance is associated with successful treatment outcome, however, it is 
possible for individuals to respond to treatment slowly and go on to achieve SVR. IFNα 
treatment can impinge upon the immune system through multiple mechanisms. These 
varying mechanisms include stimulation of the innate and adaptive branches of the 
immune system as well as the direct impact of IFNα upon HCV and infected hepatocytes. 
The relative impact of these mechanisms is not fully understood and it is likely that these 
may vary between individuals. Varying clinical responses to IFNα treatment, including 
rapid viral clearance, relapsing responders and SVR with slow viral clearance, may reflect 
the predominance of a particular immune pattern of response within an individual. 
Therefore, rate of viral clearance may be a more subtle outcome measure to assess the role 
of different cell linages during IFNα treatment of HCV. 
 
To calculate the rate of viral clearance viral loads were measured in the serum of patients 
at multiple time points (day 0, 1, 3, 7, 14, 21, 28 and then three monthly). The decline in 
viral load was calculated as a non-linear regression k (day-1) illustrated in Figure 3.9A. 
Patients who successfully cleared HCV with IFNα treatment had a higher rate of viral 
decline than those who failed treatment (mean= -0.01 k v -0.97 k, p=0.037 Figure 3.9B). 
  
Chapter 3: Results 
Peripheral blood NK cells & HCV  
	   121	  
3.9 Rate of viral control during IFNα  treatment 
A 
 
B 
 
A) Representative rates of viral clearance for 3 subjects following initiation of IFNα 
treatment. Subject with no viral clearance did not decrease the viral load and had a low 
rate constant k < -1.5 (Red crosses). The subject with slow viral clearance achieved SVR 
but had a measurable viral load at 1 month and a rate constant of k = -0.2 (black 
triangles). The individual with rapid viral control had a rate constant of k = 0.67 (blue 
inverted triangles). B) Rate of viral clearance in patients who achieved SVR following 
IFNα treatment and those who failed treatment. 
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3.9 NK cell phenotype and IFNα  treatment outcome in chronic HCV infection  
Baseline NK cell phenotype was known for 24 patients who underwent IFNα and 
ribavirin treatment for HCV, of these 17 achieved SVR and 7 failed treatment (Table 2.1). 
The mean proportion of NKp46+ NK cells was surprisingly higher in the treatment failure 
group than those patients who achieved SVR (mean= 72.0% v 80.5% respectively, 
p=0.048, Figure 3.10). There was no difference in proportion of NK cells or CD56Dim 
cells or CD16, NKp30 and NKG2D expression between the groups (Figure 3.10). 
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Figure 3.10 NK cell phenotype & treatment outcome 
 
Viral clearance following IFNα and ribavirin treatment was associated with lower 
proportions of NKp46+ NK cells at baseline but not NK cell, CD56Dim, CD16+, NKp30+ 
or NKG2D+ proportions. Mean & SEM shown. 
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Rate of viral control was calculated as described above and correlated with baseline NK 
cell phenotype. CD16+ proportion at baseline correlated with rate of viral clearance 
(r2=0.27, p=0.03). In keeping with this there was a trend towards an increased proportion 
of CD56Dim NK cells and increasing rate of viral clearance (r2=0.17, p=0.097, Figure 
3.11). CD16+ CD56Dim NK cells have a greater cytotoxic potential than CD16- CD56Bright 
NK cells. It is not clear from these data if the correlation between CD16 and rate of viral 
clearance is a reflection of NK cytotoxic potential or the impact of CD16 on NK cell 
activation. It is interesting to note that in this cohort of 17 individuals the two patients 
who did not have any reduction in viral load following initiation of IFNα and ribavirin (k 
<-1.5) had markedly lower CD16+ expression of 66% and 68% with a reduced CD56Dim 
proportion. If these individuals were excluded from the analysis statistical significance is 
lost and the r2 value in both cases is less than 0.018.  
 
Again surprisingly NKp46+ NK cell proportion inversely correlated with rate of viral 
clearance (r2= 0.36, p=0.01, Figure 3.11). The NK cell, NKp30+ and NKG2D+ proportion 
did not correlate with rate of viral clearance. 
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Figure 3.11 NK cell phenotype and rate of viral clearance during IFNα  treatment 
 
CD16+ proportion weakly correlated with rate of viral clearance following initiation of 
IFNα treatment as measured by the rate constant k.. There was an inverse correlation 
between NKp46+ proportion and rate of viral clearance but no association between 
proportion of NK, NKp30+ or NKG2D+ cells. 
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3.10 In vitro NK cytotoxic function & rate of viral clearance 
Patients who successfully cleared HCV infection with IFNα and ribavirin treatment had a 
lower cytotoxic response to low-level stimulation (50 IU IFNα and Huh7.5 target cells) 
than patients who failed treatment (mean 14.4% v 24.4% p=0.005, Figure 3.12A). 
Following stimulation with 1000 IU IFNα and K562 target cells there was a non-
significantly reduced cytotoxic response in the SVR group (mean 34.8% v 42.0%, p=0.13, 
Figure 3.12B). There was an inverse trend between rate of viral clearance and in vitro 
cytotoxic function at low-level stimulation (r2 = 0.21, p=0.067, Figure 3.12C). Following 
maximum stimulation CD107a externalisation did not correlate with rate of viral 
clearance (Figure 3.12D). 
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Figure 3.12 NK cell cytotoxic function & response to treatment  
 
A) NK cell CD107a externalisation following low stimulation (50 IU/ml IFNα and 
Huh7.5 target cells) in patients who achieved SVR and failed IFNα treatment.   
B) CD107a externalisation following high level stimulation (1000 IU/ml IFNα and K562 
target cells). Mean & SEM shown. C) Correlation of rate of viral clearance and CD107a 
externalisation low-level stimulation. D) Correlation of rate of viral clearance and 
CD107a externalisation following high-level stimulation.  
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3.11 Functional ratio 
It was surprising that patients with an SVR appeared to have populations of NK cells that 
were not as activated by IFNα compared to patients who failed treatment. However, a 
clear difference emerges when the relative changes in measured in each subject, using 
lower vs. high-level stimulation, are compared. I called this change functional ratio:  
 
Functional ratio =  % NK cells expressing CD107a high-level stimulation 
% NK cells expressing CD107a low-level stimulation 
 
FACS plots of CD107a externalisation at high and low stimulation from two 
representative individuals are shown in Figure 3.13A. Patients who achieved SVR had a 
higher functional ratio than patients who failed treatment (mean = 2.6 v 1.7, p=0.016, 
Figure 3.13B). Importantly the functional ratio correlated with rate of viral clearance 
(r2=0.30, p=0.029, Figure 3.13C) and inversely correlated with NKp46 expression 
(r2=0.29, p=0.005, Figure 3.13D). These data support the notion that the relative ability to 
increase NK cell function in response to IFNα stimulation contributes to more rapid viral 
clearance and treatment success, and the NKp46+ proportion of the NK population 
seemed to be key. 
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Figure 3.13 Functional ratio and treatment outcome 
 
A) Representative FACS plots from two HCV infected individuals demonstrating low 
(top row) and high (bottom row) relative increase in cytotoxic function and functional 
ratio. B) Functional ratio and treatment outcome. Mean & SEM shown. C) Functional 
ratio and rate of viral clearance. D) Functional ratio and % NKp46+.   
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3.12 HCV specific CD4+ T cell and NK cell responses following IFNα  treatment. 
Previous research conducted by Dr Ian Rees (MD student in Godkin/Gallimore lab) 
investigated ex vivo IFNγ producing and cultured anti-viral CD4+ T cell anti-HCV 
responses at multiple timepoints before and during IFNα treatment in a cohort of 33 
patients.199 Patients who failed treatment had absent or transient low-level CD4+ T cell 
responses. Surprisingly of those patients who achieved an SVR (and the most rapid rate of 
viral decline) had absent or minimal anti-viral CD4+ T cell responses. Patients with the 
most robust CD4+ T cell HCV specific responses had lower rates of viral clearance 
(p<0.0006, Figure 3.14).  
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Figure 3.14 IFNα  induced rapid control of hepatitis C virus results in SVR in the 
absence of robust CD4+ T cell responses 	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3.14 G 
Hepatitis C viral clearance was measured by a rate constant of viral decline following 
initiation of IFNα and ribavirin treatment k. Group 1 comprised of those who failed to 
clear HCV on treatment. Group 2 achieved SVR in the absence of or with minimal CD4+ 
T cell responses. Group 3 achieved SVR with robust CD4+ T cell responses. (Work 
undertaken by Dr Ian Rees in 199) 
 
Group 1 Group 2 Group 30
1
2
3
4
5
p=0.0009 p=0.0097
k 
(d
ay
-1
)
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Frozen PBMC were available from 8 of these patients for whom the CD4+ T cell 
responses are known and have been included in the analysis of NK cells described in the 
early part of this chapter. In this sub-group 4 patients achieved SVR with a low/minimal 
CD4+ T cell response, 2 patients achieved SVR with robust CD4+ T cell responses and 2 
failed treatment without a robust CD4+ T cell response. 
 
As in the larger cohort there was an inverse correlation between % NKp46+ NK cells and 
rate of viral clearance (r2= 0.85, p=0.001, Figure 3.15A) and functional ratio correlated 
with rate of viral clearance (r2=0.51, p=0.045, Figure 3.15B) in this subset of 8 patients. 
However, these data indicate that there is segregation in NK phenotype and function in 
individuals who have rapid viral clearance and achieve SVR and those who clear the virus 
more slowly regardless of whether they achieve SVR or failed treatment. When the 
patients are grouped in this manner the rapid responders had lower proportion of NKp46+ 
cells than individuals with slow viral decline (mean = 61.5 v 83% p=0.006, Figure 3.15C). 
In keeping with this pattern patients with rapid viral decline had greater functional ratio 
than those with slow viral decline regardless of whether the individual had a robust CD4+ 
T cell response and achieved SVR or did not and failed treatment (mean = 3.2 v 1.8 
p=0.06 Figure 3.15D). These data suggest that NK cell phenotype and function may 
dictate rate of viral clearance, rapid viral clearance may negate or prevent a CD4+ T cell 
response from developing.  Individuals who have low rates of viral clearance are 
dependent upon robust CD4+ T cell responses to achieve SVR. 
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Figure 3.15 NK cells and CD4+ T cell responses to IFNα  treatment 
  
A) NKp46+ proportion and rate of viral clearance in patients who failed treatment and 
those who achieved SVR with absent/minimal or robust CD4+ T cell responses. 
Demonstrating segregation between rapid clearers with absent/minimal CD4+ T cell 
responses and slow clearers regardless of CD4+ response and treatment outcome. B) 
Functional ratio and rate of viral clearance. C) NKp46+ proportion in patients with rapid 
viral clearance and slow viral clearance. The slow viral clearance group contains 2 
individuals who failed treatment and did not have CD4+ T cell responses and 2 individuals 
who achieved SVR and had robust CD4+ T cell responses. D) Functional ratio in patients 
with rapid and slow viral clearance. (Mean and SEM shown). 
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3.13 Discussion 
NK cells play a role in controlling viral infections. Although the exact mechanism of 
IFNα treatment is unclear, it seems plausible that its ability to activate NK cells may be 
important. NK cells have been examined as potential effectors during IFNα treatment, 
however, there is a lack of consensus regarding their phenotype and function in the 
literature as outlined in the introduction. Some of these conflicts may result from type II 
statistical errors, methodological and variation in populations sampled. In keeping with 
the studies that have larger cohorts we have found that NK cells were reduced in chronic 
HCV infection, however, with a more marked reduction in genotype 1 compared to 
genotype 3 patients (Figure 3.1). HCV genotype appears also to alter NK cell phenotype 
with more markedly reduced NKp46+ proportion in genotype 3 patients. Once the 
reduction in the proportion of NK cells is considered it is interesting to note that there is 
an equivalent reduction in NKp46+ cells as a proportion of lymphocytes in genotype 1 and 
genotype 3 patients (Figure 3.3). 
 
NKp46+ proportion correlated with NK cell function in the HCV cohort but not in the 
healthy donors or CLD cohorts (Figure 3.6). The cytotoxic response was lower in chronic 
HCV infection. Two studies have recently described two subpopulations of NK cells 
defined by NKp46 expression on a per cell basis using mean fluorescence intensity (MFI) 
and termed these cells NKp46High and NKp46Dim.175,200 In these studies NKp46High cells 
had increased cytotoxic function and produced higher levels of IFNγ and TNFα than 
NKp46Dim cells and were able to able to inhibit HCV replication in vitro. I found that 
NKp46 expression in peripheral blood NK cells tended to form a single population rather 
than two discrete populations (representative FACS plot Figure 3.2). This may relate to 
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differing methodologies between the studies but the uniting message remains that NKp46 
expression marks out NK cells with greater in vitro cytotoxic activity in chronic HCV. 
 
In an in vitro model of fibroblast pox-virus infection Jarahian et al have reported NKp30 
specifically induces greater NK cytotoxic function than NKp46. However, vacinnia virus 
haemaglutinin, either bound to the infected cell surface or as a soluble factor, is able to 
block NKp30-triggered NK cell activation.121 NK cells therefore, have attenuated 
cytotoxic function and degranulated in an NKp46 dependent manner. A similar pattern of 
the failure of NKp30 activation as the primary activating receptor may occur in chronic 
HCV permitting NKp46 expression to dictate NK cell function in the HCV. It is possible 
that there is a race between host NKp30-dependent viral control and expression of HCV 
immunoevasive factors dictating if exposure progresses to acute infection. In a cohort of 
HCV exposed intravenous drug users high NKp30 expression has been associated with 
reduced levels of seroconversion compared to individuals with low NKp30 expression.149. 
These data suggest that a viral immunoevasion strategy may block a primary activating 
receptor (possibly NKp30) in chronic HCV infection passing the role of principle 
activating receptor to NKp46, which results in lower NK cytotoxic function. 
 
Rapid viral control is a predictor of treatment success (Figure 3.9).32 The findings 
described above support a role for NK cell cytotoxic function in the rapid early control of 
viral load during IFNα treatment of HCV. These data are in keeping with those of 
Ahlenstiel et al, who sampled peripheral blood NK cells at multiple time points before 
and during IFNα treatment allowing in vivo stimulation and measured NK cell function in 
vitro. Ahlenstiel and colleagues reported patients who achieved SVR had a significantly 
greater increase in CD56Dim NK cell CD107a MFI from baseline to 24 hours following 
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initiation of IFNα treatment compared to those who failed treatment.185 In this study we 
have calculated a functional ratio to describe the relative increase in NK cell cytotoxic 
function, which correlates with rate of viral clearance and treatment success (Figures 
3.13B & C). In addition at low-level stimulation there was an inverse correlation between 
NK cell function and rate of viral clearance (Figure 3.12). Previous studies of interferon-
stimulated genes (ISG) in chronic HCV reported a higher rate of SVR in individuals with 
a low level of ISG expression at baseline and a marked increase in ISG expression 
following IFNα treatment compared to those with high baseline expression and a poor 
IFNα response.50,51,201 In my study the proportion of NKp46+ appears to drive NK 
cytotoxic function at low-level stimulation with high expression resulting in increased 
cytotoxic function at baseline but is associated with poor treatment outcome. Increased 
baseline NK cell cytotoxic function may increase selection pressure on HCV resulting in 
the expansion of more resistant quasi-species contributing to viral persistence during 
IFNα treatment. 
 
Innate & adaptive immunity 
As previously described NK cells can help to establish a successful adaptive immune 
response through the production of IFNγ and NK-DC cross talk.141-143 However to mount 
a robust adaptive immune response appropriate antigen presentation is required and there 
has been increasing interest in innate immune impingement upon adaptive immunity 
through antigen clearance in mouse models. 
 
Honke et al described a mouse model of vesicular stomatitis virus (VSV) infection, which 
demonstrated the importance of an appropriate time period of antigen presentation for the 
development of CD4+ T cell responses.202 Robust type-I IFN innate responses effectively 
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cleared VSV from the majority of tissues. Rapid clearance of the virus prevents the 
development of the adaptive immune response. However, a subgroup of splenic CD169+ 
macrophages, resistant to type-I IFN, remain permissive to on going VSV replication, 
thus allowing persistent antigen presentation and the development of adaptive immune 
responses. Following CD169+ macrophage depletion VSV infection was again effectively 
cleared by the innate immune response but without the appropriate antigen exposure there 
was a failure to prime an adaptive immune response. This resulted in a loss of specific 
adaptive immunity rendering the mice vulnerable to reinfection. 
 
Andrews et al. demonstrated that during MCMV infection depletion of NK cells increased 
ex vivo virus specific IFNγ production by CD4+ and CD8+ T cells. NK cells depleted 
infected dendritic cells in a perforin dependent manner reducing the length of antigen 
presentation and thus magnitude of the adaptive immune response. The diminished CD4+ 
T cell response to the MCMV infection increased viral replication in the salivary glands 
thus providing a viral advantage.203 Interestingly a compromised adaptive immune 
response to viral infections can also provide the host with a survival advantage. 
Lymphocytic choriomeningitis virus (LCMV) infects mice and can, depending on the 
viral load during the infection, induce a robust immune response resulting in severe 
immunopathology.204 LCMV infected cells are resistant to NK cell lysis and 
immunopathology is CD8+ T cell mediated. Waggoner et al. elegantly demonstrated that 
mice inoculated with a high LCMV viral load did not develop immunopathology as NK 
cells depleted virus–specific CD4+ T cells allowing CD8+ T cell exhaustion to occur. 
However, inoculation with moderate LCMV viral loads that fail to induce NK cell 
depletion of CD4+ T cells resulting in on-going CD8+ T cell activation and 
immunopathology (Figure 3.16). 
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The ability of NK cells to impinge on the development of adaptive immune responses has 
been corroborated by Narni-Maninelli et al. in mouse models of MCMV and ovalbumin 
expressing Listeria monocytogenes infection. Mice were bred with hyper-responsive NK 
cells, which failed to express NKp46 resulting in up regulation of the transcription factor 
Helios.205 Mice with hyper-responsive NK cells rapidly controlled both viral and bacterial 
infections reducing antigen availability and therefore failed to mount effective CD4+ and 
CD8+ responses rendering the mice susceptible to reinfection. Furthermore NK cell 
activating receptor NKG2D has been implicated in perforin mediated killing of primed 
CD8+ T cells thus moderating the adaptive immunity in both mouse virus and tumour 
models.206,207 
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Figure 3.16  Models of immune response to viral pathogens and development of 
adaptive immunity. 208 
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1a: A moderate NK cell response to viral infection allows APC priming of CD4+ T cells. 
The adaptive immune response may result in fatal immunopathology (Waggoner et al.).  
1b: An excessive NK cytotoxic response may clear viral antigen without appropriate APC 
priming of CD4+ T cells leaving the host at risk of future infection (Andrews et al. & 
Narni-Mancinelli et al.). 1c: CD169+ macrophages, IFN-α resistant and permissive to 
viral replication, enable on-going priming of adaptive immune responses during rapid 
innate viral control (Honke et al.). 
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In human disease the relationship between antigen availability and adaptive immune 
priming is harder to demonstrate owing to restriction of tissue availability to 
predominantly the blood compartment. Previous work from the lab I worked in 
demonstrated that patients with the most rapid viral clearance actually have absent or 
minimal CD4+ T cell responses.199 This study suggests that innate immune responses may 
prevent the development of adaptive immunity in human infections, as has been 
demonstrated in mice, in an NKp46 dependent manner during treatment with IFNα 
(Figure 3.17). Alter et al found that individuals who spontaneously cleared HCV had 
lower expression of NKp46 and NKp30 than those developed a persistent infection.154 
When these findings are considered in the context of NK cells impingement upon 
adaptive responses one could hypothesise that lower levels of NK activating receptors 
may reduce the innate response allowing the propagation of a robust CD4+ T cell 
response; the hallmark of successful spontaneous clearance of acute HCV infection. 
 
 
Chapter 3: Results 
Peripheral blood NK cells & HCV  
	   143	  
Figure 3.17 NKp46+ NK cells and CD4+ T cell responses during IFNα  treatment of 
chronic HCV 
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In conclusion I have demonstrated an association between NKp46+ NK cells and the 
function of peripheral blood NK cells in chronic HCV. This relationship is particularly 
important during IFNα treatment as individuals with low NKp46+ populations have the 
greatest potential to up regulate cytotoxic function and rapidly control viral load. This 
response is in essence a double-edged sword; rapid viral clearance is strongly associated 
with successful treatment outcome but also with a failure to mount a robust adaptive 
immune response. This potentially leaves the treated patient at risk of re-infection 
following further exposures. However, this opens intriguing questions regarding our 
ability to fine tune immune response to induce favourable adaptive immune responses and 
more pressingly for infected individuals – does a more active NK phenotype impact on 
disease progression? 
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4.1 Intrahepatic NK cell phenotype and function in chronic HCV 
The majority of immunological studies of chronic HCV infection have been restricted to 
clinical samples from the peripheral blood compartment rather than the site of infection: 
the intrahepatic compartment. The studies that have investigated NK cells from the 
intrahepatic compartment have reported a similar161 or reduced159,160,163 NK cell 
proportion compared to the peripheral blood. There is however, a lack of consensus 
regarding the phenotype of intrahepatic NK cells (summarised in Table 1.4).158,161,163 
These studies demonstrate that the peripheral blood offers a reflection of the intrahepatic 
compartment. However, the small sample sizes, limited phenotypic data and lack of 
functional analyses point to a hole in our knowledge of an important subset of 
lymphocytes in chronic HCV infection. 
 
In the study described in this Chapter, the following question was addressed: 
• “Does intrahepatic NK cell activity reflect peripheral blood NK function and is 
this altered with IFNα treatment?”  
 
In order to address this I utilised FNA sampling of the liver to assess NK cell phenotype 
and markers of function in 46 patients with chronic HCV and non-viral chronic liver 
diseases. In a subset of 9 patients I performed repeated FNA sampling during IFNα 
treatment of chronic HCV infection (Table 2.1 page 56). FNA samples were taken with 
paired peripheral blood samples, transported on ice to the lab and phenotypic and 
functional markers immediately assessed by flow cytometry. 
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4.2 FNA sampling 
To our knowledge this study represents the largest cohort of patients to undergo FNA 
sampling of the liver to retrieve intrahepatic lymphocytes for research purposes. However, 
a significant concern during the study design was the acceptability and safety of patients 
undergoing FNA sampling. The procedure was well tolerated and patients informally 
reported that the discomfort was approximately half way between a blood test and a liver 
biopsy. In this study a total of 81 FNA samples were taken. Following FNA sampling 42 
patients proceeded to liver biopsies and 39 FNA samples were taken without biopsies 
(including 9 patients who underwent repeat FNA sampling). Following the 39 FNA 
procedures without biopsies 1 patient required 1g of paracetamol and another received 
30mg of codeine and 500mg of paracetamol. In patients who proceeded to liver biopsy 
following FNA, 16 patients required cocodamol and 2 patients required intramuscular 
pethidine (Χ2 test = 0.0001, Figure 4.1). Of note 9 of the 12 patients who were treated 
agreed to repeat FNA sampling with up to three samples taken during the first week. This 
indicates that the majority of patients found the procedure acceptable. 
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Figure 4.1 Analgesia requirements following FNA and liver biopsy 
 
 
Analgesia requirement following FNA procedure alone and FNA and biopsy combined. 
Patients who had biopsy had a far higher requirement for opiate analgesia. A specialist 
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Fine needle aspiration is a clinical technique that provides single cell cytology samples 
and as such is unable to provide histological information. The liver is an extremely 
vascular organ and aspiration of cells from within the liver capsule contained particules 
assumed to be cellular debris that prevented flow cytometry analysis (Figure 4.2A). A 
significant hurdle in the use of FNA is the need to isolate the intrahepatic lymphocytes 
from sample debris. Sample debris may effect immunohistochemistry and flow cytometry 
analysis. Two methods to isolate intrahepatic lymphocytes from the aspirate were 
compared. As described in “Materials and Methods” the first method required layering 
aspirate upon Ficoll and isolating lymphocytes by a density gradient. The second method 
utilised saponin permeabilisation and repeated washing to clear cell debris. In both cases 
cells were stained with monoclonal antibodies. Paired peripheral blood samples were 
taken and mononuclear cells were isolated by Ficoll density gradient. For both 
intrahepatic and peripheral blood samples the following flow cytometry gating strategy 
was used:   
 
Single cells were selected using Forward scatter height and Forward scatter area gating. 
Lymphocytes were then gated based on forward and side scatter and dead cells were 
excluded with aqua live dead stain. Lymphocyte subsets (NK, NKT and T lymphocytes) 
were gated based upon expression of CD56 and CD3, CD14 and CD19 (Figure 4.2B-E).   
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Figure 4.2   Lymphocyte gating strategy for intrahepatic & peripheral blood samples 
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It was rapidly evident that the number of intrahepatic lymphocytes retrieved was 
significantly higher using the permeabilisation method compared to a density gradient 
(mean lymphocytes = 36959 v 2183 respectively p<0.0001, Figure 4.3A). The proportion 
of these lymphocytes that were NK cells was similar with both methods (10.8% v 12.1% 
p=0.7, Figure 4.3B). With the caveat that very few cells were recovered by density 
gradient, I observed no significant difference in the phenotype of NK cells isolated using 
each method (e.g. CD16: 72.5% v 67.0% p=0.46, Figure 4.3C). Given the superior 
numbers of NK cells recovered, the permeabilisation method was subsequently routinely 
used. 
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Figure 4.3 Intrahepatic NK cell isolation by permeabilisation & density gradient 
 
Intrahepatic lymphocytes were prepared by saponin permeabilisation () and washing to 
remove cellular debris or by density gradient purification over Ficoll (). (A) Comparison 
of the total number of intrahepatic lymphocytes retrieved, (B) NK cells as a proportion of 
lymphocytes and (C) CD16+ NK cells. Mean and SEM shown. 
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4.3 Intrahepatic NK cells in chronic HCV and non-viral chronic liver disease 
In keeping with previous studies,159-161,163 the frequencies of intrahepatic and peripheral 
blood NK cells were similar in the cohort of individuals chronically infected with HCV; 
the mean NK cell proportion was 9.9% in the peripheral blood and 10.6% in the FNA 
aspirate (p=0.51). Similarly, in the CLD cohort there were similar NK cell proportions in 
the peripheral blood and intrahepatic compartments (11.8% and 12.0% respectively 
p=0.9, Figure 4.4A, representative FACS plots Figure 4.2D). The proportion of 
intrahepatic and peripheral blood NK cells correlated in both the HCV and the CLD 
cohorts (HCV: r2=0.36, p=0.001 and CLD: r2=0.23, p=0.025, Figure 4.4B). The spread of 
intrahepatic NK cell proportions was greater in the CLD cohort compared to the HCV 
cohort (3.5-28% and 5-22.5% respectively). This spread is perhaps unsurprising given the 
range of pathologies within the CLD cohort (Table 4.1). There was no difference in the 
proportion of intrahepatic NK cells in patients infected with HCV genotype 1 compared to 
those with HCV genotype 3 infection (mean 9.7% and 12.3% respectively p=0.21, Figure 
4.4C). 
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Figure 4.4 Intrahepatic NK cells as a proportion of lymphocytes 
  
A) Intrahepatic and peripheral blood lymphocytes were stained with anti-CD56 and anti-
CD3, 14 & 19 antibodies to analyses the proportion of NK cells in a HCV (n=24) and 
CLD cohort (n=22). There were no significant alterations in the proportions of NK cells in 
either cohort. B) The proportion of NK cells in the intrahepatic compartment correlated 
with the peripheral blood in both cohorts. Left panel: HCV r2=0.36, p=0.001 and right 
panel: CLD r2=0.23, p=0.025. D) There was difference in the proportion of NK cells in 
patients with genotype (GT) 1 or 3 infection. Mean & SEM shown.  
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4.4 Intrahepatic NK cell phenotype  
Although the proportion of NK cells was not altered between the peripheral blood and 
intrahepatic compartments we found a marked alteration in the phenotype of intrahepatic 
NK cells. The proportions of CD16+, NKp30+ and NKG2D+ NK cells were reduced in the 
intrahepatic compartment in both the HCV and CLD cohorts (Figure 4.5 A-C, proportions 
in legend). For example the proportion of CD16+ NK cells in the peripheral blood was 
91.5% and 72.0% in the liver in the HCV cohort (p<0.0001) and 91.7% and 73.3% in the 
CLD cohort respectively, (p<0.001. Figure 4.5A). A potential explanation for the altered 
intrahepatic NK cell phenotype may have resulted from a decrease in proportion of the 
mature CD56Dim NK cell subset.  However, there was no reduction in the proportion of 
intrahepatic CD56Dim NK cells in either cohort (Figure 4.5D). An alternative explanation 
for the altered phenotype is that CD16 and other NK cell activating receptors are reduced 
upon NK cell activation, as described in detail in Chapter 3.  
 
There was no difference in the proportion of NKp46+ or NKG2A+ NK cells between the 
intrahepatic and peripheral blood compartments in either cohort (Figure 4.5E&F). There 
was no difference in intrahepatic proportions of CD16+, NKp30+, NKp46+, NKG2D+ and 
NKG2A+ NK cells between genotype 1 and genotype 3 patients (data not shown).  
 
These data demonstrate a distinct phenotype of intrahepatic NK cell population, 
confirming that a separate population of NK cells were sampled. The intrahepatic NK cell 
phenotype may reflect function within the chronically inflamed liver. 
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Figure 4.5 Intrahepatic NK cell phenotype (legend overleaf) 
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NK cell phenotype in the peripheral blood and intrahepatic compartments. Left panels 
demonstrate representative FACS plots. The proportion of activation marker+ cells are 
within the gated area and had higher expression than the FMO control. Right panels 
demonstrate HCV (blood, FNA ) & CLD (blood, FNA ) cohort phenotype. 
 A) CD16+ NK cells: HCV blood 91.5% v FNA 72.0%, p<0.001 & CLD 91.7% v 73.3% 
respectively, p<0.001. 
B) NKp30+ NK cells: HCV blood 53.7% v FNA 27.7% p<0.001 & CLD 51.5% v 24.8% 
respectively, p<0.001. 
C) NKG2D+ NK cells: HCV blood 82.0% v FNA 68.6%% p=0.01 & CLD 74.8% v 
68.9% respectively, p=0.1. 
D) CD56Dim NK cells: HCV blood 92.0% v FNA 92.7% p=ns & CLD 92.0% v 91.4% 
respectively, p=ns. 
E) NKp46+ NK cells: HCV blood 73.0% v FNA 74.5% p=ns & CLD 64.4% v 66.7% 
respectively, p=ns. 
F) NKG2A+ NK cells: HCV blood 14.4% v FNA 12.9% p=ns & CLD 10.9% v 10.1% 
respectively, p=ns.  
Mean & SEM shown. Paired t-tests.  
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Conversely, NKp46, the activating receptor that was associated with in vitro NK cell 
activity in HCV infected donors, was not downregulated in the intrahepatic compartment. 
There was a strong correlation between intrahepatic and peripheral blood NKp46+ 
proportion of NK cells (HCV: p<0.0001, r2=0.68 & CLD: p<0.0001, r2=0.73, Figure 
4.6A). The data suggests two patterns of NK cell phenotype, characterised by the 
proportions of NKp46+ cells, strikingly within the HCV (but to a lesser degree in the 
CLD) cohorts.  Twelve individuals in the HCV group demonstrated an NKp46-rich NK 
cell population with greater than 80% of NK cells NKp46+ whilst 14 patients were 
NKp46-poor with less than 70% NKp46+ cells (Figure 4.6B & C). The significance of 
these two groups was examined as described in detail below. 
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Figure 4.6 Intrahepatic NKp46 expression 
 
 
A) NKp46 expression has a strong correlation between the peripheral blood and the 
intrahepatic compartments. B) HCV infected subjects separated into those with NKp46-
rich (>80%) and NKp46 poor (<70%) individuals. C) Representative FACS plots of 
NKp46-poor (left panel) and NKp46-rich (right panel) individuals. FNA sample: thick 
black line, peripheral blood: grey line, FMO: shaded area.   
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4.5 Intrahepatic NK cell function 
The FNA sampling technique allowed aspirated lymphocytes to be assessed for functional 
markers directly ex vivo. In keeping with the altered phenotype of intrahepatic NK cells 
there was a distinct pattern of NK cell functional markers in the intrahepatic compartment. 
The proportions of CD107a+ and IFNγ+ NK cells were increased and the proportion of 
granzyme B+ NK cells was reduced in the intrahepatic compartment compared to the 
peripheral blood in both cohorts. (Figure 4.7A-C). In addition CD107a+ cells were 
granzyme B- supporting the interpretation that intrahepatic NK cells are more likely to 
have recently degranulated (Figure 4.7D). Almost all CD107a+ NK cells in the liver were 
IFNγ+, although a significant proportion of activated NK cells were IFNγ+ and CD107a- 
(Figure 4.7E&F). These data give an interesting insight into NK cell activation in vivo. 
Recent NK cell activation in the liver is in keeping with the altered CD16, NKp30 & 
NKG2D phenotype described above. 
 
 Ki67 is a marker of cell proliferation and is present during all active phases of the cell 
cycle. Proportions of Ki67+ NK cells were similar in the peripheral blood and intrahepatic 
compartment in both the HCV and CLD cohorts (Figure 4.7G). There were no differences 
in levels of functional marker expression between patients infected with either genotype 1 
& 3 virus in either the peripheral blood or the intrahepatic samples (data not shown). 
 
In summary these data demonstrate that NK cells within the intrahepatic compartment 
have increased activity in terms of degranulation and IFNγ production, both of these 
factors are likely to contribute to inflammation in both HCV and other non-viral CLD. 
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Figure 4.7 NK cell functional markers 
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Intrahepatic NK cells demonstrate increased activity compared to the peripheral blood 
(HCV blood, FNA  & CLD blood, FNA ). 
 A) Direct ex vivo proportion of NK cells CD107a+ without further stimulation in the 
intrahepatic and peripheral blood compartments. HCV: 4.3% v 0.4% respectively, 
p=0.006 & CLD: 2.8% v 0.4% p=0.001. 
B) The proportion of NK cells containing intracellular Granzyme B in the intrahepatic and 
peripheral blood compartments. HCV: 98.5% v 80.2% respectively, p=0.0003 & CLD: 
97.6% v 71.1% p=0.0016. 
C) IFNγ+ NK cells in the peripheral blood and intrahepatic compartments. HCV: 2.5% v 
8.7%, respectively p=0.0002 & CLD: 0.94% v 3.8%, p=0.0015. 
D) Representative FACS plot demonstrating NK cell CD107a and granzyme B staining 
from peripheral blood and intrahepatic samples.  
E) The majority of activated NK cells were CD107a & IFNγ+ or IFNγ+ alone. 
F) Representative FACS plot of NK cell CD107a and IFNγ staining in the liver and 
peripheral blood.  
G) Ki67+ NK cells in the peripheral blood and intrahepatic compartments of HCV and 
CLD cohorts. 
Mean and SEM shown. 
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4.6 Intrahepatic NK cells and hepatitis C viral load 
The increased functional activity of intrahepatic NK cells suggests that they may be active 
in control of virus during chronic HCV infection. There was no association between the 
viral load and the proportion of intrahepatic NK cells, T cells or NK cell phenotype as 
measured (Figure 4.8).  
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Figure 4.8 Viral load and NK cell phenotype & function in chronic HCV 
A) Correlation of NK cells as a proportion of intrahepatic lymphocytes and viral load in 
chronic HCV r2 0.1, p=0.09. B) Correlation of intrahepatic CD3+ CD56- T cells and HCV 
viral load (r2=0.1 p=0.13). Intrahepatic NK cell phenotype did not correlate with control 
of chronic HCV infection viral load; C) CD16. D) NKp30. E) NKp46. F) NKG2D. G 
NKG2A. Markers of intrahepatic NK cell function do not correlate with HCV viral load; 
H) CD107a. I) IFNγ. J) Granzyme B. K) Ki67  
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4.7 Markers of liver inflammation 
HCV associated inflammation, rather than the viral load and viral replication per se, 
appears to drive liver fibrosis leading to liver failure and cirrhosis. In addition liver 
inflammation can result in hepatocellular carcinoma although HCV NS5A protein has 
also been reported to be independently oncogenic.209 NK cells may contribute to the 
pathogenesis of HCV related disease via mechanisms of inflammation rather than direct 
control of the virus. 
 
Liver biopsy specimens were available for 23 HCV-infected and 21 CLD donors (Table 
2.1). A consultant histopathologist scored these specimens using the Ishak’s 
necroinflammatory (NI) criteria for all HCV samples and 19 of the CLD samples. 
Representative specimens of low (NI score 3) high-grade (NI score 8) inflammation are 
shown in Figure 4.9A. Iskah’s fibrosis score (0-6) was also used to stage liver fibrosis and 
cirrhosis. The NI score was significantly higher in the HCV cohort compared to the CLD 
cohort (4.9 v 1.7 respectively, p<0.0001 Figure 4.9B). There was no difference in the 
fibrosis score between the two cohorts. The marked difference in the NI score between the 
cohorts may reflect the variety of pathologies represented by the CLD cohort and how 
they result in the pathological changes to which the histopathologist applies the semi-
numerical descriptive score (periportal inflammation, interface hepatitis, focal hepatitis 
and confluent necrosis). For example steatohepatitis may be more effectively scored by 
the Brunt criteria (Appendix I).210 Within the HCV cohort NI score correlated with 
surrogate markers of hepatocyte death and dysfunction: increased serum levels of AST, 
bilirubin and prothrombin time (Figure 4.9C-E). When both the HCV and CLD cohorts 
were taken together fibrosis score correlated with age (Figure 4.9F). Necroinflammatory 
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score correlated with fibrosis score in the CLD cohort (Spearman’s rho 0.66, p=0.007) 
and the HCV cohort  (Spearman’s rho 0.4, p=0.06, Figure 4.9G).   
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Figure 4.9 Necroinflammatory and Fibrosis scores 
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A) Representative hemaotoxylin and eosin (H&E) stain liver biopsies. Left panel - 
necroinflammatory score of 3 (* = portal tract, = periportal inflammation, score=2. 
= focal hepatitis, score=1). Right panel - necroinflammatory score of 8, (periportal 
inflammation=3, interface hepatitis within broken circle=3, focal hepatitis=2). 
B) Ishak’s NI and fibrosis score in HCV () & CLD () cohorts. Mean & SEM, Mann 
Whitney U test. Six patients (2 HCV and 4 CLD) were scored as 5 to 6 out of 6 fibrosis 
by consultant histopathologist. 
C) Serum AST and NI score, HCV; Spearman’s Rho 0.53 p=0.01, CLD; Spearman’s Rho 
0.52 p=0.06.  
D) Serum bilirubin & NI score, HCV; Spearman’s Rho 0.53, p=0.01, CLD; Spearman’s 
Rho -0.17 p=0.5.  
E) Prothombin time and NI score, HCV; Spearman’s Rho 0.45 p=0.04, CLD; -0.1 p=0.7. 
F) Age and Fibrosis score HCV and CLD cohorts combined; Spearman’s rho 0.39 p=0.01. 
G) Fibrosis score and NI score, HCV; 0.4 p=0.06 CLD; 0.66 p=0.007 
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4.8 Intrahepatic NK cells and liver inflammation 
To assess the role of NK cells in driving HCV liver inflammation the NK cell proportion, 
phenotype and function were correlated with NI score. The proportion of intrahepatic NK 
cells of the HCV and CLD cohorts combined had an inverse trend with NI score, but as 
separate cohorts there were no associations (Spearman’s rho = -0.27 p=0.08 Figure 
4.10A). In the combined HCV and CLD cohorts there was a positive correlation between 
CD3+ CD56- T lymphocytes and NI score (Spearman’s rho = 0.4 p=0.019 Figure 4.10B). 
In the HCV cohort NI score correlated with the proportions of NKp46+ and CD107a+ NK 
cells (Spearman’s rho 0.55, p=0.007 & Spearman’s rho 0.6 p=0.02 respectively Figure 
4.10C-D). These associations between NK cell activating receptor expression, 
degranulation and NI score indicate a potential mechanism of liver inflammation in 
chronic HCV infection. There were no associations between liver inflammation and NK 
phenotype and function in the CLD cohort. 
 
  
Chapter	  4:	  Results-­	  
	  Intrahepatic	  NK	  cells	  &	  HCV	  	  
	   170	  
Figure 4.10 Intrahepatic NK cell proportion, NKp46 & CD107a & NI score 
 
Necroinflammatory score and intrahepatic NK cell phenotype and function in chronic HCV 
() & CLD (). A) NI score and NK cells as a proportion of intrahepatic lymphocytes 
(HCV & CLD cohorts combined: Spearman’s rho = -0.27 p=0.08).  
B) NI score and % NKp46+ NK cells. (HCV n=23, Spearman’s rho 0.55, p=0.007 and CLD 
n= 18, -0.3, p=0.17 respectively. 
C) NI score and % CD107a+ NK cells, HCV n=14, Spearman’s rho 0.6 p=0.02 and CLD 
n=11, -0.25 p=0.46   
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There were no correlation between the proportions of CD16+, NKp30+, NKG2D+, 
NKG2A+, IFNγ+, granzyme B+ or Ki67+ NK cells and NI score in either cohort (Figure 
4.11A- G).  
 
These data indicate a potential association between NKp46+ NK cells and NK cell 
cytotoxic function and liver inflammation in chronic HCV, which is discussed in detail 
below. 
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Figure 4.11 Intrahepatic NK cell phenotype and function & NI score. 
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4.9 Intrahepatic NKp46 expression and NK cell function 
Ad hoc analysis of the proportion of intrahepatic NKp46+ NK cells and NK cell function 
within the liver revealed an association between the proportions of IFNγ+ and NKp46+ 
NK cells in the HCV but not the CLD cohort (HCV r2=0.22 p=0.058, Figure 4.12A). 
There was an association between NKp46+ and CD107a+ NK cells (HCV r2=0.14, p=0.08) 
but not Granzyme B (Figure 4.12B-C). Individuals were separated into those with 
NKp46-rich (>80%) and NKp46-poor (<70%) intrahepatic NK populations as described 
above (Figure 4.6). There was increased in CD107a+ NK cells in the NKp46-rich 
individuals in the HCV cohort (mean= 1.9% v 8.8%, p=0.006), but not in the CLD cohort 
(Figure 4.12D). In keeping with these data the proportion of Granzyme BBright NK cells 
was reduced in the NKp46-rich HCV+ individuals but not the CLD cohort (HCV: mean= 
64.6% v 43.3% p=0.01 Figure 4.12E). Together these data indicate that HCV+ individuals 
with NKp46-rich intrahepatic NK cells have greater cytotoxic activity than those with 
NKp46-poor populations. Therefore, in the HCV cohort only, an increased proportion of 
NKp46+ NK cells is associated with increased liver inflammation.  
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Figure 4.12 Intrahepatic NKp46 expression & NK cell function 
NKp46 is associated with increased NK cell IFNγ production and cytotoxicity. A) IFNγ+ 
NK cells and % NKp46+ intrahepatic NK cells in HCV and CLD cohorts (n=19 & 15 
respectively). B) CD107a+ and NKp46+ NK cells (HCV n=17, r2=0.14, p=0.13 & CLD 
n=15, r2=0.05 p=0.44). C) Granzyme B Bright and NKp46+ NK cells (HCV n=17 r2=0.21 
p=0.058 & CLD n=16 r2=0.14, p=0.15). NKp46-rich and NKp46-poor intrahepatic NK 
cells have altered cytotoxic function in the HCV but not the CLD cohorts. D) CD107a 
(HCV n=17, CLD n=15) E) Granzyme B (HCV n=17 & CLD n=16). Mean and SEM 
shown.  
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Analysis of the proportion of NKp46+ NK cells and the composite components of the NI 
score revealed an association between %NKp46+ NK cells and portal inflammation 
(Spearman’s rho=0.59 p=0.004. Figure 4.13A). There was no association between NKp46 
and interface hepatitis or focal hepatitis (Spearman’s rho=0.23 p=0.29 and Spearman’s 
rho=0.32 p=0.14 respectively. Figure 4.13B-C). No patient had a confluent necrosis 
greater than 0, this is in keeping with a clinically stable outpatient cohort (Appendix I). 
Immunohistological staining of HCV+ biopsy samples demonstrated a relative enrichment 
of NKp46+ cells in the periportal regions compared to within the liver parenchyma 
(Figure 4.13D). 
 
Overall, these data strongly support the notion that in situ increased activation of NKp46-
rich populations in the context of chronic HCV infection are a driving force in liver 
inflammation. NKp46 is down-regulated upon NK cell activation in healthy individuals 
(Figure 3.6C). However, in chronic HCV infection individuals with the highest levels of 
liver inflammation (NI score) fail to down-regulate NKp46 in ex vivo degranulation 
assays at maximal stimulation (Figure 4.13E). 
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Figure 4.13 NKp46 and liver inflammation 
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4.10 Measurement of NKp46: Proportion v MFI 
It was recently reported that there is an association between NKp46 and in vitro HCV 
viral control.175,200. In these papers NKp46 expression was assessed by MFI; the 
fluorescent intensity of the labelled cells and therefore the density of NKp46 on the cell 
surface. NK cells were segregrated into NKp46Hi and NKp46Dim populations.  
 
In light of these recent reports I attempted to further analyse my data using the MFI. 
However, I was unable to divide individual the NK cell populations into discrete NKp46Hi 
and NKp46Dim sub-groups; instead in the majority of cases a single NKp46 population 
was observed (Figure 4.14A). The inability to recapitulate these published findings may 
reflect use of different fluorochromes, anti-NKp46 antibody clones and flow cytometers. 
However, in my cohort, NKp46 MFI, proportion of NKp46+ NK cells and NI score 
correlated with each other (Figure 4.14B-C). The proportion of distinct NKp46Hi NK 
cells, measured by MFI as described by Kramer et al, was associated with increasing NI 
score, in those HCV+ individuals in whom such a population was distinguishable (Figure 
4.14D).  
 
These data suggest that similar results are found with either methodology supporting the 
theme that NKp46 has a particular role in the activation of NK cells specifically in 
chronic HCV infection, as discussed below.  
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Figure 4.14  NKp46 measured by MFI and proportion 
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4.11 Intrahepatic NK cells during IFNα  treatment 
I obtained serial samples from 9 HCV+ patients with repeated FNA at multiple time points 
during the first 12 weeks of treatment. Of this cohort, seven patients had undetectable 
viral load by PCR at 12 weeks (and 6 of these eventually achieved an SVR) and two had 
no response to treatment. IFNα induced a significant increase in intrahepatic NK cells at 
days 1 and 3 but was not altered from baseline at later time points (p=0.008 repeated 
measures ANOVA). The intrahepatic NK cells approximately doubled over three days 
from the baseline mean of 10% (day 1 mean=16.0%, p=0.02; day 3 mean=17.8%, p=0.02; 
paired t-test Figure 4.15A). The proportion of intrahepatic NK cells at day 1 of treatment 
correlated with the rate of HCV viral clearance (r2=0.61 p=0.036. Figure 4.15B). In 
keeping with this the 3 patients who failed treatment had a lower proportion of 
intrahepatic NK cells compared to those who achieved SVR at Day 1 (11.9% v 18.6% 
p=0.19). At Day 3 and Day 7 there was no difference in the proportion of intrahepatic NK 
cells in the treatment failure and SVR groups (Day 1 mean = 18.3 v 16.4% Day 3 mean 
=11.8 v 9.4% respectively p=0.6. Figure 4.15C). These data from this small cohort 
suggests that IFNα treatment increases the intrahepatic NK cell proportion and an earlier 
(Day 1) increase in NK cells is associated with rapid control of viral load and successful 
viral clearance. 
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Figure 4.15 Intrahepatic NK cells during IFNα  based treatment of HCV 
 
Variations in NK cells as % of lymphocytes during the first 12 weeks of IFNα treatment 
in the peripheral blood and intrahepatic compartments (n=9). A) Proportion of 
intrahepatic NK cells increases at Day 1 & Day 3 (Mean and SEM shown). B) The rate of 
viral clearance denoted by rate constant of viral decline (k) and NK cells as the proportion 
of intrahepatic lymphocytes. C) The proportion of intrahepatic NK cells in patients who 
achieved SVR (n=6) and those who failed treatment (n=3) over the first week of IFNα 
based treatment of HCV infection.  
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To further investigate the role of the intrahepatic NK cells during IFNα based treatment I 
conducted a detailed intrahepatic analysis of NK cell phenotype and functional markers 
within this cohort of patients.  
 
In keeping with the changes in the proportion of NK cells at Days 1 and 3 there were 
permutations in proportions of NK phenotype and functional markers at these early time 
points within this cohort. At Day 1 there was a reduction in the proportions of CD16+ (but 
not CD56Dim proportion) and granzyme B and an increase in the proportion of CD107a+ 
NK cells (Figure 4.16A-D). By Day 3 these alternations in NK cell phenotype and 
function had returned to their baseline levels. The peripheral blood CD107a and granzyme 
B expression remained constant throughout treatment. The proportions of intrahepatic and 
peripheral blood IFNγ+ NK cells increased over the 1st week of treatment (Figure 4.16E). 
Although the altered proportions of NK cells were not statistically significant individually 
taken together these data support the notion that intrahepatic NK cells have increased 
cytotoxic activity at Day 1, which is reduced at Day 3. 
 
These data suggest that the proportion of NK cell cytotoxic function may be relatively 
more important than IFNγ production in the rapid control of HCV viral load during the 
first 24 hours of treatment when the greatest reductions in HCV viral load are seen 
(Figure 3.10A). However, IFNγ remains likely to be a major compontent of the anti-viral 
response and these data do not necessarily reflect the amount of IFNγ secreted by the total 
NK cell population. 
 
There was an early increase in the proportions of intrahepatic NKp30+, NKp46+ and 
NKG2D+ NK cells (Figure 4.16F-H). The proportion of peripheral blood NKp46+ NK 
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cells was similar to the intrahepatic compartment pretreatment but did not increase to the 
same level as the intrahepatic NK cell population until Day 28. These data suggest that 
IFNα treatment induces increased proportions of NK cells activating receptors and that 
NKp30+ and NKp46+ NK cells may be more readily recruited to the liver during early 
IFNα treatment.  
 
The proportions of NKG2A+ and Ki67+ NK cells were unaltered during the first month of 
IFNα treatment, however, these populations increased at Day 84 in both the peripheral 
blood and the intrahepatic compartment (Figure 4.16I-J). The increase in the proportions 
of NKG2A+, Ki67+ and the immature CD56Bright NK cells proportion at Day 84 (Figure 
4.16B),92 suggests an increase in the proportion of replicating and naïve NK cells as result 
of the long-term effects supraphysiological levels of IFNα from on lymphocyte 
production stimulation. This is in keeping with previous reports of increased Ki67 
expression during IFNα based treatment of HBV.211 
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Figure 4.16 NK cell phenotype and function during IFNα  treatment of HCV 
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Variations in NK cell phenotype and functional markers in the peripheral blood (X) and 
intrahepatic compartments () during the first 12 weeks of IFNα based treatment in a 
cohort of chronic HCV+ patients (n=9).  
A) The proportion of CD16+ NK cells. 
D) % CD56Dim NK cells. 
C) % CD107a externalisation. 
D) % Granzyme B+.  
E) % IFNγ+.  
F) % NKp30+. 
G) % NKp46+ 
H) % NKG2D+. 
I) % NKG2A+.  
J) % Ki67+  
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The changes in NK cell phenotype and functional markers overall were of a small 
magnitude, and there were no discernible differences in the changes measured 
prospectively in NK cell phenotype between the rapid responders and those who failed 
treatment in this cohort (n=3). A major hurdle to analysis of NK cell phenotype and 
functional data during this longitudinal study is the inability to distinguish between recent 
liver immigrants and the established intrahepatic NK cell population. Recent immigrants 
may not have had the opportunity to identify and respond to HCV infected cells and 
therefore potentially mask significant alterations in the resident NK cell population. 
 
These data support the notion that NK cells have increased cytotoxic activity at Day 1. In 
conjunction with the increase in NK cells at Day 1 and the correlation between rate of 
viral control and proportion of intrahepatic NK cells at Day 1 these data imply that 
intrahepatic NK cells have an effective cytotoxic role in the control of viraemia during 
early IFNα treatment.  
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4.12 Discussion 
In HCV infection chronic liver inflammation results in fibrosis, cirrhosis and increases the 
risk of hepatocellular carcinoma. There is some evidence that NK cells are an important 
component of the innate immune response to HCV.163,166,167,175,186 However, until recently 
there has a paucity of data concerning intrahepatic NK cells in chronic HCV. In this study 
I investigated NK cell phenotype and function in both blood and liver of HCV-infected 
individuals.  
 
NK cells were initially reported to account for 30-50% of lymphocytes within the 
intrahepatic compartment.173 However, by flow cytometry, we found that this proportion 
was lower and strongly correlated with the proportion of NK cells in the peripheral blood 
(mean 10.5% and 9.6% respectively Figure 4.4). These data were similar to the 
proportions of CD3+ and NKp46+ lymphocytes upon immunohistological staining (Figure 
4.12). The lower proportion of intrahepatic NK cells is in keeping with the findings of 
multiple studies, which report a mean intrahepatic NK cell proportion ranging from 2.7 – 
18%.157,159,160,163,174,175 There was an inverse trend between necroinflammatory score and 
NK cell proportion when the non-viral chronic liver disease and HCV+ cohorts were 
combined and a positive correlation with CD3+ CD56- T lymphocytes (Figure 4.10). 
These data are in keeping with a recent report by Varchetta and colleagues, which 
compared 70 HCV donors and 26 control donors with normal ALT undergoing elective 
cholecystectomy. In the HCV+ donors the mean proportion of NK cells was lower than in 
the controls (14 vs. 24%) and there was a significant reduction in NK cells in individuals 
with increased histological activity index score.174 Together these data support the notion 
that liver inflammation particularly in chronic HCV infection shifts the proportion of 
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intrahepatic lymphocytes from NK-enriched towards a similar proportion that is found in 
the peripheral blood. 
 
Intrahepatic NK cells had a markedly altered phenotypic and functional profile suggestive 
of increased NK cell activity as well as confirming that the FNA technique sampled a 
separate compartment to the peripheral blood.  HCV+ individuals with a high proportion 
of NKp46+ intrahepatic NK cells, termed NKp46-rich, have a more activated phenotype. 
In line with this, we found NKp46+ proportion correlated with higher necroinflammatory 
scores. These data are further supported by the in vitro experiments described in Chapter 
3, which demonstrated that the proportion of NKp46+ NK cells is uniquely associated 
with NK cell function in chronic HCV. 
 
It is possible that liver inflammation preferentially recruits NKp46+ NK cells into the 
liver. If this were the case one would expect an enrichment of NKp46+ NK cells in the 
intrahepatic compartment relative to the peripheral blood.  
However, the following factors suggest this is not the case: 
i. In both cohorts the proportion of NKp46+ NK cells is similar across both 
compartments. There is a strong correlation between the proportion of NKp46+ 
NK cells in the peripheral blood and intrahepatic compartments (Figure 4.6A). 
ii.  If NKp46+ NK cells were preferentially recruited to the inflamed liver one may 
expect to see an relative increase in the proportion of NKp46+ NK cells in the liver 
compared to the peripheral blood in individuals with high NI scores but this is not 
the case.  
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iii. In addition there appears to be a unique association between the activating 
receptor NKp46 and chronic HCV infection; high NI score is not associated with 
the proportion of NKp46+ NK cells in CLD patients. 
 
Therefore, these data suggest a causative relationship in HCV not a general association 
between inflammation and NKp46. This association compliments the results of in vitro 
experiments reported in Chapter 3.  
 
Golden-Mason and colleagues purified NKp46Hi NK cells and demonstrated that these 
cells have greater in vitro anti-HCV activity; they also demonstrated that the unknown 
NKp46 ligand is present on the surface of hepatoma cells infected with JFH-1 strain of 
HCV.200 Krämer and colleagues reported an association between NKp46 expression and 
NK cell function and in particular the ability to suppress in vitro viral replication. It was 
further reported that there was a non significant association between histological score 
and NKp46 expression. In that study there was a smaller sample size (n=17), a variation 
in methodologies as described above (Section 4.10) and use of Hepatitis Activity Index 
(HAI) scoring system (Appendix I).175 The HAI scores are derived from assessment of 
piecemeal and lobular necrosis and do not score portal inflammation.212 As the portal 
inflammation component of the Ishak’s NI score correlated with the proportion of 
NKp46+ NK cells in the cohort studied herein (Figure 4.13A), it is perhaps unsurprising 
that studies that use HAI scoring did not find an association between NKp46 and liver 
inflammation. Furthermore, Krämer and colleagues reported that the proportion of 
NKp46Hi intrahepatic NK cells was inversely correlated with viral load. However, in our 
cohort we did not find this pattern. Whilst it appears that NK cell phenotype is strongly 
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associated with liver inflammation the role of NK cells in suppressing viral load in the 
chronic disease state remains to be fully elucidated.  
 
In healthy donors NK cell activating ligands are down regulated upon NK activation, 
however, in chronic HCV infection there appears to be a loss of this protective 
mechanism in some individuals (Figures 3.5 & 4.13). I hypothesize that NK cell 
populations that are persistently NKp46-rich may allow continuous engagement with 
putative activating ligands in vivo contributing to liver pathology in chronic HCV. These 
data suggest that the mechanism of HCV related immunopathology results from a failure 
of intrinsic homeostatic NK cell attenuation within the chronically infected liver. 
 
In this cohort I found that the majority of CD107a+ intrahepatic NK cells in the chronic 
state were IFNγ+ (Figure 4.7) However, this is at odds with previous reports that in 
chronic HCV, NK cells are polarised towards cytotoxicity in a pSTAT1 dependent 
manner with reduced pSTAT4 related IFNγ production.180,186 The differences in these 
reports and our data are likely to reflect variations of NK responses in vitro and ex vivo. 
 
In the small cohort available I have demonstrated that there is a significant increase in 
intrahepatic NK cells during the first 72 hours of treatment. Importantly there appears to 
be an association between the proportion of intrahepatic NK cells and rate of viral 
clearance. These NK cells appear to have a more activated phenotype at 24 hours and this 
is in keeping with a previous report of increases in NK cell cytotoxicity at 24 hours and 
successful treatment outcome.185 The first 24 hours is the time period of the greatest 
reduction in viral load in rapid responder patients who are well known to have an 
increased treatment success rate.32 Whilst the data from this small cohort of 9 patients is 
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intriguing further work with a larger cohort of patients is required to determine whether 
there is a statistically significant increase in NK cell function and phenotype at the first 
24 hours. Based on the current data to achieve a sufficiently powered cohort (power 0.8) 
to demonstrate a significant (p<0.05) increase in CD107a+ NK cells at Day 1 a total 
cohort of 19 patients would have to be recruited (µ0=4.2, µ1=7.5 & σ=5.1, Statisical 
Solutions Power & Sample size calculator www.statisticalsolutions.net/pss_calc.php). 
Based on previous experience of recruitment this is achievable but would probably to 
take 20-24 months. 
 
Importantly when the association between NKp46+ NK cells and liver inflammation is 
considered in the context of the ability of these cells to respond to IFNα based treatment 
(Chapter 3.11) an important paradox emerges. Individuals who have the greatest need of 
treatment are those with high levels of liver inflammation as they are at the greatest risk 
of progression to liver failure, cirrhosis and HCC. However, these patients are likely to 
have NKp46-rich NK populations and are at the greatest risk of treatment failure. When 
this association is considered it the context of 30 years of IFNα based anti-HCV 
treatment it is likely that the identified HCV+ population is under new selection pressures 
where treatment is available. In the United States there has been a striking increase in 
standardised mortality in HCV+ individuals compared to HBV and HIV between 1998 
and 2007.213 The rise in mortality may in part be related to the removal, by IFNα therapy, 
of the low risk NKp46-poor patients from the HCV population shifting the phenotype of 
the population towards one at risk of increased mortality. These data demonstrate that 
there is potential for of measurement of NKp46+ NK cell frequency as a biomarker to 
help predict treatment outcome. In particular patients who have high proportion of 
NKp46+ NK cells may be best served by early treatment.  
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The association between NKp46 and liver inflammation may serve two purposes in the 
development of HCV treatment strategies as a therapeutic target. Reduction in NKp46 
associated NK cell activity prior to IFNα treatment may ‘rest’ NK cells allowing a 
marked abrupt increase in the subsequent NK cell response. Secondly decreased NKp46 
cytotoxicity may reduce inflammation as a long-term treatment goal in those unable to 
undergo IFNα treatment. To achieve a reduction in NKp46 activity either the HCV ligand 
would need to be blocked or the surface expression of NKp46 could be altered. Histone 
deacetylase inhibitors (HDACi) have been considered as anti-cancer agents as they 
directly arrest tumour growth and can increase tumour cell immunogenicity. HDACi 
include short chain fatty acids (phenylbutyrate and valproic acid) and derivatives of 
hydroxamic acid.214 HDACi have been considered promising anti-leukaemia and 
lymphoma agents however, it has been reported that HDACi can impinge upon NK cell 
phenotype and function.214,215 In particular expression of both NKp46 and NKG2D are 
down regulated and there is an associated reduction in NKp46- and NKG2D-cytotoxicity 
and IFNγ in vitro. Therefore, HDACi have potential to form an additional therapeutic 
option in the treatment of chronic HCV. 
 
In conclusion I have demonstrated a separate intrahepatic NK cell population with an 
altered phenotype and increased activation. Importantly NKp46 again appears to have a 
unique and important role in the pathogenesis of HCV related liver disease. Increased 
NKp46+ proportion increases NK cell activity resulting in damaging liver inflammation. 
During treatment IFNα stimulation has the potential to induce early NK cell activation, 
which may contribute to the rapid control of HCV viral load. Thus NKp46 presents itself 
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as a biomarker and a potential target for therapeutic intervention to reduce inflammation 
and increase the rates of therapeutic viral clearance. 
	  	   193	  
 
 
 
 
Chapter 5: 
 
Results – 
 
Identification of NK Cell  
 
Evasion Strategies  
 
Employed by HCV 
Chapter	  5:	  Results	  
HCV	  evasion	  of	  NK	  cells	  
	   194	  
5.1 HCV and NK cell function 
To establish a chronic infection it seems HCV must evade the anti-viral response by NK 
cells. As described in Chapter 3 and in keeping with previously published 
reports,155,159,161 we have found that NK cell function is reduced in individuals with 
chronic HCV compared to controls. There has been considerable interest in HCV 
immunoevasion and previous studies have focused upon the impact of HCV on NK cells 
and NK cell lines as described in section 1.18. Possible mechanisms include impingement 
by core protein upon IFNα-ISG pathway;178 up-regulation of NK inhibitory ligands;169 
and down-regulation of activating ligands upon infected cells.181 However, the role of 
individual HCV proteins in NK cell impingement remains to be fully elicited. To address 
this, this part of the study focussed on evaluating whether non-structural HCV proteins 
derived from different viral genotypes alter NK cell function when expressed in a target 
cell. 
 
Adenovirus vectors containing individual HCV proteins and structural polypeptides were 
generated. Individual proteins from two HCV constructs were expressed in this way: 
genotype 2a JFH-1 strain (GenBank accession no. AB047639) and the genotype 1b 
subgenomic replicon con 1 (Rep1b, accession no. AJ238799) containing proteins NS3-
NS5B (Figure 2.4 page 76). These vectors were used to infect target cells (Human 
foreskin fibroblasts (HFF)) and thus to determine which, if any, HCV proteins affect in 
vitro NK cell cytotoxic responses.  
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5.2 HCV protein expression by adenovirus vectors. 
HCV genes were cloned into adenovirus vectors as described in Materials and Methods. 
HCV protein expression from recombinant adenoviruses was confirmed by Western blot 
and immunofluorescence in HFF and HEK 293 cells.   
 
Western blot 
The adenovirus vector was designed with a V5 tag, which immediately followed the 
inserted gene, to allow identification of the expressed protein (Figure 2.6). The 
expression of JFH NS4, NS5A and Rep1b NS5A and NS5B was confirmed by Western 
blot with a monoclonal antibody to the V5 tag (Figure 5.1A). The remaining proteins 
were not identifiable in this way, perhaps due to low expression levels or post-
translational autocleaving of the V5 tag. Repeated Western blot with anti-HCV core 
monoclonal antibody demonstrated bands consistent with a 22kd protein indicating that 
the core proteins, but not the remainder of the polyproteins, were expressed albeit with 
lower expression for Core-E2 than Core-p7 (Figure 5.1B). Core, E1, E2 and p7 are 
separated by signal peptides, the N and C termini of E1 and E2 are cleaved by signal 
peptidases and core protein is cleaved from E1 by signal peptide peptidase.216-218 Thus 
these data suggest post translation processing of the core-p7 polypeptide. Unfortunately, 
glycoproteins E1 and E2 could not be similarly identified due to the lack of commercial 
reagents. Anti- NS3 and NS4 antibodies failed to demonstrate the presence of these 
proteins when HFF were infected.  
 
The integration of adenovirus E1 gene in 293 HEK cells195 enables expression of HCV 
proteins and competent recombinant adenovirus resulting in ongoing infection of cells. 
293 HEK cells were infected with the recombinant adenoviruses for the purpose of 
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maximising HCV gene expression. JFH Core protein, NS3, 4, J5A and Rep1b NS3, 4, 5A 
and 5B were detectable by Western blot (Figure 5.1C) and expression of NS3 and NS4 
proteins was confirmed by an anti-NS3 and anti-NS4 monoclonal antibody respectively. 
NS2 protein could not identified by Western blot using the V5 tag and no specific 
antibodies were available.  
 
Thus, western blotting demonstrated expression of recombinant proteins JFH core, NS3, 
4 and 5A and Rep1b NS3, 4, 5A and 5B. No expression of JFH NS2 was observed 
however in the case of JFH E1, E2 and p7, it was not possible to confirm whether this 
was simply due to cleavage of the V5 tag (Table 5.1). 
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Figure 5.1 HCV protein expression in HFF (A&B) and HEK 293 (C) cells by 
adenovirus vectors - Western blots 
 
Western blot analysis HCV proteins expressed in HFF target cells with an MOI of 5. 
Molecular weight (in kDa) marker label on left of blots A) JFH NS4 & 5A and Rep 1b 
NS5A and NS5B were identified by monoclonal antibody to V5 tag. B) Core-E2 and 
Core-p7 analysis by Western blot using monoclonal antibodies to JFH Core protein 
revealed bands of approximately 22kD; the molecular weight of cleaved core protein. C) 
Western blot analysis with HEK 293 target cells to maximise protein expression. JFH 
NS4, NS5A & NS5B and Rep 1b NS4, NS5A and NS5B were detected with anti-V5 
antibody. Core protein was detected with anti Core antibody. JFH and Rep1b NS3 and 
NS4 were detected with anti-NS3 and anti-NS4 antibodies respectively.  
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Immunofluorescence 
Protein expression was also examined by immunofluorescence. JFH NS4, NS5, NS5A & 
NS5B and Rep1b NS4, NS5, NS5A & NS5B expression was confirmed using the anti-V5 
monoclonal antibody (JFH: Figure 5.2. Rep1b: Figure 5.3). Rep NS3 expression, but not 
JFH1 NS3, was detected using an anti-NS3 antibody (Figures 5.2 & 5.3). Cells infected 
with JFH core-E2 and core-p7 vectors were confirmed to be expressing core protein with 
an anti-core monoclonal antibody (Figure 5.2). NS2 protein expression could not be 
detected. Table 5.1 summarises HCV protein expression using the adenovirus vectors. 
There was concordance between Western blot and immunofluorescence detection of 
protein expression apart for the expression of JFH NS3 & 5 and Rep1b NS3 & 5. This 
may reflect levels of protein expression and/or the susceptibility of V5 tag cleavage 
during sample preparation for Western blot analysis.   
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Figure 5.2 JFH protein expression by immunofluorescence in HFF CAR+ cells  
 
HCV proteins NS4, 5, 5A and 5B were tagged with V5 protein and stained with mouse 
anti-V5 antibodies. Mouse anti-core and anti NS3 antibodies were used to stain Core-E2, 
Core-p7 and NS3 proteins. All cells were then stained with anti-mouse AF488 secondary 
antibody (green) and cell nuclei were stained with DAPI (blue). 
Core E2 Core-p7 Uninfected 
NS3 NS2 NS4 
NS5A NS5 NS5B 
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Figure 5.3 Rep1b protein expression by immunofluorescence in HFF CAR+ cells 
 
  
Rep1b HCV proteins NS4, 5, 5A and 5B were tagged with V5 protein and stained with 
mouse anti-V5 antibodies. Mouse anti-NS3 antibodies were used to stain NS3 proteins. 
All cells were then stained with anti-mouse AF488 secondary antibody (green) and cell 
nuclei were stained with DAPI (blue).  
NS5 NS5A NS5B 
Uninfected NS3 NS4 
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Table 5.1 Summary of HCV proteins expressed in HFF and HEK 293 
cells using adenovirus vectors 
 
 
Protein Western blot Immunofluorescence 
JFH-1 
(Genotype 2) 
Core E2* ✓ ✓ 
Core p7* ✓ ✓ 
NS2 ✗ ✗ 
NS3 ✓ ✗ 
NS4 ✓ ✓ 
NS5 ✗ ✓ 
NS5A ✓ ✓ 
NS5B ✓ ✓ 
Rep1b 
(Genotype 1) 
NS3 ✓ ✓ 
NS4 ✓ ✓ 
NS5 ✗ ✓ 
NS5A ✓ ✓ 
NS5B ✓ ✓ 
 
*Detected by anti-Core antibody protein size on Western blot suggests E1, E2 and p7 
have been cleaved or possibly even not transcribed.  
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5.3 The impact of HCV protein expression on NK cell function. 
 
In order to examine the impact of HCV protein expression upon NK function HFF were 
cultured for 24 hours and then infected with recombinant adenoviruses with a multiplicity 
of infection (MOI) of 5*. The HFF were then cultured for a further 48 hours to allow 
protein expression. 16 hours prior to the end of the culture period fresh PBMC were 
isolated from healthy donors and incubated overnight with 1000 IU/ml of IFNα. The 
PBMC were then cultured in the presence of the infected target cells and anti-CD107a 
antibody for 4 hours to assess the impact of HCV protein on NK cell function. PBMC 
were then stained with surface antibodies and fix-permeabilised and stained for IFNγ and 
TNFα and assessed by flow cytometry (gating strategy as demonstrated in Figure 2.2). 
The NK cell cytotoxic function and cytokine expression was compared between target 
cells expressing HCV protein and both negative and positive control target cells.  
Negative controls comprised HFF cells infected with an adenovirus vector containing an 
empty cassette. Positive control target cells comprised those infected with a vector 
containing CMV UL141 protein, known to markedly affect NK cell function through the 
down regulation of NK activating ligands CD112 (for DNAM-1 NK receptor) and 
CD155 (for DNAM-1 and CD96 NK receptors).219,220 As reported in Chapter 3 the range 
of CD107a+ NK cells following exposure to K562 target cells and 1000 IU/ml IFNα was 
30-60%  (Figure 3.4). Therefore, to determine whether HCV proteins impinge upon NK 
cell function the individual donor’s response was expressed as a percentage of NK 
function when exposed to just control target cells. The cytotoxic and cytokine responses 
of 5 healthy donors were assessed in duplicate for each infected cell line. 
 
* MOI of 5 = 5 virions to 1 HFF cell  
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NK cell cytotoxic responses 
Analysis of the data revealed that JFH NS5 and NS5B proteins reduced NK cell function 
relative to negative control cells (36% p=0.001 and 52% p=0.0079 respectively). This 
reduction in NK cell cytotoxic function was similar to the effect of CMV UL141 (-34% 
degranulation). Expression of JFH Core-E2, Core-p7, NS4 and NS5A had no effect on 
NK cell function (Figure 5.4A). Rep 1b NS5 and NS5B proteins induced similar 
reductions in NK cell cytotoxic function (75% p=0.021 and 67% p=0.0001 respectively). 
Conversely Rep1b NS5A protein expression induced increased NK cell cytotoxicity 
(114% p=0.04) compared to infection control cells (Figure 5.4B). These data demonstrate 
NS5B is able to reduce NK cell cytotoxic function. The same effector function or an 
alternative mechanism may be induced by NS5 protein, when NS5B is expressed in 
conjunction with NS5A. NS5A, which is known to aid viral immunoevasion through 
IFNα signalling inhibition,221 is unable to impinge directly upon NK cell function. 
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Figure 5.4 The impact of HCV protein expression on NK cell cytotoxic function 
A) JFH-1 proteins 
 
 
 
B) Rep1b proteins 
 
 
 
HCV proteins and polyproteins were expressed in HFF targets together with infection 
control (negative) and CMV UL141 (positive) control. % CD107a+ NK cells induced by 
HFF infected with varying HCV proteins expressed relative to infection controls for 5 
donors in duplicate in at least 2 separate experiments for each protein. Mean and SEM 
shown, paired t test, significant p values shown.  
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NK cell cytokine responses 
The impact on cytokine production (IFNγ and TNFα) by NK cells was also assessed. 
Expression of JFH NS5 and NS5B resulted in a significant decrease in the proportion of 
IFNγ- (34% p=0.027 and 58% p=0.009 respectively) and to a lesser extent, TNFα- (37%, 
p=0.0005 and 51% p=0.01 respectively) producing NK cells (Figure 5.5A-C). Following 
target HFF infection with Rep1b NS5 and NS5B there were smaller reductions in IFNγ+ 
NK cells (86% p=0.5, 66% p=0.13 respectively, Figure 5.5B). Rep1b vectors expressing 
NS5 and NS5B induced modest reductions in the proportion of TNFα+ NK cells (71%, 
p=0.1 and 85% p=0.39 respectively, Figure 5.5D). There was a modest reduction in 
TNFα+ NK cells following target HFF infection with JFH NS4 expressing vectors (85% 
p=0.02). No effects were observed following expression of any of the other HCV proteins 
tested. 
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Figure 5.5 HCV protein impingement upon NK cell cytokine production 
A) JFH-1 & IFNγ+ NK cells 
 
B) Rep1b & IFNγ+ NK cells 
 
 
HCV proteins and polyproteins were expressed in HFF targets together with infection 
control (negative) and CMV UL141 (positive) control. % IFNγ+ NK cells induced by 
infected targets relative to infection controls for 5 donors in duplicate in at least 2 
separate experiments for each protein. Mean and SEM shown, paired t test, significant p 
values shown.  
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C) JFH-1 & TNFα+ NK cells 
 
 
D) Rep1b & TNFα+ NK cells 
 
 
HCV proteins and polyproteins were expressed in HFF targets together with infection 
control (negative) and CMV UL141 (positive) control. % TNFα+ NK cells induced by 
infected targets relative to infection controls for 5 donors in duplicate in at least 2 
separate experiments for each protein. Mean and SEM shown, paired t test, significant p 
values shown.  
Mock Core-E2 Core-p7 NS2 NS3 NS4 NS5A NS5B NS5 UL141
0.00
0.25
0.50
0.75
1.00
1.25
Not tested
p=0.02
p=0.01
p=0.195
p=0.0005
Re
lat
iv
e T
N
F!
 ex
pr
es
sio
n
Mock Core-E2 Core-p7 NS2 NS3 NS4 NS5A NS5B NS5 UL141
0.00
0.25
0.50
0.75
1.00
1.25
Not available     Not tested
p=0.1
Re
lat
iv
e T
N
F!
 ex
pr
es
sio
n
Chapter	  5:	  Results	  
HCV	  evasion	  of	  NK	  cells	  
	   208	  
Overall, the data on cytotoxicity and cytokine production clearly point to NS5 and NS5B 
as proteins that have the greatest impact upon NK cell function for both the JFH and 
Rep1b strains of HCV (Figure 5.6A&B). JFH NS5 and NS5B impinge equally on both 
cytotoxicity and cytokine function. Similarly, Rep1b NS5 and NS5B both impinge on NK 
cytotoxicity but to a lesser extent on IFNγ and TNFα production with greater variability 
between individuals. These inter-genotype variations in the relative impingement upon 
NK cytotoxicity and cytokine production may contribute to the relative responsiveness of 
varying genotypes to IFNα based treatments. 
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Figure 5.6 Summary - NK cell response to HCV protein expression in target cells 
A) JFH-1 protein expression & NK cell cytotoxicity and cytokine production 
 
B) JFH-1 protein expression & NK cell cytotoxicity and cytokine production 
 
HCV proteins and polyproteins were expressed in HFF targets together with infection 
control (negative) and CMV UL141 (positive) control. CD107a – white bars, IFNγ - red 
bars TNFα - blue bars. The proportion of positive NK cells relative to infection control 
cells for each protein for 5 donors in duplicate in at least 2 separate experiments for each 
protein.  
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5.4 Discussion 
The data described in this Chapter demonstrate that HCV proteins have the ability to 
impinge upon NK cell function with NS5 and NS5B having the greatest effect. NS5B is 
one of the most variable regions of the HCV genome and genotype 2a and 1b strains of 
HCV have been reported to exhibit merely 64% homology.222 Variability within NS5B 
has presumably conferred a survival advantage to the virus, and these results suggest one 
mechanism is viral immunoevasion of NK responses. A previous study has reported an 
inverse correlation between HCV viral load and NS5B mutation rate,223 suggesting 
balanced selection between viability of viral protein and host immunoevasion. 
 
The inhibition of both NK cell cytotoxic function and cytokine production may be an 
important step for HCV to establish a chronic infection. Inhibition of NK cell function 
may however, also benefit the host due to reduced liver inflammation and associated 
immunopathology as described in Chapter 4. Whilst potentially exciting, the data 
described in this Chapter, which revealed the inhibitory effects of NS5B, are preliminary. 
In particular, the impact of NS5B and NK cell function during chronic HCV infection and 
IFNα treatment remains to be elucidated. I have previously demonstrated that the 
proportion of NKp46+ cells dictates NK function in chronic HCV. However, the 
experiments carried out to assess the effect of NS5B were performed with healthy donor 
samples where no such effect of NKp46 was observed (Figure 3.6C). Thus, in order to 
determine whether there is a link between the impact of NS5B on NK cell function and 
expression of NKp46, the experiments described in this Chapter should be repeated using 
blood obtained from individuals chronically infected with HCV. 
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The relationship NS5B impingement and NK cell function during IFNα treatment may be 
viewed as potentially beneficial or problematic to the host: NS5B mediated reduction in 
NK function in chronic disease that is subsequently overcome by IFNα could result in 
rapid viral decline during treatment. However, it is also possible that NS5B will remain a 
barrier to NK function during IFNα treatment. In this case, disabling the inhibitory 
effects of NS5B may represent a means through which the success of IFNα therapy can 
be improved.  
 
Further experiments are clearly required to confirm and establish the mechanisms 
underpinning HCV protein impingement upon NK cell function: i) Assess the effect of 
IFNα titration upon NS5B impingement of NK function. ii) Assess the function of NK 
cells from HCV+ donors with a range of NKp46 phenotypes to exposed to NS5B 
expressing target cells. iii) Assess impact of HCV proteins expressed in hepatoma cell 
lines on NK cell. iv) Determine whether viral proteins impinge directly or indirectly on 
NK cell function.  
 
Whilst the experiments conducted thus far indicate a role for NS5 and NS5B, they do not 
rule out a role for other HCV proteins, which remain untested. These include NS2, NS3 
and NS3/4 protease.  
 
In conclusion, the preliminary data presented in this Chapter demonstrate that HCV 
proteins can down modulate NK cell cytotoxic and cytokine function in keeping with 
previous ex vivo NK functional data. These data provide insights into immunoevasive 
strategies utilised by HCV and how these same strategies may be beneficial to the 
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infected host. Furthermore, these data underline NS5 and NS5B proteins as important 
targets for anti-HCV therapies. 
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In this thesis I have aimed to address the impact of chronic HCV infection upon NK cell 
phenotype and function. In addition I have sought to explore the roles that NK cells play 
in shaping the pathogenesis of HCV related illness and how this impacts on IFNα based 
treatment of HCV. Several key features of the role of NK cells in chronic HCV infection 
have emerged (summarised below and in Figure 6.1): 
 
i) NK cell function is reduced in chronic HCV infection (Figure 3.4), these findings 
are in keeping with previously studies.155,159,161,171 In an as yet unreported finding I have 
demonstrated that target cells that are infected with vectors expressing HCV NS5 and 
NS5B proteins interfere with the NK cytotoxic and cytokine response (Figure 5.6). The 
full implications and mechanism of this interaction are yet to be fully understood. 
 
ii) Although NK cell function in chronic HCV is reduced I have demonstrated that it 
is dictated by NKp46 expression in vitro, an association not found in healthy donors or 
patients with non-viral chronic liver disease (Figure 3.7). This observation has been 
support by two further recent reports of a unique role for NKp46 in chronic HCV.175,200  
 
iii) I have demonstrated a strong association between NKp46, NK cell cytotoxicity 
and liver inflammation by FNA sampling of a large cohort of the liver HCV+ patients 
(Figures 4.10-12). These findings are supported by those of Krämer and colleagues.175 
Importantly it has been demonstrated in vitro that hepatoma cell lines infected with JFH-1 
HCV up regulated NKp46 ligand adding further evidence of NKp46 activation in chronic 
HCV.200 A further study of a large cohort of HCV+ individuals has demonstrated reduced 
intrahepatic NK cell cytotoxicity and IFNγ assays ex vivo compared to the peripheral 
blood.224 This is keeping with the theme that NK cells within the liver are activated and 
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therefore have reduced cytotoxic potential when rechallenged ex vivo compared to the 
peripheral blood.  
 
iv) There is a strong correlation between the marked relative increase in NK 
cytotoxicity in vitro and the rapid control of HCV viraemia during IFNα treatment 
(Figure 3.13). These data are supported by the near doubling in the proportion of 
intrahepatic NK cells and evidence of NK cytotoxic activity during very early IFNα 
treatment (Figures 4.15-16). These data corroborate the findings of Ahlenstiel et al.167 
Furthermore, the concept of relative response to IFNα is in keeping with previous 
findings of interferon-stimulated genes (ISG) in chronic HCV infection suggesting a 
common theme to treatment resistance.50,51,201 Intriguingly NKp46 phenotype again 
impacts upon these findings as NKp46-poor individuals have the greatest increase in 
cytotoxic function and therefore most rapid viral clearance.  
 
v) In keeping with evidence from multiple mouse models,203,205-207 we have found that 
rapid viral clearance effectively abrogates the need and/ or the ability to mount an 
adaptive immune response by the rapid clearance of viral antigen. Importantly those 
individuals with NKp46-rich NK cell populations have the highest risk of liver 
inflammation. They are less likely to rapidly control viraemia by innate responses and 
appear reliant upon adaptive immune response to clear HCV. The failure to develop 
effective innate and CD4+ T cell responses during IFNα treatment results in viral 
persistence (Figure 3.15). 
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Figure 6.1 NK cells and chronic HCV infection 
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A recurrent theme throughout this body of work is the importance of NKp46 as an 
activating receptor in chronic HCV infection. Individuals who are exposed to HCV but do 
not seroconvert are reported to have high expression of NKp30.149 During chronic HCV 
infection NKp30 expression does not appear to dictate NK cell function. However, NK 
cell function is diminished in chronic HCV infection and correlates with NKp46 
expression.175,200 There are striking similarities between the loss of NK cell function and 
the relative increase in significance of NKp46 as the major activating ligand in chronic 
HCV and a report by Jarahian and colleagues of mouse pox-virus infections.121 It was 
reported that usurpation of NKp30 as the primary NK activating molecule resulted in 
NKp46 associated NK cell activation. A similar scenario might occur in HCV infection –
HCV proteins may block NKp30-activation. This could be tested using the adenovirus – 
expression system described in this thesis. In addition, the use of recombinant adenovirus 
to express individual HCV proteins, together with recombinant chimeric NKp46-Fc 
proteins, should allow screening for the HCV specific ligand of NKp46. The ligand could 
subsequently be captured and characterised using proteomic and biochemical methods. 
This would enable further examination of the interaction between NKp46 and a ligand of 
known important pathological sequelae. 
 
Two striking factors mark NKp46 apart from other NCRs and NK cell activating 
receptors: i) the functional necessity for NKp46 dimerization providing a hinge region as 
a potential ligand binding site.117,118 ii) it is the most conserved NK activating receptor 
across several mammal species.110,119 Although NKp46 triggering may be less important 
for NK function in acute infections and have a lower activating potential compared to 
other NK activating receptors, the broad evolutionary conservation suggests that NKp46 
expression may continue to confer a host advantage to a broad range viral pathogens.  
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The conserved nature of NKp46 has important implications in its consideration as a 
therapeutic target. As discussed in Chapter 4, the reduction of NKp46 expression may be 
a useful goal of anti-HCV associated inflammation treatment. However, further research 
is required to assess whether loss of such a widely expressed and conserved activating 
receptor has adverse outcomes particularly relating to failure of tumour recognition, 
especially HCC, and risk of viral infection. Further work leading on from this thesis could 
include treating primary NK cells and NK cell lines with HDACi to reduce NKp46 
expression and assessing their cytotoxic and cytokine responses to HCV specific antigens 
and a variety of tumour and common viral infections including influenza. Following these 
experiments the impact of HDACi upon NKp46 phenotype and markers of liver 
inflammation could be assessed in longitudinal studies using FNA sampling.  
 
NS5B inhibitors are currently under evaluation as potential therapies to prevent viral 
replication in addition to IFNα and ribavirin regimens or as part of IFNα free regimens. 
The data presented in Chapter 5 suggests that an additional outcome of NS5B inhibitor 
treatment may be restoration of NK cell function in chronic HCV in addition to reducing 
viral replication. A potential risk of using NS5B inhibitors in conjunction with IFNα 
stimulation is that the innate response from uninhibited NK cells will rapidly control viral 
antigen in all individuals preventing the development of an anti-HCV adaptive immune 
responses. If such individuals were re-exposed to HCV a lack of adaptive immune 
responses would place them at increased risk of a repeated chronic infection. Therefore, 
lower doses of IFNα or IFNα free regimens may actually increase the development of 
robust CD4+ responses, which successfully clear HCV. ‘Lead-in’ or pre-treatment with 
NS5B inhibitors prior to IFNα based treatment may increase SVR rates purely through 
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increased NK cell response. In addition the reduction in viral replication by NS5B 
inhibitors may further reduce the potential for establishing IFNα associated 
immunoevasive quasi-species during HCV treatment. Further studies could assess the 
mechanisms of the interaction between NS5B and NK cell function in vivo by flow 
cytometry and microarray. In addition, to assess the longitudinal effect of this treatment 
upon intrahepatic NK cells using FNA sampling potential research could compare the 
effects of NS5B inhibition in vivo in conjunction with in vitro experiments.  
 
At present two of the greatest pressures upon modern healthcare systems are the 
requirement to deliver personalised medicine, with reduced risk of adverse events and 
increased rates of successful outcomes, and the need to control healthcare spending. The 
data presented in this thesis suggests the potential use of NKp46 as a biomarker to direct 
treatment and as a novel target for treatment either to control chronic HCV-inflammation 
or to promote viral clearance. There is considerable excitement surrounding the possibility 
of IFNα free therapy for chronic HCV. However, if HCV NK immunoevasive 
mechanisms can be inhibited with single agent small molecular inhibitors then effective 
clearance may be achievable with lower doses of IFNα over shorter periods of time. 
There is a potentially significant economic advantage to shorter, low-dose IFNα based 
regimes. In addition whilst IFNα is a ‘dirty’ drug with a broad range of potential adverse 
events, these side effects are dose dependent, well-defined and monitoring protocols are 
established.  
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Conclusion 
In conclusion, chronic HCV infection related inflammation results in fibrosis, cirrhosis 
and increases the risk of hepatocellular carcinoma. The ability to clear HCV with IFNα 
based treatments is unusual compared to other human chronic viral infections. There is 
increasing evidence that NK cells are an important component of the innate immune 
response to HCV and may be involved in the successful eradication of HCV.163,166,167,175,186  
 
I have demonstrated that NK cells are closely associated with the pathogenesis of HCV 
related liver inflammation and impact upon IFNα based treatment of HCV. The 
mechanisms by which NK cells are inhibited by HCV and the ligands that activate NK 
cells in the chronic disease state remain unclear. However, initial work reported in this 
thesis indicates a role for the highly variable NS5B viral protein. This findings represents 
the starting point for a significant further body of research, which by expanding a critical 
area of HCV pathology and therapeutics will potentially alter HCV assessment and 
treatment on an individual patient basis. 
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Appendix I: 
 
Histological scoring systems of liver inflammation and fibrosis 
 
i) Ishak’s Necroinflammatory score (Maximum score = 18) 187 
 Score 
A) Periportal or periseptal interface hepatitis (piecemeal necrosis) 
Absent 0 
Mild (focal few portal areas) 1 
Mild/moderate (focal most portal areas) 2 
Moderate (continuous around <50% of tracts or septa) 3 
Severe (continuous around >50% of tracts or septa) 4 
  
B) Confluent necrosis  
Absent 0 
Focal confluent necrosis 1 
Zone 3 necrosis in some areas 2 
Zone 3 necrosis in most areas 3 
Zone 3 necrosis & occasional portal central (P-C) bridging 4 
Zone 3 necrosis and multiple P-C bridging 5 
Panacinar or multiacinar necrosis 6 
  
C) Focal (spotty) lytic necrosis, apoptosis and focal inflammation 
Absent 0 
One focus or less per 10x objective 1 
Two to four foci or less per 10x objective 2 
Five to ten foci or less per 10x objective 3 
More than ten foci per 10x objective 4 
  
D) Portal inflammation  
None 0 
Mild, some or all portal areas 1 
Moderate, some or all portal areas 2 
Moderate/marked all portal areas 3 
Marked, all portal areas 4 
 
 
Ishak’s fibrosis and cirrhosis staging criteria (Maximum score 6) 
 Score 
No fibrosis 0 
Fibrosis expansion of some portal areas, with or without short fibrous septa 1 
Fibrosis expansion of most portal areas, with or without short fibrous septa 2 
Fibrosis expansion of most portal areas, with or without short fibrous septa with 
occasional portal to portal (P-P) bridging 
3 
Fibrosis expansion of portal areas, with marked bridging (P-P as well as portal to 
central (C-P) 
4 
Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis 5 
Cirrhosis, probable or definite 6 
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ii) Metavir Histological Activity Index 212 
 Score 
Piecemeal Necrosis  
No 0 
Mild 1 
Moderate 2 
Severe 3 
  
Lobular Necrosis  
No or mild 0 
Moderate 1 
Severe 2 
 
METAVIR Algorithm for evaluation of histological activity 
 
 LN = 0 A = 0 
PMN = 0 LN = 2 A = 1 
 LN = 3 A = 2 
   
PMN = 1 LN = 0 or 1 A = 1 
 LN = 2 A = 2 
   
 LN = 0 or 1 A = 2 
PMN = 2 LN = 2  
   
PMN = 3 LN = 0,1, or 2 A = 3 
 
 
 
 
iii) Brunt criteria for grading and stating non-alcoholic steatohepatitis 210 
   Inflammation 
 Steatosis Ballooning Lobular Portal 
Grade 1 
mild 
1-2 Minimal zone 3 L = 1-2 P = 0-1 
Grade 2 
moderate 
2-3 Present zone 3 L = 1-2 P = 1-2 
Grade 3 
severe 
2-3 Marked,  
predominantly zone 3 
L = 3 P = 1-2 
 
Steatosis:    1≤33%, 2= 33-66%, 3≥66% 
Lobular inflammation:  0= absent; 1 <2 foci per x20 field; 2=2-4 foci per x20 field; 
3= >4 foci per x20 field 
Portal inflammation:  0= absent; 1= mild; 2= moderate; 3= severe 
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